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Summary 
Alcohol and other drug treatment services across Australia provide a broad range of 
treatment services and support to people using drugs and to their families and friends. This 
report presents the latest annual snapshot of information about publicly funded alcohol and 
other drug treatment service agencies, the people they treat and the treatment received. For 
the first time in 2012–13, the AIHW has been able to estimate the number of clients receiving 
treatment. 
Around 108,000 clients received almost 162,400 treatment episodes from 714 publicly 
funded alcohol and other drug treatment agencies across Australia 
There has been a steady increase in both the number of agencies and treatment episodes 
provided over the last decade. More specifically, in 2012–13, alcohol and other drug 
treatment agencies provided a total of 162,362 closed treatment episodes, an increase of 6% 
from 2011–12. These services were provided by 714 agencies, an increase of 8% from 2011–12. 
The age profile of people using services suggests that there is an ageing cohort of people 
in alcohol and other drug treatment 
Over the 5 years to 2012–13, the proportion of people treated who were aged 20–29 fell from 
31% to 27% while the proportion for those aged 40 and over rose from 29% to 32%. The 
proportions for those aged 10–19 and 30–39 remained steady.  
Alcohol continues to be the most common principal drug of concern and treatment for 
amphetamines is increasing 
Alcohol, cannabis, amphetamines and heroin have remained the most common principal 
drugs of concern since 2003–04. Since 2009–10, the proportion of episodes where alcohol was 
the most common principal drug has decreased (from 48% to 41%), while the proportion for 
amphetamines has increased (from 7% to 14%). 
The majority of clients have more than 1 drug of concern 
In 3 out of 5 (63%) closed episodes, the client reported additional drugs of concern. Of these, 
31% reported 1 additional drug and 17% reported 2. Nicotine was the most common 
additional drug along with cannabis (both 23%), although nicotine was the principal drug for 
only 2% of episodes. 
Counselling continues to be the most common type of treatment with diversion 
influencing increases in assessment 
Over the 10 years from 2003–04 to 2012–13, the proportion of episodes for each main 
treatment type has remained quite stable, with counselling (46%), assessment only (17%) and 
withdrawal management (16%) being the most common types of treatment over that period. 
In 2012–13, assessment only overtook withdrawal management as the second most common 
main treatment type for the first time since these data have been collected.  
Aboriginal and Torres Strait Islander people continue to be over represented in alcohol 
and other drug treatment services 
Despite comprising just 3% of the Australian population, 14% of episodes were provided to 
Indigenous Australians by publicly funded alcohol and other drug treatment services. In 
addition, 73,991 alcohol and other drug treatment episodes were delivered by specialist 
Indigenous services.  
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1 About the collection 
In Australia, publicly funded treatment services for alcohol and other drug use are available 
in all states and territories. Most of these services are funded by state and territory 
governments while some are funded by the Australian Government. Treatment services are 
provided to people for their own drug use and to those seeking assistance for someone else’s 
drug use.  
This report presents information on clients and treatment episodes provided by publicly 
funded treatment services for alcohol and other drug use from the Alcohol and Other Drug 
Treatment Services National Minimum Data Set (AODTS NMDS) and related sources such 
as hospitals, homelessness and Indigenous data. For more information on the data used in 
this report, see Section 1.4 and Appendix A. 
1.1 Drug use in Australia 
Drug use can be either licit or illicit. ‘Licit drug use’ refers to the use of legal drugs in a legal 
manner, and includes tobacco smoking and alcohol consumption. ‘Illicit drug use’ refers to a 
number of broad concepts including: 
• the use of illegal drugs—a drug that is prohibited from manufacture, sale or possession 
in Australia, for example, cannabis, cocaine, heroin and ecstasy 
• misuse, non-medical or extra-medical use of pharmaceuticals—drugs that are available 
from a pharmacy, over-the-counter or by prescription, which may be subject to misuse, 
for example opioid-based pain relief medications, opioid substitution therapies, 
benzodiazepines, over-the-counter codeine, and steroids 
• use of other psychoactive substances—legal or illegal, potentially used in a harmful way, 
for example, kava, or inhalants such as petrol, paint or glue (but not including tobacco or 
alcohol) (MCDS 2011). 
Licit and illicit use of drugs is a significant issue in Australia and cost an estimated $56 
billion in 2004–05, of which $8 billion was for illicit drug use (Collins & Lapsley 2008). The 
2013 National Drug Strategy Household Survey (NDSHS) found that alcohol and tobacco 
were the most common drugs used in Australia, with 78% of Australians aged 14 and over 
drinking alcohol in the previous 12 months and 13% smoking tobacco daily (AIHW 2014b). 
Nearly 1 in 5 (18%) people drank at levels that put them at increased risk of harm over their 
lifetime (more than 2 standard drinks a day on average), while 26% of people drank at least 
once a month at levels that put them at risk of accident or injury (more than 4 standard 
drinks in a session). 
Although less prevalent than the use of licit drugs, illicit drug use is still relatively common. 
In 2013, about 2 in 5 people (42%) aged 14 and over reported using illicit drugs in their 
lifetimes, while 1 in 7 (15%) reported using illicit drugs within the previous 12 months 
(AIHW 2014b). Cannabis was the most common illicit drug; 1 in 3 (35%) Australians aged 14 
and over had used cannabis in their lifetime, while 1 in 10 (10%) had used it in the previous 
12 months. Ecstasy and hallucinogens were the second and third most common drugs for 
use in their lifetime (11% and 9%, respectively), while pain killers (analgesics) for 
non-medical purposes and ecstasy were the second and third most common for use in the 
previous 12 months (3% and 2%, respectively). 
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1.2 National Drug Strategy 
Australia has had a coordinated approach to alcohol and other drugs since 1985. The current 
strategy, the National Drug Strategy 2010–2015, is a cooperative venture between Australian, 
state and territory governments and the non-government sector. It has an overarching 
approach of harm minimisation and encompasses 3 pillars, each with specific objectives 
(MCDS 2011): 
• demand reduction to prevent and reduce the use of drugs, support people to recover 
from dependence and support efforts to promote social inclusion and resilient 
individuals, families and communities 
• supply reduction to reduce the supply of illegal drugs and control and manage the 
supply of alcohol, tobacco and other legal drugs 
• harm reduction to reduce harms to individuals, families and community safety. 
Harm reduction actions in the Strategy include enhancing treatment ‘across settings to 
provide help at all stages of drug use, particularly for disadvantaged populations’, 
preventing drug overdoses through the use of ‘substitution therapies, withdrawal treatment 
and other pharmacotherapies’ and continuing drug diversion programs.  
1.3 Types of agencies and treatment 
Alcohol and other drug treatment services assist people to address their drug use through a 
range of treatments. Treatment objectives can include reduction or cessation of drug use as 
well as improvements to social and personal functioning. Services are also provided to 
people who are seeking assistance for someone else’s drug use. 
This report focuses on publicly funded treatment agencies. It does not include information 
on agencies that provide services primarily concerned with health promotion or 
accommodation, private treatment agencies that do not receive public funding, or needle and 
syringe programs. Information on agencies whose sole function is to prescribe or provide 
dosing for opioid pharmacotherapy, services provided in prisons, and primary health care 
services and substance-use services funded by the Australian Government is in Section 8. 
Many types of treatment are available in Australia. Most aim to reduce the harm of drug use, 
while some use a structured drug-free setting with abstinence oriented interventions to help 
prevent relapse and develop skills and attitudes that assist clients to make changes leading to 
drug-free lifestyles (AIHW 2011). 
This report looks at the following types of treatment: 
• assessment only. Most types of treatment include an assessment to identify the nature of 
the drug issue, the needs of the client and the type of treatment most appropriate for the 
client. This category is used when only an assessment is provided in a treatment episode, 
for example, by an agency whose main function is to assess and refer people to 
appropriate treatment agencies.  
• counselling, both individual and group. This is the most common treatment for 
problematic alcohol and/or other drug use and can include cognitive behaviour therapy, 
brief intervention, relapse intervention and motivational interviewing (ADCA 2013). 
  Alcohol and other drug treatment services in Australia 2012–13 3 
• information and education only, for individuals and groups.  
• pharmacotherapy, where the client receives another type of treatment in the same 
treatment episode. Pharmacotherapy includes drugs such as naltrexone, buprenorphine 
and methadone used as maintenance therapies or relapse prevention for people who are 
addicted to certain types of opioids. Where a pharmacotherapy is used for withdrawal, it 
is included in the ‘withdrawal’ category. Due to the complexity of the pharmacotherapy 
sector, this report provides only limited information on agencies whose sole function is 
to provide pharmacotherapy. 
• rehabilitation. This focuses on supporting clients in stopping their drug use and helping 
to prevent psychological, legal, financial, social and physical consequences of 
problematic drug use. Rehabilitation can be delivered in a number of ways including 
residential treatment services, therapeutic communities and community-based 
rehabilitation services (AIHW 2011). 
• support and case management only. Support includes activities such as helping a client 
who occasionally calls an agency worker for emotional support. Case management is 
usually more structured than ‘support’. It can assume a more holistic approach, taking 
into account all client needs including general welfare needs, and it includes assessment, 
planning, linking, monitoring and advocacy (Vanderplaschen et al. 2007). 
• withdrawal management, both medicated and non-medicated. This is the process of 
stopping or reducing drug use, often after a period of long or frequent use. 
Rehabilitation, withdrawal management (detoxification) and pharmacotherapy are not 
provided to clients seeking treatment for someone else’s drug use. 
1.4 Scope of the AODTS NMDS 
The main source of data for this report is the AODTS NMDS. This data set contains 
information on treatment episodes provided by publicly funded alcohol and other drug 
treatment services. Data are collected by treatment agencies that forward these data to state 
and territory government health departments. These departments then extract the required 
data according to definitions and technical specifications agreed to by the departments and 
the Australian Institute of Health and Welfare (AIHW). Agencies funded by the Australian 
Government through the Non-Government Organisation Treatment Grants Program 
(NGOTGP) generally forward data directly to the AIHW. 
The 2012 National Healthcare Agreement (COAG 2012) seeks to improve health outcomes 
for all Australians and the sustainability of the Australian health system. The Agreement 
mandates the collection of data for several National Minimum Data Sets; one of which is the 
AODTS NMDS as part of governments’ efforts to report regularly on the status, quality and 
performance of the healthcare system. This information is used to inform policy and help 
improve service delivery. 
Other sources of data included in this report to support a more complete picture of alcohol 
and other drug treatment in Australia include the National Hospital Morbidity Database, 
Online Services Report (OSR) Database, Specialist Homelessness Services collection, the 
National Opioid Pharmacotherapy Statistics Annual Data (NOPSAD) collection and the 
National Prisoner Health Data collection. 
For more information about these other sources of data, the data quality statements for the 
data sources and the methods used in this report, see the appendixes. 
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Data on agencies 
The AODTS NMDS contains information on publicly funded alcohol and other drug 
treatment services. Agencies are excluded from the AODTS NMDS if they: 
• do not receive any public funding 
• provide accommodation as their main function (including half-way houses and 
sobering-up shelters) 
• are located in prisons or detention centres 
• are located in acute care or psychiatric hospitals and provide treatment only to admitted 
patients 
• have the sole function of prescribing or providing dosing for opioid pharmacotherapy 
(these agencies are excluded because of the multi-faced nature of service delivery in this 
sector). 
Australian Government-funded primary health care services and substance-use services are 
in scope for the AODTS NMDS but most of these agencies do not contribute to the collection 
as they currently provide data to the Online Services Report (OSR) collection. To minimise 
reporting burden, agencies reporting to the OSR do not usually also report to the AODTS 
NMDS; however, there is some overlap. See Appendix B for further information. 
For each agency in the AODTS NMDS, data are collected on the geographical location of the 
agency. 
Data on treatment episodes 
The AODTS NMDS contains information on all treatment episodes provided by in-scope 
agencies where the episode was closed in the relevant financial year. A treatment episode is 
considered closed where any of the following occurs: 
• The treatment is completed or has ceased. 
• There has been no contact between the client and treatment provider for 3 months. 
• There is a change in the main treatment type, principal drug of concern or delivery 
setting. 
Treatment episodes are excluded from the AODTS NMDS if they: 
• are not closed in the relevant financial year 
• are for clients who are receiving pharmacotherapy and not receiving any other form of 
treatment that falls within the scope of the collection 
• include only activities relating to needle and syringe exchange 
• are for a client aged under 10. 
For each treatment episode in the AODTS NMDS, data are collected on: 
• the client: sex, date of birth, Indigenous status, country of birth, preferred language, 
source of referral and injecting drug status 
• whether the client is receiving treatment for their own drug use or someone else’s drug 
use 
• the drugs of concern (principal drug of concern and up to 5 additional drugs of concern)  
• the method of use for the principal drug of concern 
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• types of treatment (main treatment type and up to 4 additional treatment types) 
• the start and end dates of the episode and the reason the episode was closed. 
Data on drugs of concern 
‘Principal drug of concern’ refers to the main substance that the client stated led them to seek 
treatment from the alcohol and other drug treatment agency. In this report, only clients 
seeking treatment for their own substance use are included in analyses involving principal 
drug of concern because it is assumed that only substance users themselves can accurately 
report their own principal drug of concern. 
‘Additional drugs of concern’ refers to any other drugs reported by the client, in addition to 
the principal drug of concern. Clients can nominate up to 5 additional drugs of concern. 
‘All drugs of concern’ refers to all drugs reported by clients, including the principal drug of 
concern as well as any additional drugs of concern reported. 
Data on clients 
The AODTS NMDS does not contain a unique identifier for clients and information about 
clients is collected at the episode level. For the 2012–13 collection, a statistical linkage key 
(SLK) was introduced. While the SLK is not a unique identifier, it enables the number of 
clients receiving treatment to be counted while continuing to ensure the privacy of these 
individuals receiving treatment. 
Because SLK data are not available for all clients, an imputation strategy has been developed 
to adjust the data to account for this. Further information about the imputation methodology 
applied to these data can be found in Appendix C. 
Coverage and data quality 
It is difficult to fully quantify the scope of alcohol and other drug services in Australia, in 
particular the number of clients, as, until recently, the national collection has been based on 
counts of treatment episodes. In addition, there are a variety of settings in which people 
receive treatment for alcohol or other drug-related issues that are not in scope for this 
collection, such as in hospital, from general practitioners or in pharmacies (where a large 
proportion of opioid pharmacotherapy treatment is provided).  
Over 90% of in-scope agencies submitted data to the AODTS NMDS (Table 3.1) in all 
jurisdictions, except New South Wales (approximately 80%). Overall, there was an increase 
of 1 percentage point since 2011–12 in the number of in-scope agencies that reported to the 
collection. However, there was a decrease in the number of in-scope agencies reporting for 
New South Wales (6 percentage points) and Victoria (4 percentage points).  
Several factors can contribute to changes in the number of agencies reporting between years. 
As well as changes in the actual numbers of agencies, some jurisdictions may change data 
collection approaches, for example, moving from collecting data at an administrative or 
management level to a service outlet level. 
Data are affected by variations in service structures and collection practices between states 
and territories and care should be taken when making comparisons between them. Also, the 
AODTS NMDS has been implemented in stages, so comparisons across years, particularly 
the earlier years of the collection, need to be made with caution.  
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The AODTS NMDS reports on both main and additional treatment types. However, Victoria, 
Western Australia and Tasmania do not differentiate between main and other treatment 
types. Caution should be used in comparing episodes from these states with those of other 
states and territories. Despite variations in reporting practices between jurisdictions, there is 
very little difference between the proportions for principal drug of concern and all drugs of 
concern when these 3 jurisdictions are excluded from analysis. For example, the top 4 drugs 
of concern retain their size and their order. 
Further information on coverage and data quality is available in Chapter 4 and in the Data 
Quality Statement for the AODTS NMDS in Appendix A.  
1.5 Report structure 
This report contains the following chapters: 
• Chapter 1: About the collection—(this chapter) introduces the report; provides a 
background to the alcohol and other drug sector in Australia; and outlines the data and 
methods used. 
• Chapter 2: Overview—provides an overview of results from the AODTS NMDS for 
2012–13. 
• Chapter 3: Treatment agencies—presents data on alcohol and other drug treatment 
agencies and episodes closed in the financial year. 
• Chapter 4: Clients—provides information on client characteristics. 
• Chapter 5: Treatment episodes for own drug use—provides information on the 
characteristics of the episodes closed in the financial year for clients receiving treatment 
for their own drug use, including drugs of concern and treatment types. 
• Chapter 6: Treatment episodes for someone else’s drug use— provides information on 
the characteristics of the episodes closed in the financial year for clients receiving 
treatment for someone else’s drug use, including treatment types. 
• Chapter 7: State and territory comparisons—compares key information across each state 
and territory.  
• Chapter 8: Other data sources—summarises information from other data sources. 
Four appendixes accompany this report: 
• Appendix A—Data quality statement for the AODTS NMDS 
• Appendix B—Information about the data and methods  
• Appendix C—Imputation methodology for AODTS clients. 
• Appendix D—State and territory summaries (online) 
Supplementary tables referred to in this report (tables with ‘S’ as a prefix) can be 
downloaded from <http://www.aihw.gov.au/publications/>. Past reports in this series are 
also available for downloading. 
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2 Overview 
The Australian Government and state and territory governments fund a range of alcohol and 
other drug treatment services provided by non-government and government organisations. 
Services are delivered in residential and non-residential settings and include treatment such 
as detoxification and rehabilitation programs, information and education courses, 
counselling and pharmacotherapy. 
The AODTS NMDS contains information on a subset of publicly funded alcohol and other 
drug treatment agencies. These agencies provide services to people for their own drug use 
and those seeking assistance for someone else’s drug use. Alcohol and other drug treatment 
varies considerably depending on the demographic features of clients, the drug of concern, 
the nature of treatment provided, the type of agencies involved and the location at which 
treatment is provided. In contrast to later chapters, which focus on more detailed 
information, this chapter gives an overview of results from the AODTS NMDS for 2012–13. 
2.1 Agencies 
A total of 714 publicly funded alcohol and other drug treatment agencies reported to the 
AODTS NMDS in 2012–13. The number of reporting agencies increased from 622 in 2003–04. 
Over half (56%) of treatment agencies were non-government, and these agencies provided 
almost two-thirds (63%) of episodes closed in 2012–13. Nationally, 55% of treatment agencies 
were in Major cities, while 23% of agencies were in Inner regional areas (Figure 3.3). Relatively 
few agencies were in Remote or Very remote areas. 
2.2 Clients  
While the AODTS NMDS is based on information about treatment episodes, the inclusion of 
a statistical linkage key in the 2012–13 data collection enabled the number of clients to be 
estimated for the first time (for more detail see Chapter 4).  
In 2012–13, there were 108,910 individual clients estimated to have received treatment 
(Figure 2.1). About 2 in 3 clients were male (68%) and about 1 in 7 clients were Aboriginal 
and Torres Strait Islander people (14%). These proportions were similar for clients receiving 
treatment for their own drug use, who comprised 96% of total clients (Figure 2.2 and tables 
S4.2 and S4.4). Clients seeking treatment for someone else’s drug use were more likely to be 
female (64%) and less likely to report as being Indigenous (7%) when compared with the 
client group as a whole. 
Clients aged 20–39 represented over half (55%) of all clients; this is strongly influenced by the 
large proportion of clients seeking treatment for their own drug use where 57% of clients 
were aged 20–39 (Figure 4.1). Clients seeking treatment for someone else’s drug use tended 
to be older, with more clients aged 40–59 (42%) than 20–39 (30%). For less than 1% of clients, 
treatment was received for both their own drug use and for someone else’s drug use within 
the 2012–13 collection period. 
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Clients receiving treatment in 2012–13
108,910
Male
(68%)
Female
(32%)
Indigenous
(14%)
Non-Indigenous
(79%)
Indigenous
(15%)
Non-Indigenous
(79%)
 
Notes:  
1. Total includes episodes for people of unknown age and Indigenous status. 
2. Percentages are based on the total number of clients so may not add to the total 
due to episodes for people of unknown age and Indigenous status. 
Source: Table S4.5. 
Figure 2.1: Estimated number of clients receiving alcohol 
and other drug treatment services, 2012–13  
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2.3 Episodes 
Information on clients and treatment agencies is included in the AODTS NMDS when an 
episode of treatment provided to a client is closed. In 2012–13, alcohol and other drug 
treatment agencies provided a total of 162,362 closed treatment episodes (Figure 2.2), an 
increase of 6% from 2011–12.  
Clients receiving treatment for their own drug use
155,151 (96%)
Clients receiving treatment for someone else’s drug use
7,211 (4%)
Treatment episodes closed in 2012–13
162,362
Male
105,713 (68%)
Female
49,330 (32%)
Indigenous
14,271 (13%)
Non-Indigenous
84,904 (80%)
Indigenous
7,921 (16%)
Non-Indigenous
38,862 (79%)
Male
2,666 (37%)
Female
4,536 (63%)
Indigenous
255 (10%)
Non-Indigenous
2,208 (83%)
Indigenous
291 (6%)
Non-Indigenous
3,943 (87%)
 
Source: Table S2.7. 
Figure 2.2: Alcohol and other drug treatment services, client characteristics, 2012–13 
Demographic patterns relating to treatment episodes—including for age, sex and Indigenous 
status—are generally consistent with those found for individual clients. 
A large majority of treatment episodes provided in 2012–13 (96%) were provided to clients 
receiving treatment for their own drug use. Of these, around 2 in 3 episodes (68%) were 
provided to male clients. The reverse was found among clients receiving treatment for 
someone else’s drug use, where about 2 in 3 episodes (63%) were provided to female clients.  
More than half (55%) of closed episodes were for clients aged 20–39. This is strongly 
influenced by episodes where clients received treatment for their own drug use, where 56% 
of episodes were for those aged 20–39. For episodes involving clients seeking treatment for 
someone else’s drug use, clients tended to be older. Half (51%) of these episodes were 
provided to clients 40 and over compared with less than one-third (31%) of episodes for 
clients receiving treatment for their own drug use. (Table S6.9). 
The age profile of people using services suggests that there is an ageing cohort of people in 
alcohol and other drug treatment. Over the 5 years to 2012–13, the percentage of people 
being treated who were aged 20–29 fell from 31% to 27% while the percentage for those aged 
40 and over rose from 29% to 32%. The percentages for those aged 10–19 and 30–39 remained 
steady (Figure 2.3).  
There was an overall increase over the 10 years from 2003–04 to 2012–13 for the number of 
episodes closed in the financial year, from 136,869 to 162,362 (Table S2.2). The number of 
episodes closed in 2012–13 increased from 2011–12 (up 6% from 153,668).  
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Source: Table S2.8.  
Figure 2.3: Closed episodes provided by alcohol and other drug treatment services, by age group, 
2008–09 to 2012–13 
Nationally, 69% of episodes closed in 2012–13 were in Major cities, while 18% of episodes 
closed were in Inner regional areas (Figure 2.4). Relatively few episodes were in Remote or 
Very remote areas. This general pattern was found across most states and territories 
(Table S3.3). 
 
Source: Table S3.3. 
Figure 2.4: Closed episodes by remoteness of agency, 2012–13 
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Drugs of concern 
This section focuses on the drugs of concern reported by clients of alcohol and other drug 
treatment services. This includes the main drug that led them to seek treatment, called the 
‘principal drug of concern’ and additional drugs reported to be of concern to the client. 
The most common principal drugs of concern were alcohol (41%), cannabis (24%), 
amphetamines (14%) and heroin (8%) (Figure 2.5). In 3 of every 5 (63%) closed episodes, the 
client reported drugs of concern in addition to their principal drug of concern (Table S5.4). 
Almost one-third (31%) had 1 additional drug and 17% had 2, while 2% had 5 additional 
drugs. When both principal and additional drugs are considered, alcohol was the most 
common drug (59%), followed by cannabis (46%), amphetamines (28%), nicotine (24%) and 
heroin (12%) (Figure 2.5).  
 
Source: Table S5.6.  
Figure 2.5: Closed episodes for own drug use, by principal drug of concern and additional drugs of 
concern, 2012–13 
Nicotine was the principal drug of concern in just 2% of episodes, but it was the most 
common additional drug along with cannabis (both 23%) (Figure 2.6). The low proportion of 
episodes with nicotine as a principal drug is likely due to the ability of people with nicotine 
dependence to access support and treatment from other services including pharmacies and 
general practitioners. 
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Additional
Other stimulants and hallucinogens
Cocaine
Ecstasy (MDMA)
Benzodiazepines
Buprenorphine
Codeine
Other opioids
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Other analgesics
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Principal drug
63,755 (41%)
No additional drugs of concern
28,229 (44% of episodes with alcohol as principal)
Additional drugs of concern
Cannabis (34%)
Nicotine (30%)
Amphetamines (14%)
Benzodiazepines (6%)
Heroin (3%)
Principal drug
36,560 (24%)
No additional drugs of concern
13,084 (36%)
Additional drugs of concern
Alcohol (34%)
Nicotine (24%)
Amphetamines (20%)
Benzodiazepines (4%)
Ecstasy (4%)
Principal
22,265 (14%)
No additional drugs of concern
 5,857 (26%)
Additional drugs of concern
Cannabis (30%)
Alcohol (23%)
Nicotine (18%)
Benzodiazepines (6%)
Heroin (5%)
Ecstasy (5%)
Principal
2,574 (2%)
Principal
2,377 (2%)
No additional drugs of concern
603 (25%)
Additional drugs of concern
Alcohol (18%)
Cannabis (18%)
Nicotine (14%)
Amphetamines (13%)
Heroin (8%)
Alcohol
91,091 (59% of 
episodes) Additional drug
27,336 (18%)
Cannabis
71,916 (46%)
Additional drug
35,356 (23%)
Amphetamines
44,028 (28%)
Additional
21,763 (14%)
Nicotine
37,913 (24%)
Principal
12,817 (8%)
No additional drugs of concern
3,332 (26%)
Additional drugs of concern
Cannabis (22%)
Amphetamines (18%)
Nicotine (15%)
Alcohol (14%)
Benzodiazepines (12%)
Heroin
18,995 (12%)
Additional
35,339 (23%)
Additional
6,178 (4%)
Benzodiazepines
13,236 (9%)
Additional
10,859 (7%)
No additional drugs of concern
975 (38%)
Additional drugs of concern
Cannabis (32%)
Alcohol (26%)
Amphetamines (15%)
Other stimulants and hallucinogens (11%)
Ecstasy (6%)
 
Note: Totals may not add due to rounding. 
Sources: Tables S5.4, S5.5 and S5.6.  
Figure 2.6: Closed episodes for own drug use, by principal drug of concern and additional drugs of 
concern, 2012–13  
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Treatment  
This section focuses on the types of treatment provided to the client. ‘Main treatment type’ 
refers to the principal activity, as judged by the provider, necessary for the completion of the 
treatment plan for the principal drug of concern. Agencies are asked to provide the main 
treatment type for each episode. One main treatment type is reported for each episode and 
additional treatment types are recorded as appropriate. Up to 4 are recorded in the AODTS 
NMDS.  
Some types of treatment are only available to clients receiving treatment for their own drug 
use (withdrawal management, rehabilitation and pharmacotherapy), while others are only 
main treatment types, not additional (assessment only, support and case management only 
and information and education only). ‘Pharmacotherapy’ refers to episodes where 
pharmacotherapy was the main treatment and at least 1 additional treatment was provided, 
or where it was an additional type of treatment (see Chapter 1 for details). 
Unlike other states and territories, Victoria, Western Australia and Tasmania do not supply 
data on additional treatment types. Instead, each type of treatment (main or additional) 
results in a separate episode. Nationally, this results in an underestimate of the number of 
episodes with additional treatment types and an overestimate of episodes per client 
nationally, and in those jurisdictions.  
Over the 10 years from 2003–04 to 2012–13, the proportion of episodes for each main 
treatment type has remained quite stable, with counselling, withdrawal management and 
assessment only being the most common types of treatment over that period (Figure 2.7). 
Counselling continues to be the most common main treatment type provided, comprising 
about 2 in every 5 episodes since 2003–04. In 2012–13, assessment only overtook withdrawal 
management as the second most common main treatment type for the first time since  
2003–04. This has been influenced in part by the inclusion of the South Australian Police, 
Drug Diversion Assessment Program data in the collection, which has seen an increase in 
episodes with a main treatment type of assessment only. 
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Source: Table S6.3. 
Figure 2.7: Closed episodes provided by alcohol and other drug treatment services, by main 
treatment type, 2003–04 to 2012–13 
When both main and additional types of treatment are considered, counselling was the most 
common type of treatment (46% of episodes), followed by assessment only (17%), 
withdrawal management (which is only possible for clients receiving treatment for their own 
drug use) (16%) and support and case management only (9%) (Figure 2.8). These types of 
treatments were also the most common main treatment types: counselling (42%), assessment 
only (17%), withdrawal management (16%) and support and case management only (9%) 
(note that assessment, support and case management, and information and education are 
available only as main treatments).  
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Note: Victoria, Western Australia and Tasmania do not supply data on additional treatment types. Instead, each type of treatment (main or 
additional) results in a separate episode. 
Source: Table S6.6. 
Figure 2.8: Closed episodes provided by alcohol and other drug treatment services, by treatment 
type, 2012–13  
Of the treatment types that were available both to clients receiving treatment for their own 
drug use and to those receiving treatment for someone else’s drug use, most episodes were 
for clients receiving treatment for their own drug use; this ranged from 92% for information 
and education only to 99% for assessment only (Figure 2.9).  
Counselling was the most common main treatment type both for clients receiving treatment 
for their own drug use and for those receiving treatment for someone else’s. Clients receiving 
treatment for someone else’s drug use were more likely to receive counselling as a main 
treatment (68% of closed episodes compared with 41% for own use) (Table S6.1). 
Other than counselling, clients receiving treatment for their own drug use were more likely 
to have assessment only as a main treatment (18% of closed episodes compared with 5% for 
clients receiving treatment for someone else’s use). Information and education only was 
more common for clients receiving treatment for someone else’s drug use (14% of closed 
episodes compared with 8% for clients receiving treatment for their own use) (Table S6.1). 
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Counselling
75,490 (46%)
Main treatment
68,570 (91%)
Additional treatment
6,920 (9%)
Withdrawal management
26,243 (16%)
Additional treatment
819 (3%)
Main treatment
25,424 (97%)
Assessment only
27,524 (17%)
Main treatment
27,524 (100%)
Support and case management only
15,013 (9%)
Main treatment
15,013 (100%)
Rehabilitation
8,837 (5%)
Additional treatment
848 (10%)
Main treatment
7,989 (90%)
Other treatment
6,836 (4%)
Additional treatment
4,306 (63%)
Main treatment
2,530 (37%)
Information and education only
13,464 (8%)
Main treatment
13,464 (100%)
Pharmacotherapy (with at least 1 
additional treatment)
4,242 (3%)
Additional treatment
2,394 (56%)
Main treatment
1,848 (44%)
Clients receiving treatment for their own drug use
63,691 (93%)
Clients receiving treatment for someone else’s drug use
4,879 (7%)
Clients receiving treatment for their own drug use
25,424 (100%)
Clients receiving treatment for their own drug use
27,157 (99%)
Clients receiving treatment for someone else’s drug use
367 (1%)
Clients receiving treatment for their own drug use
14,254 (95%)
Clients receiving treatment for someone else’s drug use
768 (5%)
Clients receiving treatment for their own drug use
2,356 (93%)
Clients receiving treatment for someone else’s drug use
174 (7%)
Clients receiving treatment for their own drug use
7,989 (100%)
Clients receiving treatment for their own drug use
12,441 (92%)
Clients receiving treatment for someone else’s drug use
1,023 (8%)
Clients receiving treatment for their own drug use
1,848 (100%)
 
Source: Table S6.1. 
Figure 2.9: Summary treatment characteristics (main and additional) of closed episodes, 2012–13 
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Counselling 
Counselling was a treatment type for 46% of the episodes closed in 2012–13; it was the main 
treatment type in 42% of episodes and an additional treatment type in 4% (Table S6.1). Most 
(93%) of the episodes with counselling as the main treatment type were provided to clients 
for their own drug use. Counselling was the most common main treatment type both for 
clients receiving treatment for their own drug use, and those receiving treatment for 
someone else’s. Counselling was the main treatment for 4 in 10 (41%) episodes provided to 
clients receiving treatment for their own drug use; it was the main treatment for 7 in 10 (68%) 
episodes where clients were receiving treatment for someone else’s drug use (Table S6.1). 
Withdrawal management 
Withdrawal management is only provided in episodes for clients receiving treatment for 
their own drug use. Withdrawal management was a treatment type for 16% of episodes 
closed in 2012–13. It was the main treatment type in 16% of episodes and an additional 
treatment type in 1% (Table S6.1).  
Assessment only 
Assessment only was the main type of treatment for 17% of episodes closed in 2012–13 (it is 
not available as an additional treatment type) (Figure 2.9). Nearly all (99%) of the closed 
episodes where assessment only was a main treatment type were provided to clients for their 
own drug use (Figure 2.9). Assessment only was the second most common main treatment 
type for clients receiving treatment for their own drug use, accounting for nearly one-fifth 
(18%) of closed episodes (Table S6.6). It was far less popular as a main treatment type for 
clients receiving treatment for someone else’s drug use, accounting for only one-twentieth 
(5%) of those episodes. 
Support and case management only 
Support and case management only was the main treatment type for 9% of episodes closed 
in 2012–13 (it is not available as an additional treatment type) (Figure 2.9). Nearly all (95%) of 
these episodes were provided to clients for their own drug use (Figure 2.9). This may be 
because clinicians view this treatment type as most appropriate for clients seeking treatment 
for their own alcohol and drug issues. Support and case management only accounted for a 
similar proportion of closed episodes for both clients receiving treatment for their own or 
someone else’s drug use (9% and 11%, respectively) (Table S6.1). 
Rehabilitation 
Rehabilitation is only provided in episodes for clients receiving treatment for their own drug 
use. Rehabilitation was the main type of treatment in 5% of episodes and an additional 
treatment type in 1% (Table S6.1). 
Information and education only 
Information and education only was the main treatment type for 8% of the episodes closed in 
2012–13 (it is not available as an additional treatment type) (Figure 2.9). Nearly all (92%) of 
these episodes were provided to clients receiving treatment for their own drug use 
(Figure 2.9). Clients receiving treatment for someone else’s drug use were more likely to 
have information and education only as a main treatment type (14% of closed episodes 
compared with 8% for client’s own drug use) (Table S6.1). 
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Pharmacotherapy 
Pharmacotherapy was the treatment type (main or additional) for 3% of the episodes closed 
in 2012–13 (it is only reported if there is at least 1 other treatment type provided) (Figure 2.9). 
Of these, it was the main treatment type in 44% of episodes and an additional treatment type 
in 56% (Figure 2.9). Pharmacotherapy is only available to clients receiving treatment for their 
own drug use.  
Other treatment 
Other treatment refers to treatment types such as nicotine replacement therapy or outdoor 
therapy. Nationally in 2012–13, ‘other’ was the treatment type (main or additional) for 4% of 
episodes. Of these, it was the main treatment type in 37% of episodes and an additional 
treatment type in 63% (Figure 2.9). Nearly all (93%) were provided to clients receiving 
treatment for their own drug use. 
Referral source 
‘Referral source’ is the avenue through which clients are referred to drug treatment services. 
Nationally, the most common source of referral in 2012–13 was self or family (42%), followed 
by referral from a health service (24%) (Table S2.13). Referrals from police or court diversion 
programs accounted for 17% of episodes (these programs divert people with minor drug 
offences from the criminal justice system) (Table S2.13). Clients referred by diversion 
programs tended to be younger; 24% of these episodes were for clients aged 10–19 and 36% 
were for clients aged 20–29, compared with 13% and 27%, respectively, for all episodes 
(Table S6.16). In 1 in 11 (9%) episodes, the client was referred by a correctional service.  
Self or family was the most common source of referral both for clients receiving treatment for 
their own drug use and for those receiving treatment for someone else’s drug use (40% and 
50% respectively). Health services were also a common source of referral for clients receiving 
treatment for their own drug use and for those receiving treatment for someone else’s use 
(27% and 14% respectively); however, people receiving treatment for their own drug use 
were more likely to be referred by police or court diversion than clients receiving treatment 
for someone else’s drug use (15% compared to 9%) (Figure 2.10 and Table S2.13).  
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Note: ‘Other’ includes persons referred under a legislative act (other than the Drug Diversion Act), or persons referred to treatment through 
community services, government departments, remand or prison, education (through teachers and schools), and the Australian Community 
Service Organisation/Community Offenders Advice and Treatment Service. 
Source: Table S2.13. 
Figure 2.10: Closed episodes provided by alcohol and other drug treatment services, by referral 
source and client type, 2012–13 
Over the 10 years from 2003–04, the proportion of episodes where the client was referred by 
a diversion program increased from 8% to 17% with a peak of 18% in 2009–10, while the 
proportion of episodes with a referral source of self or family decreased from 46% to 42% 
with a low of 38% in 2009–10 (Figure 2.11). There was also a decline in referrals from a health 
service, from 28% to 24% for the same period. There was little change in the other sources of 
referral.  
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Source: Table S2.13. 
Figure 2.11: Closed episodes provided by alcohol and other drug treatment services, by referral 
source, 2003–04 to 2012–13 
Length of treatment episodes 
Four in 5 (80%) closed episodes ended within 3 months. Of these, more than one-quarter 
(27%) ended within 1 day, almost 3 in 10 (28%) between 2 days and 1 month, and 
one-quarter (25%) between 1 and 3 months (Figure 2.12). Only 8% of episodes lasted 
6 months or longer.  
Over time, the proportion of episodes that ended within 3 months remained at around  
82–83% from 2003–04 to 2008–09, but decreased slightly in more recent years to 80% (with a 
low of 78% in 2011–12) (Table S2.20). 
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Source: Table S2.19. 
Figure 2.12: Closed episodes provided by alcohol and other drug treatment services, by duration, 
2012–13  
Nationally, the median duration of episodes closed in 2012–13 was just over 3 weeks 
(22 days) (Figure 2.13). The median duration of closed episodes gradually increased from 
17 days in 2003–04 to 23 days in 2009–10 and 2010–11, peaking at 26 days in 2011–12 before 
falling to 22 days in 2012–13 (Figure 2.13). This trend is strongly influenced by data quality 
improvements (see Appendix A for further information). 
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Source: Table S2.22.  
Figure 2.13: Closed episodes provided by alcohol and other drug treatment services, by median 
duration, 2008–09 to 2012–13 
Reason for cessation 
The AODTS NMDS does not contain an indicator of treatment outcomes; however reasons 
for cessation can provide some insight into the client situation at the end of treatment. It is 
possible to group cessation reasons into broader categories for this purpose. These can be 
defined as ‘expected’ cessations, ‘unexpected’ cessations and ‘administrative’ cessations, 
where there was a change in the treatment.  
In 2012–13, around 2 in 3 closed treatment episodes (63%) had an expected cessation. 
Unexpected cessations accounted for about 1 in 5 (20%) closed episodes and about 1 in 20 
treatment episodes (6%) were administrative cessations (Table 2.16).  
Over the 5 years from 2008–09, the proportion of episodes with an expected cessation has 
decreased slightly, from 66% to 63% with a high of 68% in 2009–10 and 2010–11. There was 
very little change to the proportion of episodes in the unexpected category, remaining 
around 20%, and no change for episodes ending due to an administrative cessation (6% over 
the same period) (Table S2.16). 
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Table 2.1: Reason for cessation grouped by indicative outcome type, 2012–13 
Expected cessation 
(63%) 
Unexpected cessation 
(20%) 
Administrative cessation 
(6%) 
Other 
(10%) 
Reasons reported: 
• treatment completed 
• legally mandated 
treatment expiated(a) 
• ceased to participate by 
mutual agreement 
Reasons reported: 
• ceased to participate 
against advice 
• ceased to participate 
without notice 
• ceased to participate 
involuntarily 
(non-compliance) 
Reasons reported: 
• change in treatment type 
• change in delivery setting 
• change in principal drug 
of concern 
• transferred to another 
service provider 
Reasons reported: 
• sanctioned into jail by 
court diversion service 
• imprisoned, other than 
drug court sanctioned 
• died 
• other 
• not stated 
(a) This category is reported as ‘ceased to participate at expiation’. This is an expected cessation in the sense that legally mandated treatment 
is completed. It is not possible to exclude episodes reported as ‘ceased to participate at expiation’ where clients finished enough treatment 
to expiate their offence but did not return for further treatment as expected. 
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3 Treatment agencies 
This chapter provides information on the alcohol and other drug treatment agencies that 
provided data to the AODTS NMDS and the number of treatment episodes that were closed 
in the financial year 2012–13.  
3.1 Number of agencies 
There were 714 publicly funded alcohol and other drug treatment agencies in 2012–13 
(Figure 3.1). The number of agencies ranged from 10 in the Australian Capital Territory up to 
245 in New South Wales. 
  
Source: Table S3.1.  
Figure 3.1: Publicly funded alcohol and other drug treatment agencies, by states and territories, 
2012–13 
Over the 10 years from 2003–04 to 2012–13, the number of agencies supplying data to the 
AODTS NMDS increased in most states and territories, the largest increases being in Western 
Australia (from 34 to 68 agencies) and South Australia (from 53 to 93) (Table S3.1). The 
number was unchanged in the Northern Territory, and fell in both Victoria (from 143 to 129 
agencies) and New South Wales (from 259 to 245 agencies).  
In 2012–13 there was an 8% increase in the number agencies nationally. Queensland and 
South Australia had a substantial increase in the number of agencies (from 97 to 133, and 56 
to 93 agencies, respectively), while the number of agencies decreased in New South Wales 
and Victoria.  
The number of agencies reporting to the NMDS increased from 659 in 2011–12 to 714 in 
2012–13. Jurisdictions were asked to provide information on the coverage of in-scope 
agencies. According to the information supplied, between 80–100% of in-scope agencies 
within jurisdictions submitted data to the collection (Table 3.1). Overall, there was an 
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increase of 1% in the number of in-scope agencies that reported to the collection. However, 
there was a decrease in the number of in-scope agencies reporting for New South Wales 
(6%), and Victoria (4%). 
Table 3.1: In-scope agencies, AODTS NMDS 2011–12 and 2012–13 
 2011–12  2012–13   
 
Agencies 
that 
submitted 
data 
Agencies 
in-scope 
% that 
submitted 
data 
 
Agencies 
that 
submitted 
data 
Agencies 
in-scope 
% that 
submitted 
data 
 
Percentage 
points 
difference 
NSW 261 306 85.3 
 
242 304 79.6 
 
–5.7 
Vic 136 139 97.8 
 
129 137 94.1 
 
–3.7 
Qld 83 84 99.0 
 
*121 125 96.8  –2.2 
WA 56 56 100.0 
 
*64 64 100.0 
 
0.0 
SA 47 52 90.4 
 
*85 88 96.5 
 
6.1 
Tas 16 16 100.0 
 
16 16 100.0 
 
0.0 
ACT 9 11 81.8 
 
*10 11 90.9 
 
9.1 
NT 19 19 100.0 
 
19 19 100.0 
 
0.0 
DoH 32 39 82.1 
 
28 28 100.0 
 
17.9 
Total 659 722 89.1 
 
714 792 90.1 
 
1.0 
* Denotes increase in agency numbers for 2012-13. 
Note: Some agencies that are in scope for DoH submitted data via their state health authorities (not directly to AIHW). These counts are included 
in the relevant state scope rather than the DoH scope (see Appendix 1). 
Several factors can contribute to change in the number of agencies reporting between years. 
As well as changes in the actual numbers of agencies, some jurisdictions may change data 
collection approaches, for example, moving from collecting data at an 
administrative/management level to a service outlet level (see Appendix A for more details). 
3.2 Service sector: government and 
non-government 
While all agencies supplying data to the AODTS NMDS are publicly funded, some are 
government agencies and others are non-government. Government agencies are those that 
operate from the public accounts of the Australian Government or a state or territory 
government; are part of the general government sector; and are financed mainly from 
taxation. Non-government agencies receive some government funding but are not controlled 
by the government; are directed by a group of officers or an executive committee; and may 
be an income tax exempt charity. Nationally, over half (56%) of treatment agencies were 
non-government, and these agencies provided almost two-thirds (63%) of episodes closed in 
2012–13 (Table 3.2).  
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Table 3.2: Publicly funded alcohol and other drug treatment agencies and closed episodes, by 
service sector, states and territories, 2012–13 
Service sector NSW Vic Qld WA SA Tas ACT NT Aust 
 
Treatment agencies 
Government 186 0 56 14 48 7 1 5 317 
Non-government 59 129 77 54 45 10 9 14 397 
Total 245 129 133 68 93 17 10 19 714 
 
Closed episodes 
Government  26,197 0 18,923 2,475 6,566 1,570 2,383 1,177 59,291 
Non-government 9,105 54,184 11,641 18,139 4,757 768 2,033 2,444 103,071 
Total 35,302 54,184 30,564 20,614 11,323 2,338 4,416 3,621 162,362 
Note: Western Australia has a number of integrated services that include both government and non-government providers. These agencies are 
predominantly reported as ‘government providers’. 
Source: AIHW analysis of the Alcohol and Other Drug Treatment Services NMDS 2012–13. 
The majority of agencies in most states and territories were non-government, although this 
was not the case for New South Wales (24%) or South Australia (48%). In the remaining 
states and territories, the percentage that was non-government ranged from 58% in 
Queensland to 100% in Victoria (Table 3.1).  
The proportion of non-government agencies has increased slightly since 2003–04 (Figure 3.2). 
  
Note: Interpretation of trends prior to 2009–10 should be interpreted with caution: 
1. Sector reporting of agencies funded under the Non-Government Organisation Treatment Grants Program (NGOTGP) has varied over time 
but has been consistent since 2007–08.  
2. From 2007–08 onwards, growth in integrated services that include both government and non-government agencies in Western Australia 
was reported. These agencies were predominantly reported as ‘government providers’. 
Source: Table S3.1. 
Figure 3.2: Publicly funded alcohol and other drug treatment agencies by service sector, 2003–04 to 
2012–13 
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3.3 Remoteness 
Nationally, 55% of treatment agencies in 2012–13 were in Major cities, while 23% of agencies 
were in Inner regional areas (Figure 3.3). Relatively few agencies were in Remote or Very remote 
areas. This general pattern was found across most states and territories (note that not all 
remoteness areas occur in all states and territories) (Table S3.4). 
There has been a change in methodology used for previous reports and therefore remoteness 
data are not comparable to earlier data on remoteness from this collection. See Appendix B 
for further information. 
 
Source: Table S3.3. 
Figure 3.3: Publicly funded alcohol and other drug treatment agencies by remoteness area, 2012–13 
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4 Clients 
From the inception of this collection in the late 1990s, data have been collected only about 
treatment episodes provided by alcohol and other drug treatment services. Data about the 
clients those episodes relate to have not been available at a national level. 
An SLK was introduced into the AODTS NMDS for the 2012–13 collection to enable the 
number of clients receiving treatment to be counted while continuing to ensure the privacy 
of these individuals receiving treatment. Developing client-based analyses for reporting on alcohol 
and other drug treatment services (AIHW 2013a) documented methods for generating distinct 
client counts and explored possible client-based analyses.  
That report determined that the number of clients should be estimated initially by using a 
simple deterministic method, due to anticipated levels of data quality and completeness. As 
data with unique client counts accumulate over time, more complex analyses on patterns of 
drug use and pathways through treatment will be possible. 
4.1 Client counts and data quality 
An SLK was reported for the vast majority (88%) of episodes in 2012–13. There are a number 
of records that had missing or invalid SLK data, which cannot be attributed to a client. This 
could lead to an underestimate of the total number of clients using the services, as some (but 
not all) of the records will belong to clients who are not observed via a valid SLK. Nationally, 
the proportion of episodes with a valid SLK was 88%, ranging from 67% in New South Wales 
to nearly 100% in Tasmania (Table 4.1). An imputation strategy for the collection was 
developed to correct for the impact of invalid or missing SLKs on the total number of clients. 
This strategy takes into account a number of factors relating to the number of episodes per 
client and makes assumptions relating to spread across agencies. It also takes into 
consideration the likelihood that a client with an episode missing and SLK has already been 
counted. See Appendix C for more information on the imputation strategy. 
Using the imputation strategy to adjust for non-response and data quality issues, it is 
estimated there were nearly 108,000 clients who received treatment in 2012–13. 
Table 4.1: Imputed numbers of distinct clients, by states and territories, 2012–13 
 NSW Vic Qld WA SA Tas ACT NT Aust 
Number of episodes 35,302 54,184 30,564 20,614 11,323 2,338 4,416 3,621 162,362 
Number of episodes with valid SLKs 23,482 53,340 25,214 19,539 11,007 2,327 4,331 3,377 142,617 
Percentage of episodes with valid SLKs (%) 66.5 98.4 82.5 94.8 97.2 99.5 98.1 93.3 87.8 
Number of episodes with invalid SLKs 11,820 844 5,350 1,075 316 11 85 244 19,745 
Number of distinct clients (from valid SLKs) 17,271 29,040 21,105 15,789 8,332 2,004 3,164 2,429 98,902 
Imputed number of distinct clients 23,084 29,319 24,772 16,502 8,522 2,012 3,212 2,562 108,910 
Clients received an average of 1.5 treatment episodes nationally. Comparing states and 
territories, Queensland, Western Australia and Tasmania had the lowest average episodes 
per client (1.2) and Victoria the highest (1.8). The rate of clients who received alcohol and 
other drug treatment nationally was 475 clients per 100,000 people in the general population, 
but this varied greatly between states and territories. New South Wales had the lowest rate 
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of clients (314 per 100,000 population), while the Northern Territory had the highest (1,082 
per 100,000 population), more than triple the rate of New South Wales (Table 4.2). 
Table 4.2: Clients, episodes and rates, by states and territories, 2012–13 
 
NSW Vic Qld WA SA Tas ACT NT Aust 
Number of episodes 35,302 54,184 30,564 20,614 11,323 2,338 4,416 3,621 162,362 
Number of clients 23,084 29,319 24,772 16,502 8,522 2,012 3,212 2,562 108,910 
Episodes per client 1.5 1.8 1.2 1.2 1.3 1.2 1.4 1.4 1.5 
Rate of episodes(a) (per 100,000 population) 480 954 663 834 681 456 1,163 1,529 709 
Rate of clients(a) (per 100,000 population) 314 516 537 667 513 393 846 1,082 475 
(a) Crude rate is based on the preliminary Australian estimated resident population as at 31 December 2012. 
4.2 Client characteristics 
This section looks at characteristics of clients and compares clients seeking treatment for 
their own drug use with those seeking treatment for another person, in 2012–13. All client 
percentages reported (such as for age, sex and Indigenous status) are based on episodes with 
valid SLK responses. This varied slightly for some jurisdictions, however. See Appendix 
Table C1 for details. 
There were about 104,000 clients receiving treatment for their own drug use and 5,300 
receiving treatment for someone else’s drug use (Table S4.2). For 1% of clients, treatment was 
received for their own drug use and for someone else’s drug use within the collection period. 
This indicates that there was very little overlap between these 2 client groups. 
Sex 
Among those clients receiving treatment for their own drug use, about 2 in 3 (69%) were 
male (Table 4.3). This equates to about 72,400 males who received treatment for their own 
drug use in 2012–13. The opposite was found among those receiving treatment for someone 
else’s drug use, with about 2 in 3 (64%, 3,300 clients) being female. The relatively small 
number of clients receiving treatment for someone else’s drug use meant that, overall, clients 
were more likely to be male (68%), with a total of 73,800 male clients estimated to be 
receiving treatment for their own or someone else’s drug use in 2012–13 (Table S4.2). 
Table 4.3: Clients, by sex and client type (%), 2012‒13 
 
Own drug use  
(%) 
Other’s drug use  
(%) 
All clients  
(%) 
Sex    
Male 69.4 36.3 67.8 
Female 30.6 63.7 32.1 
Total 100.0 100.0 100.0 
Note: Totals include people of unknown sex. 
Age 
Clients seeking treatment for their own drug use tended to be younger, on average, than 
clients seeking treatment for someone else’s drug use (Figure 4.1). Clients aged 20–39 
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represented over half (57%, 58,900 clients) of all clients seeking treatment for their own drug 
use, but only about one-third (30%, 1,600 clients) of all clients seeking treatment for someone 
else’s drug use (Table S4.3). Clients aged 40 and over, however, comprised nearly one-third 
(30%) of all clients receiving treatment for their own drug use, but comprised over half (56%) 
of all clients receiving treatment for someone else’s drug use. This equates to an estimated 
31,500 clients aged 40 and over receiving treatment for their own drug use, and 3,000 
receiving treatment for someone else’s drug use (Table S4.3).  
 
Source: Table S4.3. 
Figure 4.1: Clients, by age group and client type (%), 2012–13  
Indigenous status 
The proportion of clients reporting as Indigenous varied between client types. About 1 in 7 
(14%) clients receiving treatment for their own drug were Indigenous, whereas 7% of the 
clients receiving treatment for someone else’s drug use were Indigenous (Table 4.4). This 
equates to an estimated 15,000 clients reporting as Indigenous who received treatment for 
their own drug use, and 400 who received treatment for someone else’s use (Table S4.4). 
However as previously mentioned, Indigenous people are under-represented in the AODTS 
NMDS as most information on drug services specifically provided to Indigenous Australians 
(funded by the Australian Government) is included in other collections (see Section 8.2 and 
Appendix B). 
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Table 4.4: Clients, by Indigenous status and client type (%), 2012‒13 
 
Own drug use  
(%) 
Other’s drug use  
(%) 
All clients  
(%) 
Indigenous status    
Indigenous 14.4 7.2 14.1 
Non-Indigenous 78.7 86.5 79.1 
Not stated 6.8 6.3 6.8 
Total 100.0 100.0 100.0 
Country of birth and preferred language 
The majority (86%) of AODTS NMDS clients were born in Australia (Table S4.6). This 
percentage is higher than that found in the general population (70%) (ABS 2012a). 
Clients born in other countries were only a small proportion of all clients, with the United 
Kingdom and New Zealand (both 3%) being the next most common countries of birth 
(Table S4.6) after Australia. In comparison, in 2011, 5% of people in Australia were born in 
the United Kingdom and 2% in New Zealand (ABS 2012b). 
English was the most frequently reported preferred language (96% of all clients) (Table S4.7). 
Less than 1% of episodes involved clients who reported an Australian Indigenous language 
as their preferred language. 
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5 Treatment episodes for own drug use 
This chapter explores the treatment provided to clients receiving treatment for their own 
drug use and reports on closed treatment episodes. 
5.1 Demographics 
Nearly all (96%) of the episodes closed in 2012–13 were for people receiving treatment for 
their own drug use (Figure 2.12). Of these, more than two-thirds (68%) were for male clients, 
and this has remained relatively unchanged since 2003–04 (Table S2.4). Over half (56%) of 
episodes were provided to clients aged 20–39 (28% for both 20–29 and 30–39 year olds). One 
in 5 (20%) were for clients aged 40–49 and 1 in 8 (13%) were aged 10–19. Proportions were 
similar for males and females (Figure 5.1). There was little change in the proportion of 
episodes provided to clients of different age groups from 2003–04 to 2012–13 (Table S2.9).  
One in 7 (14%) closed episodes for people receiving treatment for their own drug use were 
for Indigenous clients. For both Indigenous and non-Indigenous client episodes, males were 
more likely to receive treatment for their own drug use (64% and 69% of closed episodes, 
respectively) (Table S2.7). However, many Indigenous clients receive treatment from 
Australian Government-funded agencies and data for these agencies are largely not included 
in this report. Data on the number of episodes of care provided by these Australian 
Government-funded agencies are available from the AIHW Online Services Report (OSR) 
Database. Data for 2012–13 is in Chapter 8 and Appendix B. 
 
Source: Table S2.10.  
Figure 5.1: Closed episodes provided for own drug use, by age group and sex, 2012–13  
Most (87%) of the episodes for the client’s own drug use were provided to clients whose 
country of birth was Australia (Table S2.11). A further 3% were born in the United Kingdom 
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and 2% were born in New Zealand. In almost all (97%) episodes, the client had a preferred 
language of English (Table S2.12).  
5.2 Drugs of concern 
Overview 
This section focuses on the drugs of concern for episodes reported by clients of alcohol and 
other drug treatment services. This includes the main drug that led them to seek treatment, 
called the ‘principal drug of concern’ and additional drugs reported to be of concern. 
Alcohol, cannabis, amphetamines and heroin have remained the most common principal 
drugs of concern since 2003–04 (Figure 5.2). Since 2009–10, the proportion of episodes where 
alcohol was the most common principal drug has decreased (from 48% to 41%), while the 
proportion of amphetamines has increased (from 7% to 14%). 
 
Source: Table S5.2.  
Figure 5.2: Closed episodes provided for own drug use, by selected principal drug of concern,  
2003–04 to 2012–13  
Drugs of concern varied considerably with age. People in older age groups were more likely 
to have sought treatment for alcohol than those in younger age groups. For people aged  
10–19, alcohol was the principal drug of concern in 23% of treatment episodes, while for 
those aged 60 and over it was the principal drug in 82% of episodes (Table S5.10).  
For people aged 60 and over, cannabis was the principal drug of concern in only 3% of 
episodes, while for people aged 10–19 it was the principal drug in 55% of episodes. 
The largest percentage of episodes provided to clients receiving treatment for alcohol as their 
principal drug of concern was for clients aged 30–39 years and 40–49 years (both 26%). For 
cannabis and amphetamines, the largest proportion of episodes was for clients aged 20–29 
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year (36% and 41%, respectively), while for heroin, the largest proportion was for those aged 
30–39 years (45%) (Figure 5.3) 
 
Source: Table S5.10.  
Figure 5.3: Closed episodes provided for own drug use, by selected principal drugs of concern and 
age group, 2012–13  
When looking at specific age groups, there may be other drugs that are more commonly 
treated. For example, for clients aged 10–19 and 60 and over, nicotine was in the top 4 most 
common principal drugs of concern (3% and 4% of episodes, respectively). For very young 
people (those aged 10–15) the pattern was different again. About 3% (5,293) of episodes 
provided for the client’s own drug use were provided to this age group, 30% of whom were 
Indigenous. Among 10–15 year olds, the top 4 most common principal drugs of concern were 
cannabis (52%), alcohol (29%), volatile solvents (8%) and nicotine (4%). 
Alcohol was the most common principal drug in all remoteness areas, ranging from 65% of 
episodes in Remote areas to 38% of episodes in Major cities (Figure 5.4).  
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Note: Heroin treatment is provided in Remote and Very remote areas, but the numbers are too small to appear in this figure. 
Source: Table S5.11.  
Figure 5.4: Closed episodes provided for own drug use, by selected principal drugs of concern and 
remoteness area of treatment agency, 2012–13 
Based on principal drug of concern, the majority of clients receiving treatment for alcohol 
(66%), heroin (67%), amphetamines (70%) or cannabis (72%) received treatment in a 
non-residential treatment facility (Figure 5.5). Residential treatment facilities were the second 
most common treatment setting for clients with alcohol (17%), heroin (18%) or 
amphetamines (15%) as their principal drugs, while outreach settings were the second most 
common for clients receiving treatment for cannabis (11%) as their principal drug. 
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Source: Table S5.12.  
Figure 5.5: Closed episodes provided for own drug use, by selected principal drugs of concern and 
treatment delivery setting, 2012–13 
Over the 5 years to 2012–13, clients receiving treatment for heroin or amphetamines as their 
principal drug of concern have tended to receive longer treatment episodes compared to 
those receiving treatment for alcohol or cannabis (Figure 5.6). In 2012–13, the median 
duration of episodes was 32 days for clients receiving treatment for heroin as their principal 
drug of concern. The median episode duration was 23 days where alcohol or amphetamines 
were the principal drugs of concern, and 15 days for cannabis. 
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Source: Table S5.2.  
Figure 5.6: Closed episodes provided for own drug use, by selected principal drugs of concern and 
median duration, 2008–09 to 2012–13 
Alcohol 
Alcohol is a central nervous system depressant that inhibits brain functions, dampens the 
motor and sensory centres and makes judgment, coordination and balance more difficult 
(NDARC 2010).  
According to the 2009 Australian guidelines to reduce health risks from drinking alcohol 
(NHMRC 2009), people who drink more than 2 standard drinks on any day have an 
increased lifetime risk of harm from alcohol-related disease or injury, while those who drink 
more than 4 standard drinks on a single occasion are at risk of harm from that occasion 
(AIHW 2014b). 
Results from the 2013 NDSHS (AIHW 2014b) showed: 
• About 78% of Australians aged 14 years and over drank alcohol in the previous 12 
months. 
• A significant proportion of the Australian population drank at risky levels—1 in 5 (17%) 
aged 14 years and over drank at a level that put them at risk of alcohol-related harm over 
their lifetime, while 1 in 4 (26%) drank at levels that put them at risk of harm from a 
single drinking occasion at least once in the previous 12 months. 
• Males are more likely than females to drink at levels that place them at risk of harm over 
their lifetime and on a single occasion. 
Alcohol was a drug of concern (principal or additional) in 59% of episodes closed in 2012–13 
and was the principal drug in 41% of episodes (Figure 2.6).  
In more than half (54%) of episodes with alcohol as the principal drug of concern, the client 
reported additional drugs of concern (Figure 2.6). This was most commonly cannabis (34%) 
or nicotine (30%).  
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Over the 5 years from 2008–09, the proportion of closed episodes where alcohol was the 
principal drug of concern decreased from 46% to 41%, with a high of 48% in 2009–10 
(Figure 5.7 and Table S5.2). 
 
Source: Table S5.2.  
Figure 5.7: Closed episodes provided for own drug use where alcohol was the principal drug of 
concern, 2008–09 to 2012–13  
Demographics 
When alcohol was the principal drug of concern, more than two-thirds of the episodes were 
for males (67%) and one-fifth were for Indigenous clients (21%) (Table S5.21).  
More than one-quarter (26%) of episodes with alcohol as a drug of concern were provided to 
clients aged 30–39, followed by those aged 20–29 (25%) and 40–49 (22%) (Table S5.19). Only 
4% of these episodes were provided to clients aged 60 or over. However, alcohol was more 
likely to be the principal drug of concern in episodes provided to older clients. For nearly all 
(96%) the episodes for clients aged 60 or over, alcohol was the principal drug. In contrast, 
less than half (44%) of the episodes where alcohol was a drug of concern for clients aged  
10–19 had alcohol as the principal drug.  
In almost two-thirds (64%) of episodes, the client reported they had never injected a drug 
(injecting status was not reported for 18% of episodes) (Table S5.9).  
Treatment 
The most common source of referral for clients where alcohol was the principal drug of 
concern was self or family (45%) followed by a health service (28%) (Table S5.13).  
The most common main treatment type was counselling (45%), followed by withdrawal 
management (19%) and assessment only (17%) (Table S5.24). Counselling was the most 
common main treatment type for all age groups (from 42% of episodes for those aged 10–19 
and 60 and over; to 48% for those aged 20–29), followed by withdrawal management for 
those aged 30–39 and over, while support and case management and assessment only were 
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the second most common types of main treatment for those aged 10–19 and 20–29, 
respectively (Table S5.24). Counselling was also the most common main treatment type 
where alcohol was an additional drug of concern (42%), followed by assessment only (17%) 
(Table S5.28). 
Over the 5 years from 2008–09, counselling, withdrawal management and assessment only 
have remained the most common main treatment types for episodes where alcohol was the 
principal drug of concern. The proportion of episodes where counselling was the main 
treatment type has increased (from 39% to 45%), while there was little change from 2008–09 
to the proportion of episodes for withdrawal management and assessment only (remaining 
at 19% and 17% respectively) (Figure 5.8).  
 
Source: Table S5.25.  
Figure 5.8: Closed episodes provided for own drug use where alcohol was the principal drug of 
concern by main treatment type, 2008–09 to 2012–13  
Treatment episodes where alcohol was the principal drug of concern were most likely to take 
place in a non-residential treatment facility (66%) or a residential treatment facility (17%) 
(Table S5.30). Most (91%) alcohol-related episodes where counselling was the main treatment 
type took place in a non-residential treatment facility, while episodes with a main treatment 
type of withdrawal management were most likely to take place in a residential treatment 
facility (59%). 
About 3 in 5 (63%) closed episodes where alcohol was the principal drug of concern ended 
with an expected cessation, while 21% ended due to an unexpected cessation (see the 
Glossary for explanation of terms) (Table S5.16). Expected cessations were most common 
where the referral source was diversion (74%), and where the main treatment type was 
information or education only (88%) (Table S5.31). 
More than half (54%) of the episodes with alcohol as the principal drug lasted less than 
1 month (22% ended within 1 day) (Table S5.33). The median duration of episodes with 
alcohol as the principal drug of concern was just over 3 weeks (23 days). Episodes with 
counselling as the main treatment type were more than 7 times as long as episodes with 
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withdrawal management as the main treatment type (median duration of 57 days compared 
with 8) (Table S5.34). 
Cannabis 
Cannabis (‘marijuana’ or ‘gunja’) is derived from the cannabis plant (usually Cannabis sativa) 
and is used in whole plant (usually the flowering heads), resin or oil forms. Cannabis has a 
range of stimulant, depressant and hallucinogenic effects. The risks associated with 
long-term or regular use of cannabis include damage to lungs and lung functioning, effects 
on memory and learning, psychosis and other mental health conditions, and addiction with 
cannabis withdrawal now also listed as a discrete syndrome (NCPIC 2011). According to the 
2013 NDSHS (AIHW 2014b), 1 in 3 Australians aged 14 and over have used cannabis at some 
point in their lifetime, while 1 in 10 have used it in the previous 12 months. 
Cannabis was the second most common drug of concern (principal or other) in episodes 
closed in 2012–13 (46%), and was the principal drug for almost one-quarter of treatment 
episodes (24%) (Figure 2.6).  
In almost two-thirds (64%) of episodes with cannabis as the principal drug of concern, the 
client reported additional drugs of concern (Figure 2.6). The most common of these were 
alcohol (34%) and nicotine (24%). 
Smoking was the most common usual method of use in most episodes (88%) where cannabis 
was the principal drug (Table S5.8). 
Over the 5 years from 2008–09, the proportion of closed episodes where cannabis was the 
principal drug of concern has remained relatively stable, fluctuating from 22–24% (Figure 5.9 
and Table S5.2). However, there was an increase of 13% in the number of episodes from 
2011–12 to 2012–13 which may be due to a number of factors. For example, in South 
Australia, the inclusion of the Drug Diversion Assessment Program data for the first time in 
the collection has led to an increase in episodes with a principal drug of concern of cannabis. 
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Source: Table S5.2.  
Figure 5.9: Closed episodes provided for own drug use where cannabis was the principal drug of 
concern, 2008–09 to 2012–13 
Demographics 
Where cannabis was the principal drug of concern, 72% of episodes were for male clients and 
21% were for Indigenous clients.  
Almost two-thirds (60%) of episodes with cannabis as a drug of concern were provided to 
clients aged 20–39, while more than one-fifth (21%) were for those aged 10–19 (Table S5.38). 
Cannabis was more likely to be the principal drug (rather than an additional drug) among 
younger age groups. Four-fifths (86%) of episodes with cannabis as the principal drug of 
concern were for clients aged under 40. 
In almost two-thirds (65%) of episodes, clients reported that they had never injected a drug 
(injecting status was not reported for 14% of episodes) (Table S5.9). 
Treatment 
The most common source of referral for clients where cannabis was a principal drug of 
concern was diversion (32%), followed by self or family (31%) and a health service (20%) 
(Table S5.13). 
The most common main treatment type was counselling (40%), followed by information and 
education only (19%). Assessment only (14%) and withdrawal management and support and 
case management only (both 11%) were also common main treatment types (Table S5.43). 
Counselling was also the most common main treatment type where cannabis was an 
additional drug of concern (40%), followed by assessment only (20%) and withdrawal 
management (18%) (Table S5.47). 
Over the 5 years from 2008–09, in episodes where cannabis was the principal drug, the 
proportion of episodes with counselling as a main treatment type increased from 34% to 
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40%, with a high of 43% in 2011–12. The opposite is true for information and education, 
which declined over the same period from 24% to 19%, with a low of 12% in 2011–12 
(Figure 5.10).  
 
Source: Table S5.44.  
Figure 5.10: Closed episodes provided for own drug use where cannabis was the principal drug of 
concern, by main treatment type, 2008–09 to 2012–13  
Seven in 10 (69%) closed episodes where cannabis was the principal drug of concern ended 
with an expected cessation, while 18% ended due an unexpected cessation (Table S5.16). 
Expected cessations were most common for episodes where the referral source was diversion 
(89%) and least common for referrals from corrections (42%). For main treatment types, 
expected cessations were most common for information and education only (97%) and least 
common for rehabilitation (39%) (Table S5.50). This is to be expected as information and 
education only treatment can be completed in as little as 2 hours whereas rehabilitation 
treatment tends to take 3–6 months to complete.  
Treatment episodes where cannabis was the principal drug of concern were most likely to 
take place in a non-residential treatment facility (72%) (Table S5.49). Most (92%) episodes 
where counselling was the main treatment type took place in a non-residential treatment 
facility. 
More than half (59%) of the episodes with cannabis as the principal drug lasted less than 
1 month (36% ended within 1 day) (Table S5.52). The median duration of episodes with 
cannabis as the principal drug of concern was just over 2 weeks (15 days). Episodes with 
support and case management only as the main treatment type had a median duration of 
more than 7 weeks (52 days), compared with 1 week (9 days) for withdrawal management 
and 1 day for information and education only and assessment only (Table S5.53). 
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Amphetamines 
Amphetamines stimulate the central nervous system and can result in euphoria, increased 
energy, decreased appetite and increased blood pressure (ADCA 2013). Long-term effects 
include high blood pressure, extreme mood swings, paranoia, depression and anxiety, and 
seizures. Evidence is inconclusive regarding the efficacy of pharmacotherapies in managing 
amphetamine withdrawal or relapse; however, trials with dexamphetamine show promise as 
a replacement therapy (NCETA 2004). According to the 2013 NDSHS (AIHW 2014b), 1 in 14 
Australians aged 14 and over have used amphetamines at some point in their lifetime, while 
1 in 50 have used them in the previous 12 months. 
Amphetamines were a drug of concern (principal or additional) in 28% of closed episodes in 
2012–13 and were the principal drug in 1 in 7 episodes (14%) (Figure 2.6).  
In 74% of episodes with amphetamines as the principal drug, the client reported additional 
drugs of concern (Figure 2.6). The most common of these were cannabis (30%) and alcohol 
(23%). 
Injecting was the most common usual method of use in most episodes (45%) where 
amphetamines were the principal drug, followed by smoking (35%) (Table S5.8). 
Over the 5 years from 2008–09, the proportion of episodes where amphetamines were the 
principal drug of concern has increased (from 9% to 14%), with a low of 7% in 2009–10 
(Figure 5.11 and Table S5.2). According to the 2013 NDSHS (AIHW 2014b) the proportion of 
the population using methamphetamine has remained stable; however, there has been a 
significant increase in the use of crystal methamphetamine or ‘ice’ among methamphetamine 
users. 
 
Source: Table S5.2.  
Figure 5.11: Closed episodes provided for own drug use where amphetamines were the principal 
drug of concern, 2008–09 to 2012–13 
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Demographics 
Where amphetamines were the principal drug of concern, 70% of episodes were for male 
clients and 20% were for Indigenous clients.  
Three-quarters (75%) of episodes with amphetamines as a drug of concern were for clients 
aged 20–39, followed by those aged 40–49 (14%) and 10–19 (9%) (Table S5.57). 
In 37% of episodes, clients reported that they had last injected drugs in the previous 
3 months, while in a further 36%, clients reported they had never injected drugs (injecting 
status was not reported for 11% of episodes) (Table S5.9). 
Treatment 
The most common source of referral for clients where amphetamines were the principal drug 
of concern was self or family (43%), followed by diversion (22%) (Table S5.3).  
The most common main treatment was counselling (45%), followed by assessment only 
(21%) and withdrawal management (12%) (Table 5.61) 
Counselling was also the most common main treatment type where amphetamines were an 
additional drug of concern (38%), followed by withdrawal management (19%) and 
assessment only (18%) (Table S5.66). 
Over the 5 years from 2008–09, where amphetamines were the principal drug, the proportion 
of episodes with counselling as a main treatment type increased from 42% to 45%; however, 
the proportion declined from a high of 51% in 2009–10. The proportion of episodes with 
rehabilitation as a main treatment type declined over the same period, from 13% to 8% 
(Figure 5.12). 
 
Source: Table S5.63.  
Figure 5.12: Closed episodes provided for own drug use where amphetamines were the principal 
drug of concern, by main treatment type, 2008–09 to 2012–13  
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Three-fifths (61%) of closed episodes where amphetamines were the principal drug of 
concern ended with an expected cessation, while 25% ended with an unexpected cessation. 
Expected cessations were most common for episodes where diversion was the referral source 
(78%) and least common for referrals from corrections (47%). As seen for cannabis, expected 
cessations were most common for information and education only (86%) and least common 
for rehabilitation (29%) (Table S5.69). 
Treatment episodes where amphetamines were the principal drug of concern were most 
likely to take place in a non-residential treatment facility (70%) or a residential treatment 
facility (15%). Most (91%) episodes where counselling was the main treatment type took 
place in a non-residential treatment facility (Table S5.68). 
More than half (55%) of the episodes with amphetamines as the principal drug lasted less 
than 1 month (25% ended within 1 day) (Table S5.71). The median duration of episodes with 
amphetamines as the principal drug of concern was more than 3 weeks (23 days). Episodes 
with counselling as the main treatment type had a median duration of 7.3 weeks (51 days), 
compared with 1 week (8 days) for withdrawal management and 1 day for assessment only 
and information and education only (Table S5.72). 
Heroin 
Heroin is an opioid, which are strong pain killers with addictive properties. It can result in 
feelings of euphoria and wellbeing, and pain relief, while long-term effects can include 
lowered sex drive and infertility (for women), along with risk of overdose, coma and death 
(ADCA 2013).  
Heroin users seeking treatment can enter a withdrawal program or attend an opioid 
maintenance substitution program (NCETA 2004). 
Results from the 2013 NDSHS (AIHW 2014b) showed: 
• In 2013, 1.2% of people in Australia aged 14 years or over had used heroin in their 
lifetime and 0.1% had used it in the previous 12 months. 
• There was a significant decline in the proportion of people using heroin between 2010 
and 2013. 
Heroin was a drug of concern (principal or additional) in 12% of episodes closed in 2012–13 
(Figure 2.6). It was the principal drug in 1 in 12 episodes (8%), a decrease from 18% in  
2003–04 (Table S5.7).  
Almost three-quarters (74%) of the episodes with heroin as the principal drug of concern had 
an additional drug of concern (Figure 2.6). The most common additional drugs of concern 
were cannabis (22%) and amphetamines (18%). 
Injecting was the most common usual method of use for clients whose principal drug of 
concern was heroin (86% of episodes) (Table S5.8).  
Over the 5 years from 2008–09, the proportion of episodes where heroin was the principal 
drug of concern has decreased steadily from 10% to 8% (Figure 5.13 and Table S5.2). 
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Source: Table S5.2.  
Figure 5.13: Closed episodes provided for own drug use where heroin was the principal drug of 
concern, 2008–09 to 2012–13 
Demographics 
Where heroin was the principal drug of concern, 67% of episodes were for male clients and 
14% were for Indigenous clients (Table S5.97).  
Nearly half (45%) of episodes with heroin as a drug of concern were provided to clients aged 
30–39, followed by those aged 20–29 (25%) and 40–49 (21%) (Table S5.95). Heroin was more 
likely to be the principal drug rather than an additional drug for all age groups except 10-19. 
In 3 in 5 (57%) episodes, the client reported they had injected drugs in the previous 3 months, 
while in 15%, they reported they last injected 3–12 months ago (injecting status was not 
reported for 9% of episodes) (Table S5.9).  
Treatment 
The most common source of referral for clients where heroin was the principal drug of 
concern was self or family (49%), followed by a health service (19%) and diversion programs 
(15%) (Table S5.3).  
The most common types of main treatment were counselling (33%), withdrawal 
management (22%) and assessment only (17%) (Table S5.100). 
Counselling was the most common type of main treatment for clients aged 20–29 (31%),  
30–39 (34%), 40–49 (34%), 50–59 (32%) and 60 and over (38%), while support and case 
management only was most common for clients aged 10–19 (28%) (Table S5.82). 
Similar to episodes with heroin as the principal drug, counselling (39%), assessment only 
(21%) and withdrawal management (19%) were the most common types of main treatment in 
episodes with heroin as an additional drug (Table S5.104). 
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Over the 5 years from 2008–09, in episodes where heroin was the principal drug, the 
proportion of episodes with counselling as the main treatment type increased from 30% to 
33%, with a high of 36% in 2010–11, while the opposite is true for withdrawal management, 
which declined from 29% to 22%. Assessment only remained relatively stable, over the 
4 years from 2008–09 to 2011–12, increasing only in the last year (by 2% from 15% to 17%) 
(Figure 5.14). 
 
Source: Table S5.101. 
Figure 5.14: Closed episodes provided for own drug use where heroin was the principal drug of 
concern, by main treatment type, 2008–09 to 2012–13 
More than half (53%) of closed episodes with heroin as the principal drug of concern ended 
with an expected cessation, while 20% ended due to an unexpected cessation (Table S5.16). 
Once again, expected cessations were most common for episodes where the main treatment 
was information and education only (87%) as this treatment type is usually completed within 
a day. 
Treatment episodes with heroin as the principal drug of concern were most likely to take 
place in a non-residential treatment facility (67%) or a residential treatment facility (18%) 
(Table S5.106). Most (95%) episodes where counselling was the main treatment type took 
place in a non-residential treatment facility. 
Almost half (49%) of the episodes with heroin as the principal drug lasted less than 1 month 
(21% ended within 1 day) (Table S5.109). The median duration of episodes with heroin as the 
principal drug of concern was almost 5 weeks (32 days) (Table S5.110). Episodes with 
support and case management only as the main treatment type had a median duration of 
more than 11 weeks (79 days), compared with just over 1 week (9 days) for withdrawal 
management and 1 day for both information and education only and assessment only. 
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Selected other drugs  
Treatment services are provided for a number of other drugs, which make up a smaller 
proportion of the overall services due to them being less common or where treatment 
services are less likely to be sought. Information on the following drugs is presented in this 
section due to the size of the population using the drug and/or harms associated with use of 
that drug. 
Nicotine 
Nicotine is the stimulant drug in tobacco smoke. It is highly addictive and causes 
dependency (ADCA 2013). Almost 8% of Australia’s burden of disease was attributable to 
tobacco smoking in 2003 (Vos et al. 2007). The health effects of smoking include premature 
death and tobacco-related illnesses such as cancer, chronic obstructive pulmonary disease 
and heart disease. According to the 2013 NDSHS (AIHW 2014b) almost 1 in 6 Australians 
were current smokers and 1 in 8 were daily smokers. 
Most of the population generally access various forms of treatment for nicotine addiction 
through their local GP, pharmacy, helplines or web services. Smoking cessation treatment 
and support services include brief intervention by trained health professionals, individual or 
group counselling, telephone counselling, and pharmacotherapies including nicotine 
replacement therapies and non-nicotine products. 
Nicotine was a principal drug of concern in just 2% of episodes (Figure 2.6). However, it was 
an additional drug of concern in a further 23% of episodes. The proportion of episodes with 
nicotine as the principal drug has remained from 1–2% since 2003–04 (Table S5.2). Possible 
reasons for the low proportion of episodes in which nicotine was the principal drug include 
the wide availability of support and treatment for nicotine use in the community, and that 
people tend to view alcohol and other drug treatment services as most appropriate for drug 
use that is beyond the expertise of general practitioners. 
Demographics 
Where nicotine was a principal drug of concern, 60% of episodes were for male clients and 
31% were for Indigenous clients (Table S5.78).  
More than half (54%) of episodes with nicotine as a drug of concern were provided to clients 
aged 20–39. Only 3% of these episodes were provided to clients aged 60 or over (Table S5.76). 
Nicotine was more likely to be an additional drug rather than the principal drug (93%) for all 
age groups (Table S5.76). 
Treatment 
The most common source of referral for clients where nicotine was the principal drug of 
concern was a police or court diversion program (41%), followed by self or family (26%) 
(Table 5.13).  
The most common types of main treatment were counselling (33%), information and 
education only (27%) and assessment only (19%) (Table S5.81). Counselling was also the 
most common type of main treatment where nicotine was an additional drug of concern 
(36%) (Table S5.85). 
More than three-quarters (78%) of episodes with nicotine as the principal drug of concern 
ended with an expected cessation, while one-fifth (13%) ended due to an unexpected 
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cessation (Table S5.16). As previously reported, expected cessations were most common 
where the main treatment type was information and education only (97%) (Table S5.88). 
Treatment episodes where nicotine was the principal drug of concern were most likely to 
take place in a non-residential treatment facility (60%) or an outreach service (16%) 
(Table S5.87). 
Almost two-thirds (65%) of the episodes with nicotine as the principal drug lasted less than 
1 month (48% ended within 1 day) (Table S5.90). The median duration of episodes with 
nicotine as the principal drug of concern was 4 days (Table S5.91). Episodes with counselling 
as the main treatment type had a median duration of 9 weeks (64 days), compared with 3.7 
weeks (26 days) for withdrawal management and 1 day for assessment only and information 
and education only. 
Ecstasy 
Ecstasy is the popular street name for a range of drugs containing the substance 
3, 4-methylenedioxymethamphetamine (MDMA)—a stimulant with hallucinogenic 
properties. Ecstasy is usually sold in tablet or pill form, but is sometimes found in capsule or 
powder form. The short-term effects of ecstasy include euphoria and a feeling of wellbeing 
and closeness to others and increased energy. Other serious harms include psychosis, heart 
attack and stroke. Little is known about the long-term effects of ecstasy use, but there is some 
research linking regular and heavy use of ecstasy to memory problems and depression 
(ADCA 2013). According to the 2013 NDSHS (AIHW 2014b), 2% of people aged 14 or over 
used ecstasy in the previous 12 months in 2013. 
Ecstasy was a drug of concern (principal or additional) in 4% of closed episodes in 2012–13 
and was the principal drug in less than 1% (Figure 2.6). Counselling was the most common 
type of main treatment in episodes with ecstasy as the principal drug (40%), followed by 
information and education only (29%) and assessment only (22%) (Table S5.138). Counselling 
was also the most common main treatment type where ecstasy was an additional drug of 
concern (40%), followed by assessment only (17%), and information and education only 
(15%) (Table S5.142). 
Benzodiazepines 
Benzodiazepines are depressant drugs—they slow down the activity of the central nervous 
system and the speed of messages going between the brain and the body. Also known as 
‘minor tranquillisers’, benzodiazepines are most commonly prescribed by doctors to relieve 
stress and anxiety and to help people sleep. Some people use benzodiazepines illegally to 
become intoxicated or to 'come down' from the effects of stimulants such as amphetamines 
or cocaine (ADF 2013). 
According to the 2013 NDSHS (AIHW 2014b), 4.5% of the Australian population had used 
tranquillisers/sleeping pills (including benzodiazepines) for non-medical purposes at some 
stage in their lifetime. 
Benzodiazepines were a drug of concern (principal or other) in 9% of episodes closed in 
2012–13 and they were the principal drug in 2% of episodes (Figure 2.6). There was no 
change in the proportion of episodes with benzodiazepines as the principal drug in the 
10 years from 2003–04. 
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In 75% of the episodes with benzodiazepines as the principal drug, the client reported 
additional drugs of concern (Figure 2.6). The most common additional drugs were alcohol 
and cannabis (both 18%). 
Ingestion was the most common usual method of use (86%) in episodes with 
benzodiazepines as the principal drug (Table S5.8). 
Demographics 
Where benzodiazepines were the principal drug, 51% of episodes were for male clients and 
11% were for Indigenous clients (Table S5.116).  
More than one-third (36%) of episodes with benzodiazepines as a drug of concern were 
provided to clients aged 30–39, followed by those aged 20–29 (28%) and 40–49 (20%). Only 
5% of these episodes were provided to clients aged 60 or over (Table S5.114). 
Benzodiazepines were more likely to be an additional drug rather than the principal drug 
(82%) for all age groups. 
In more than one-third (34%) of closed episodes, the client reported they had never injected a 
drug, while in 1 out of every 5 episodes (20%), the client reported they had injected drugs in 
the previous 3 months (injecting status was not reported for 21% of episodes) (Table S5.9). 
Treatment 
The most common source of referral for clients where benzodiazepines were the principal 
drug of concern was self or family (46%), followed by a health service (34%) (Table S5.13). 
The most common types of main treatment were counselling (38%), withdrawal 
management (26%) and assessment only (18%) (Table S5.119). Counselling was most 
common for clients aged 30–39 (35%) and least common for clients aged 10–19 (5%) 
(Table S5.119). Withdrawal management was most common for clients aged 30–39 (36%) and 
least common for clients aged 10–19 (2%). 
Counselling was also the most common type of main treatment type where benzodiazepines 
were an additional drug of concern (34%) (Table S5.123). 
Three in 5 (61%) episodes with benzodiazepines as the principal drug of concern ended with 
an expected cessation, while 1 in 5 (20%) ended due to an unexpected cessation (Table S5.16). 
Expected cessations were more common for episodes where the main treatment type was 
information and education only (84%) or withdrawal management (66%) (Table S5.126). 
Treatment episodes where benzodiazepines were the principal drug of concern were most 
likely to take place in a non-residential treatment facility (69% of closed episodes) or a 
residential treatment facility (16%) (Table S5.125). Most (92%) episodes where counselling 
was the main treatment type took place in a non-residential treatment facility. 
More than half (54%) of the episodes with benzodiazepines as the principal drug lasted less 
than 1 month (21% ended within 1 day) (Table S5.128). The median duration of episodes 
with benzodiazepines as the principal drug of concern was 3 weeks (23 days) (Table S5.129). 
Episodes with rehabilitation as the main treatment type had a median duration of almost 
10 weeks (68 days), a similar length of time as rehabilitation for heroin and cocaine. In 
comparison, benzodiazepine withdrawal management episodes had a median duration of 
less than 2 weeks (10 days) and assessment only and information and education only 
episodes had a median of 1 day (Table S5.129). 
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Licit opioids 
Licit opioids can be obtained by prescription, for example, morphine, buprenorphine, 
methadone, oxycodone, fentanyl and pethidine; or over-the-counter, for example, codeine. 
They do not include illicit opioids, such as heroin. As a group, licit opioids are the principal 
drug of concern in 5% of episodes (Table S5.1). 
Oxycodone is a pharmaceutical opioid (whether prescribed for the person or obtained 
illicitly) used to help control pain and is an alternative to morphine. There has been a large 
growth in oxycodone prescriptions in Australia in the last decade, with an increase of around 
152% during the 6 years spanning 2002–03 to 2007–08. (Roxburgh et al. 2011).  
After morphine (27%) and methadone (25%), oxycodone (16%) comprises the next highest 
proportion of treatment episodes where licit opioids are the principal drug of concern 
(Table S5.2). This proportion has grown from 5% in 2008–09.  
While the proportion of episodes with licit opioids as a principal drug of concern has 
remained relatively stable over the 5 years from 2008–09, there has been a considerable 
increase in the number of episodes of people receiving treatment for their own drug use 
where oxycodone was a principal drug of concern (from 305 episodes to 1,140) (Figure 5.15 
and Table S5.2). This has coincided with a decrease in the proportion of episodes with 
morphine or methadone as a principal drug of concern. 
 
Source: Table S5.2. 
Figure 5.15: Closed episodes provided for own drug use where oxycodone was the principal drug of 
concern, 2008–09 to 2012–13 
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5.3 Treatment provided 
Overview 
Among clients receiving treatment for their own drug use, counselling was the most 
common main treatment type provided in 2012–13 (41%). This was followed by assessment 
only (18%) and withdrawal management (16%) (Table S6.1). There was little difference in the 
proportion of main treatment types provided to males and females, although assessment 
only was more common in episodes provided to males (19%) than to females (14%) 
(Table S6.7). There was little difference in the proportion of main treatments provided by 
Indigenous status. The largest difference existed for withdrawal management, which was 
more likely to be provided to Indigenous clients (18%) than to non-Indigenous clients (10%) 
(Table S6.8).  
More than half (56%) of episodes provided for own drug use were to clients aged 20–39, with 
clients aged 20–29 or 30–39 accounting for the largest proportion of episodes across all 
treatment types (Table S6.9). 
Episodes with support and case management or information and education as a main 
treatment type were more likely to be provided to younger clients, with 55% and 62% of 
episodes provided to 10–29 year olds, respectively. Episodes provided to clients aged 10–19 
were most likely to have a main treatment type of support and case management only or 
information and education only, with 26% and 29% of episodes respectively, compared with 
13% for 10–19 year olds across all treatment types. About 2 in 5 (41%) episodes where 
pharmacotherapy was a main treatment type were provided to clients aged 30–39. While 
only a small proportion of total episodes (11%), episodes provided to clients aged 50 and 
over were most likely to have a main treatment type of counselling followed by withdrawal 
management (Figure 5.16). 
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Source: Table S6.9. 
Figure 5.16: Closed episodes provided for own drug use, by main treatment type and age group, 
2012–13 
Over the 10 years from 2003–04 to 2012–13, the proportion of episodes for each main 
treatment type has remained quite stable, with counselling, withdrawal management and 
assessment only being the most common types of treatment over that period (Figure 5.17). 
Counselling continues to be the most common main treatment type provided, comprising 
about 2 in every 5 episodes since 2003–04. In 2012–13, assessment only overtook withdrawal 
management as the second most common main treatment type for the first time since  
2003–04. This may be influenced by changes to administrative practices in some states and 
territories. 
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Source: Table S6.3. 
Figure 5.17: Closed episodes provided for own drug use, by main treatment type, 2003–04 to  
2012–13 
Counselling 
Two in 5 (41%) of the episodes provided to clients for their own drug use had counselling as 
the main treatment type (Table S6.2). 
More than two-thirds (67%) of the closed episodes provided to clients for their own drug use 
with a main treatment type of counselling were provided to male clients. One in 5 (20%) 
episodes were for Indigenous clients (Table S6.28). Female clients were as likely to be 
Indigenous as male clients (16% compared with 15%). 
Most (58%) of these episodes were for those in the 20–29 and 30–39 age groups (both 29%) 
(Figure 5.18). A further 20% were for clients aged 40–49, 11% were for clients aged 10–19 and 
3% were for clients aged 60 and over. 
Male clients tended to be younger; two-fifths (42%) of the episodes provided to males were 
for clients aged 10–29, compared with 36% for females (Table S6.26). There has been little 
variation in the age proportions over the 5 years from 2008–09 (Figure 5.18). 
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Source: Table S6.27.  
Figure 5.18: Closed episodes provided for own drug use where counselling was the main treatment 
type, by age group, 2008–09 to 2012–13 
More than one-third (35%) of the episodes for the client’s own use with a main treatment 
type of counselling lasted 1–3 months, while a further one-fifth (21%) lasted 2–29 days 
(Table S6.24). Compared with 2008–09, closed episodes in 2012–13 tended to be longer. Over 
the 5 years from 2008–09, the proportion of episodes ending within 1 month decreased 
slightly (from 44% to 36%), while the proportion of episodes lasting more than 1 month 
increased (from 56% to 64%) (Table S6.25). 
Withdrawal management 
Withdrawal management is only provided in episodes for clients receiving treatment for 
their own drug use. Withdrawal management was a treatment type for 16% of episodes 
closed in 2012–13 (Table S6.1). 
Two-thirds (66%) of the closed episodes provided to clients for their own drug use with a 
main treatment type of withdrawal management were provided to male clients. One in 10 
(13%) episodes, were for Indigenous clients (Table S6.40). Female clients were equally as 
likely to be Indigenous as male clients (9% compared with 8%). 
Most (56%) of these episodes were for those in the 30–39 (31%) and 40–49 (25%) age groups 
(Figure 5.19). A further 22% were for clients aged 20–29; just 5% were for clients aged 60 and 
over.  
Over the 5 years from 2008–09, there has been an increase in the proportion of episodes 
provided to older clients where withdrawal management was the main treatment type. More 
than one-third (36%) of episodes were for clients aged 40 and over in 2008–09 compared with 
42% in 2012–13 (Figure 5.19).  
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Source: Table S6.39. 
Figure 5.19: Closed episodes provided for own drug use where withdrawal management was the 
main treatment type, by age group, 2008–09 to 2012–13 
Nearly 8 in 10 (77%) episodes with a main treatment type of withdrawal management lasted 
less than 30 days while a further one-seventh (15%) lasted 1–3 months (Table S6.36). Short 
treatment durations may reflect a lack of engagement by clients in ambulatory withdrawal 
programs (outpatient detoxification). They may also be the result of a change to a more 
appropriate treatment type (for example, providing opioid pharmacotherapy for opioid 
dependence). Over the 5 years from 2008–09, there has been little change in the distribution 
of closed episodes among the duration groups (Table S6.37). 
Assessment only 
Assessment only was a treatment type for 17% of episodes closed in 2012–13 (Table S6.1). 
Almost three-quarters (74%) of the closed episodes for the client's own drug use with a main 
treatment type of assessment only were provided to male clients, and 27% were for 
Indigenous clients (Table S6.48). Female clients were more likely to be Indigenous than male 
clients (19% compared with 14%). 
Three-fifths (59%) of these episodes were for those in the 20–29 (29%) and 30–39 (30%) age 
groups (Figure 5.20). A further 20% of episodes were for clients aged 40–49; just 3% were for 
clients aged 60 and over. Some of the assessment only episodes for young people are 
conducted as part of early intervention and diversion from the youth justice system. Over the 
5 years from 2008–09, the proportion of episodes for clients aged 10–19 increased from 7% to 
11%, while the proportion for those aged 20–29 decreased from 35% to 29% (Figure 5.20). 
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Source: Table S6.47. 
Figure 5.20: Closed episodes provided for own drug use where assessment only was the main 
treatment type, by age group, 2008–09 to 2012–13 
Seven in 10 (69%) episodes for the client's own drug use with a main treatment type of 
assessment only lasted just 1 day, while a further 19% lasted from 2–29 days (Table S6.49). 
The proportion of episodes that lasted 1 day ranged from 10% in Tasmania to 100% in 
Victoria. Over the 5 years from 2008–09, the proportion of closed episodes ending within 
1 day increased substantially (from 49% to 69%), while the proportion of episodes lasting  
2–29 days decreased (from 31% to 19%). The proportion of episodes in all other duration 
groups (from 1–3 months to more than 12 months) also decreased for the same time period 
(Table S6.50). These trends are influenced by differences in jurisdictional service delivery 
practices and data quality improvement over time.  
The large increase to the proportion of closed episodes ending within 1 day has been 
influenced by changes to data collection practices across some states and territories. The 
increase in the proportion of episodes ending within 1 day is particularly evident in Victoria, 
(an increase from less than 1% in 2010–11 to 100% in 2012–13) (Table S7.44). Following 
implementation of a new operational system for brokerage services in Victoria in October 
2011, brokerage assessments for treatment are closed when the client is referred to the 
nominated agency funded to deliver, rather than at the completion of treatment by that 
agency. This new system resulted in a decline in episode duration and reflects the increase in 
those ending within 1 day, as most assessments are completed in a day. 
Support and case management only 
Almost two-thirds (64%) of the closed episodes provided to clients for their own drug use 
with a main treatment type of support and case management only were provided to male 
clients, and 22% were for Indigenous clients (Table S6.56). Female clients were more likely to 
be Indigenous than male clients (20% compared with 14%).  
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More than half (55%) of these episodes were for those in the 10–19 (26%) and 20–29 (29%) age 
groups (Figure 5.21). A further 22% were for clients aged 30–39; just 2% were for clients aged 
60 and over. Over the 5 years from 2008–09, the proportion of episodes for clients aged  
40–49 increased from 11% to 15%, while the proportion for those aged 20–29 decreased from 
35% to 29% (Figure 5.21). 
 
Source: Table S6.55. 
Figure 5.21: Closed episodes provided for own drug use where support and case management only 
was the main treatment type, by age group, 2008–09 to 2012–13 
More than one-third (35%) of the episodes for the client's own drug use with a main 
treatment type of support and case management lasted 1–3 months, while 27% lasted 2–29 
days and 2 in 5 (19%) lasted 3–6 months (Table S6.57). Over the 5 years from 2008–09, the 
proportion of closed episodes ending within 2 days to 3 months decreased (from 69% to 
62%), while both the proportion of episodes ending within 1 day and those ending within 
6 months or more, increased (from 6% to 9% and from 6% to 10%, respectively) (Table 6.58). 
  
2008–09 2009–10 2010–11 2011–12 2012–13
0
10
20
30
40
50
10–19 20–29 30–39 40–49 50–59 60 and over
Per cent
Age group (years)
  Alcohol and other drug treatment services in Australia 2012–13 59 
Information and education only 
As mentioned previously, information and education only is not available as an additional 
treatment type. 
Almost three-quarters (73%) of the closed episodes provided to clients for their own drug 
use with a main treatment type of information and education only were provided to male 
clients, and 19% were for Indigenous clients (Table S6.64). Female clients were more likely to 
be Indigenous than male clients (20% compared with 11%). 
More than three-fifths (62%) of these episodes were for those in the 20–29 (33%) and 10–19 
(29%) age groups (Figure 5.22). A further 19% were for clients aged 30–39; 1% were for 
clients aged 60 and over. Female clients tended to be older; almost one-quarter (23%) of the 
episodes provided to females were for those aged 40 and over, compared with 16% for 
males. (Table S6.54). Over the 5 years from 2008–09, the proportion of episodes for clients 
aged 10–19 increased from 25% to 29%, while the proportion for those aged 20–29 decreased 
from 40% to 33% (Figure 5.22). 
 
Source: Table S6.63. 
Figure 5.22: Closed episodes provided for own drug use where information and education only was 
the main treatment type, by age group, 2008–09 to 2012–13 
As expected for this type of treatment, most (82%) of the information and education only 
episodes for the client's own drug use lasted just 1 day (Table S6.57). Over the 5 years from 
2008–09, the proportion of closed episodes ending within 1 day decreased from 89% to 82% 
with a trough of 65% in 2011–12, while the proportion of episodes ending within 2–29 days 
increased from 6% to 9% with a peak of 17% in 2011–12 (Table S6.58). 
  
2008–09 2009–10 2010–11 2011–12 2012–13
0
10
20
30
40
50
10–19 20–29 30–39 40–49 50–59 60 and over
Per cent
Age group (years)
 60 Alcohol and other drug treatment services in Australia 2012–13 
Rehabilitation 
As mentioned previously, rehabilitation is only available to clients receiving treatment for 
their own drug use. Rehabilitation was a treatment type for 5% of episodes closed in 2012–13 
(Table S6.1). 
Almost two-thirds (65%) of the closed episodes with a main treatment type of rehabilitation 
were provided to male clients, and 22% were for Indigenous clients (Table S6.74). 
Three in 5 (62%) of these episodes were for those in the 20–29 (30%) and 30–39 (32%) age 
groups (Table S6.73). A further 20% were for clients aged 40–49; just 2% were for clients aged 
60 and over. There has been little variation in the age proportions over the 5 years from 
2008–09 (Figure 5.23). 
 
Source: Table S6.73. 
Figure 5.23: Closed episodes provided for own drug use where rehabilitation was the main 
treatment type, by age group, 2008–09 to 2012–13 
More than one-third (35%) of the episodes with a main treatment type of rehabilitation lasted 
from 1–3 months, while a further 31% lasted 2–29 days (Table S6.70). Compared with  
2008–09, closed episodes in 2012–13 were more likely to be slightly longer. Over the 5 years 
from 2008–09, the proportion of episodes ending within 29 days decreased (from 42% to 
35%), while the proportion of episodes ending within 1–12 months increased (from 55% to 
62%) (Table S6.71). 
Pharmacotherapy 
Only episodes where pharmacotherapy was an additional treatment, or where it was the 
main treatment and an additional treatment was provided, are included in the AODTS 
NMDS. Episodes where pharmacotherapy was the main treatment and no additional 
treatment was provided are excluded from the AODTS NMDS. Pharmacotherapy is only 
available to clients receiving treatment for their own drug use. As most pharmacotherapy 
services are outside the scope of the AODTS NMDS, this information is a significant 
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underestimate. More comprehensive information on pharmacotherapy treatment provided 
in Australia is available from the AIHW’s National Opioid Pharmacotherapy Statistics 
Annual Data (NOSPAD) collection. See Chapter 8 for more information. 
For those services that were within scope of the AODTS NMDS, nationally in 2012–13, 3% of 
episodes were provided with a treatment type of pharmacotherapy (main or additional) 
(Table S6.1). In more than half (56%) of these episodes, pharmacotherapy was an additional 
treatment; this is a result of the AOTDS NMDS scope, which excludes episodes in which 
pharmacotherapy is the main treatment type, and no additional treatment is provided. 
Of the closed episodes where pharmacotherapy was the main treatment type, almost 
one-quarter (24%) lasted up to 1 month, while a further 18% lasted 1–3 months (Table S6.80). 
Two-thirds (67%) of the closed episodes with a main treatment type of pharmacotherapy 
were provided to male clients, and 17% to Indigenous clients (Table S6.84). Almost 
two-thirds (65%) of these episodes were for those in the 20–29 (24%) and 30–39 (41%) age 
groups. A further 26% were for clients aged 40–49; just 1% were for clients aged 60 and over. 
Of the closed episodes provided to clients with a main treatment type of pharmacotherapy, 
more than half (54%) had heroin as a principal drug of concern, while almost 1 in 8 (12%) 
had a principal drug of methadone. Morphine (10% of episodes) was also a common 
principal drug of concern (Table S6.85). 
5.4 Referral source 
Nationally, the most common source of referral for clients receiving treatment for their own 
drug use in 2012–13 was self or family (41%). Referral from a health service was also 
common (24%). Referrals from police or court diversion programs accounted for 18% of 
episodes (these programs divert people with minor drug offences from the criminal justice 
system) (Table S6.16). Clients referred by diversion programs tended to be younger; 24% of 
these episodes were for clients aged 10–19 and 36% were for clients aged 20–29, compared 
with 13% and 28%, respectively, for all episodes. In 1 in 11 (9%) episodes, the client was 
referred by a correctional service (Table S6.16). 
Source of referral varied according to clients’ principal drugs of concern. Self or family 
referral was the most common source of referral for clients receiving treatment for heroin 
(49%), alcohol (45%) or amphetamines (43%) as their principal drug of concern (Figure 5.24). 
For clients receiving treatment for cannabis as their principal drug, diversion (32%) was the 
most common referral source, followed closely by self/family (31%). Clients receiving 
treatment for alcohol as their principal drug were less likely to be referred through diversion 
(9%) and more likely to be referred from a health service (28%), when compared to clients 
receiving treatment for heroin, amphetamines or cannabis.  
 62 Alcohol and other drug treatment services in Australia 2012–13 
 
Note: ‘Other’ includes persons referred under a legislative act (other than the Drug Diversion Act), or persons referred to treatment through 
community services, government departments, remand or prison, education (through teachers and schools), and the Australian Community 
Service Organisation/Community Offenders Advice and Treatment Service. 
Source: Table S5.13.  
Figure 5.24: Closed episodes provided for own drug use, by selected principal drugs of concern and 
referral source, 2012–13  
Over the 5 years from 2008–09, the proportion of episodes where the client was referred by 
self or family increased from 38% to 41%, while the proportion referred by a health service 
decreased from 27% to 24% (Figure 5.25). There was little change in the other sources of 
referral over the same period. 
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Note: ‘Other’ includes persons referred under a legislative act (other than the Drug Diversion Act), or persons referred to treatment through 
community services, government departments, remand or prison, education (through teachers and schools), and the Australian Community 
Service Organisation/Community Offenders Advice and Treatment Service. 
Source: Table S6.17. 
Figure 5.25: Closed episodes provided for own drug use, by referral source, 2008–09 to 2012–13  
5.5 Length of treatment episodes 
Four-fifths (79%) of closed episodes for the client’s own drug use ended within 3 months, 
more than half (55%) ended within 1 month and over one-quarter (26%) ended within 1 day 
(Table S6.18). Just 8% of episodes lasted 6 months or more.  
Over the 10 years from 2003–04, the proportion of episodes that ended within 3 months 
decreased slightly from 83% to 79% (Table S6.19). 
As expected, episodes with a main treatment type of information and education only or 
assessment only were most likely to end within 1 day. Episodes with counselling, 
rehabilitation and support and case management had similar duration patterns, most 
commonly lasted 1–3 months (35% of episodes each) (Figure 5.26). The majority (70%) of 
withdrawal management episodes lasted 2–29 days. 
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Source: Table S6.18. 
Figure 5.26: Closed episodes provided for own drug use, by duration, 2012–13  
Nationally, the median duration of closed episodes for the client’s own drug use was just 
over 3 weeks (22 days) (Table S6.20). The median duration of closed episodes for the client’s 
own drug use increased over the 5 years from 2008–09 from 18 days to 22 days in 2012–13, 
peaking at 25 days in 2011–12.  
This increase over time is largely due to increased median duration for episodes with a main 
treatment type of counselling, rehabilitation or other. The median duration of episodes 
where counselling was a main treatment type increased by 10 days (from 45 to 55), while the 
median duration for rehabilitation increased by 9 days (from 42 to 51) over the same period.  
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Note: Median duration where ‘other’ is a main treatment type has been excluded due to data quality issues. 
Source: Table S6.20. 
Figure 5.27: Closed episodes provided for own drug use, by main treatment and median duration, 
2008–09 to 2012–13  
5.6 Reason for cessation 
In 2012–13, around 3 in 5 (63%) completions recorded a reason for cessation in the ‘expected’ 
category. Unexpected cessations accounted for more than one-fifth (21%) and administrative 
cessations around 6% (Table 5.1). The proportion of episodes with expected cessations 
remained at around one-third over the 4 years from 2008–09, (with proportions between 65% 
and 68%), declining to 63% in 2012–13. There was little change to the proportion of episodes 
in the ‘unexpected’ category for clients receiving treatment for their own drug use, with the 
proportion remaining between 20% and 22% over the same period (Table S2.16). 
Table 5.1: Reason for cessation grouped by indicative outcome type, 2012–13 
Reason for cessation % 
Expected cessation 62.9 
Unexpected cessation 20.8 
Administrative cessation 6.3 
Other 10.0 
Total 100.0 
When all reasons were considered, ‘treatment completed’ was the most common reason for 
cessation for clients receiving treatment for their own drug use (53%), followed by ‘ceased to 
participate without notice’ (15%), ‘other’ (8%) and ‘ceased to participate at expiation’ (7%) 
(Table 5.2). ‘Transferred to another service provider’ and ‘ceased to participate against 
advice’ were also reasons for cessation (both 4%). 
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Table 5.2: Reason for cessation of treatment episodes, 2012–13 
Reason for cessation % 
Treatment completed 52.9 
Ceased to participate without notice 14.9 
Ceased to participate at expiation 7.2 
Transferred to another service provider 4.3 
Ceased to participate against advice 3.9 
Ceased to participate by mutual agreement 2.8 
Ceased to participate involuntary (non-compliance) 1.9 
Imprisoned, other than drug court sanctioned 1.2 
Change in delivery setting 1.0 
Change in main treatment type 0.9 
Drug court and/or sanctioned by court diversion service 0.2 
Died 0.2 
Change in principal drug of concern 0.1 
Other 8.4 
Total 100.0 
In 2012–13, clients whose principal drug of concern was ecstasy were the most likely to have 
an expected cessation, with almost 9 in 10 (88%) falling into this category. The lowest rate of 
expected cessations was for episodes with morphine as the primary drug of concern (43%). 
Amphetamines had the highest rate of unexpected cessations (25%), while the lowest rate 
was observed where ecstasy was the principal drug of concern (6%) (Table 5.3). 
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Table 5.3: Reason for cessation grouped by indicative outcome type, by principal drug of concern 
(%), 2012–13 
Principal drug of 
concern 
Expected 
cessation 
(%) 
Unexpected 
cessation 
(%) 
Administrative 
cessation 
(%) 
Other 
(%) 
Total 
(%) 
Analgesics      
Codeine 55.4 21.7 15.4 7.5 100.0 
Morphine 43.1 24.5 17.6 14.7 100.0 
Buprenorphine 52.5 17.7 19.8 9.9 100.0 
Heroin 53.2 20.6 10.3 15.9 100.0 
Methadone 57.1 15.7 17.2 10.1 100.0 
Total analgesics 52.6 20.8 13.0 13.6 100.0 
Sedatives and hypnotics     
Alcohol 63.0 21.4 6.1 9.6 100.0 
Benzodiazepines 60.6 20.3 9.5 9.6 100.0 
Total sedatives and 
hypnotics 62.9 21.4 6.2 9.5 100.0 
Stimulants and hallucinogens     
Amphetamines 61.2 25.4 5.3 8.1 100.0 
Ecstasy 88.4 5.8 2.0 3.8 100.0 
Cocaine 72.1 15.8 4.1 8.0 100.0 
Nicotine 77.7 12.9 3.2 6.3 100.0 
Total stimulants and 
hallucinogens 64.2 23.1 5.0 7.7 100.0 
Cannabis 69.3 18.7 3.9 8.1 100.0 
For episodes with alcohol or cannabis as the principal drug of concern, expected cessations 
remained the most common over the 5 years from 2008–09, although the proportion of these 
episodes declined slightly (from 66%—with a high of 69% in 2010–11—to 63% and from 73% 
to 69% respectively).  
Over the same period, there was very little change to the reason for cessation for episodes 
with amphetamines as the principal drug of concern (Table S5.17). 
The proportion of episodes with an expected cessation or an unexpected cessation where 
heroin was the principal drug of concern both declined (from 57% to 53% and 25% to 21%, 
respectively). ‘Other’ reasons increased from 9% in 2008–09 to 16% in 2012–13. 
 
 68 Alcohol and other drug treatment services in Australia 2012–13 
6 Treatment episodes for someone else’s 
drug use 
This chapter explores the treatment provided to clients receiving treatment for someone 
else’s drug use. Those people who sought treatment in relation to someone else’s drug use 
may include people looking for ideas to help someone with their drug use and people 
seeking assistance because of the personal impact on them of someone else’s drug use. Not 
all treatments related to someone else’s drug use are reported through the NMDS as it is 
likely that many people approach other services for assistance, such as relationship 
counsellors. What is reported though, is this assistance when it is sought from an alcohol and 
other drug treatment service. 
Data relating to drug of concern are not reported for those who sought treatment for 
someone else’s drug use. In addition, rehabilitation, withdrawal management 
(detoxification) and pharmacotherapy are not provided to clients seeking treatment for 
someone else’s drug use. 
6.1 Demographics 
Just 4% (7,211) of episodes closed in 2012–13 were for people receiving treatment for 
someone else’s drug use (Table S2.1). Of these 7,211 episodes, 63% were for female clients, 
which is the same proportion as for 2011–12 but a decline from 74% in 2003–04 (Table S2.4). 
These clients tended to be older than those receiving treatment for their own drug use; 
one-fifth (20%) of episodes were for clients aged 40–49 while a further 19% were for clients 
aged 50–59 (Table S2.9). There was little change in the distribution of episodes among the 
different age groups in the 10 years from 2003–04 (Table S2.9).  
Among clients seeking treatment for someone else’s drug use, the AODTS NMDS does not 
capture information about the relationship between the client and the associated drug user. 
However, given the age and sex profile of this client group it is possible that a large 
proportion are parents (most likely mothers) or relatives and the one-fifth of clients that are 
aged 10–19 may be children of drug users. 
Male clients tended to be slightly younger than female clients (Figure 6.1). More than half 
(57%) of episodes provided to female clients were for people aged 40 or over, compared with 
43% for those provided to male clients (Figure 6.1). Clients who received treatment for 
someone else’s drug use were more likely to be female. Non-Indigenous clients (64%) were 
more likely to be female than Indigenous clients (53%) (Table S2.7). 
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Source: Table S2.10. 
Figure 6.1: Closed episodes provided for someone else’s drug use, by age group and sex,  
2012–13  
More than four-fifths (81%) of the episodes for someone else’s drug use were provided to 
clients whose country of birth was Australia (Table S2.11). A further 4% of episodes were 
provided to clients born in the United Kingdom and 2% were born in New Zealand. In 
nearly all (95%) episodes, the client had a preferred language of English (Table S2.12).  
6.2 Treatment provided 
Overview 
Counselling (68%) was most common type of treatment provided, followed by information 
and education only (14%), support and case management only (11%) and assessment only 
(5%). Rehabilitation, withdrawal management and pharmacotherapy are not provided to 
clients receiving treatment for someone else’s drug use (Table S6.1). 
Episodes with support and case management only, information and education only and 
other were most likely to be provided to clients aged 10–19 (51%, 26% and 64%, respectively). 
Counselling and assessment only were most common among clients aged 40–59 (44% and 
49% of episodes for these treatment types, respectively). 
Over the 10 years from 2003–04 to 2012–13, there was little fluctuation in the proportion of 
episodes for each main treatment type (Figure 6.2). While counselling continues to be the 
most common main treatment type provided it has decreased from 80% of episodes in  
2003–04 to 68% in 2012–13.  
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Source: Table S6.3. 
Figure 6.2: Closed episodes provided for someone else’s drug use, by main treatment type, 2003–04 
to 2012–13 
Counselling 
Compared with episodes for the client’s own drug use, episodes for someone else’s drug use 
with a main treatment type of counselling were more likely to be provided to female clients 
(66%). Male clients were more likely to be Indigenous than female clients (9% compared with 
5%) (Table S6.28). 
These episodes tended to be provided to older clients. More than half (58%) were for clients 
aged 40 and over; 22% of episodes were provided each to clients in the 40–49 and 50–59 age 
groups, while a further 14% of episodes were for clients aged 60 or over (Figure 6.3). Female 
clients were more likely to be older than males: 48% of episodes provided to females were 
for clients aged 40–59, compared with 37% of episodes for male clients (Table S6.26). There 
has been little variation in the age proportions over the last 5 years from 2008–09 (Figure 6.3). 
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Source: Table S6.27. 
Figure 6.3: Closed episodes provided for someone else’s drug use with a main treatment type of 
counselling, by age group, 2008–09 to 2012–13 
More than one-third (36%) of the closed episodes provided to clients for someone else’s drug 
use with a main treatment type of counselling lasted 1–3 months, while a further quarter 
(24%) lasted 2–29 days (Table S6.24). Over the 5 years from 2008–09, the proportion of closed 
episodes lasting 1–3 months increased (from 30% to 36%), while the proportion lasting 
12 months or more decreased (from 7% to 3%) (Table S6.25). There was little change in the 
proportions of episodes across all other durations for the same period. 
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Assessment only 
In this context, assessment only refers to assessing the needs of the client who is seeking 
treatment to help them cope with someone else’s drug use. Episodes for someone else’s drug 
use with a main treatment type of assessment only were more likely to be provided to female 
clients (58%) (Table S6.48).  
The episodes for someone else's drug use tended to be provided to older clients. Almost half 
(49%) were for clients in the 40–49 (28%) or 50–59 (21%) age groups (Figure 6.4). 
Female clients were more likely to be older than males: 54% of episodes provided to females 
were for clients aged 40–59, compared with 42% of episodes for male clients (Table S6.46). 
Over the 5 years from 2008–09, there was an increase in the proportion of episodes provided 
to older clients. More than half (52%) of episodes were provided to clients aged 40 and over 
in 2008–09 compared with 60% in 2012–13 (Table 6.4). 
 
Source: Table S6.47. 
Figure 6.4: Closed episodes provided for someone else’s drug use with a main treatment type of 
assessment only, by age group, 2008–09 to 2012–13 
Four-fifths (83%) of the episodes for someone else’s drug use with a main treatment type of 
assessment only lasted only 1 day, while a further 7% lasted 2–29 days (Table S6.49). Over 
the 5 years from 2008–09, the proportion of episodes ending within 1 day increased (from 
80% to 83%), while the proportion of those ending within 2–29 days decreased (from 9% to 
7%). There was little change to the episodes lasting other durations over the same period 
(Table S6.50).  
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Support and case management only 
Episodes for someone else’s drug use with a main treatment type of support and case 
management only were more likely to be provided to female clients (56%) (Table S6.56). 
They also tended to be provided to younger clients, with more than half (51%) the episodes 
for clients aged 10–19 (Figure 6.5). 
Female clients were more likely to be older than males: 41% of episodes provided to females 
were for clients aged 30 and over, compared with 34% of episodes for male clients 
(Table S6.54). Over the 5 years from 2008–09, the proportion of episodes provided to clients 
aged 50 and over increased (from 11% to 21%), while episodes provided to clients aged  
20–29 decreased (from 15% to 9%). The proportion of episodes provided to clients aged  
10–19 increased substantially in 2009–10 (from 51% to 74%); however, it has since declined, 
returning to 51% and resulting in no overall change since 2008–09 (Figure 6.5). 
 
Source: Table S6.55. 
Figure 6.5: Closed episodes provided for someone else’s drug use with a main treatment type of 
support and case management only, by age group, 2008–09 to 2012–13 
Almost half (49%) of closed episodes provided to clients for someone else’s drug use with a 
main treatment type of support and case management lasted 1–3 months, while over 
one-quarter (26%) lasted 2–29 days (Table S6.57). The proportion of closed episodes lasting  
1–3 months and 2–29 days have changed substantially over the 5 years from 2008–09. Both 
episode durations accounted for a similar proportion of closed episodes in 2008–09 (36% for 
2–29 days and 33% for 1–3 months). However, since then, the proportion of episodes lasting 
2–29 days has declined (to 26%), while the opposite is true for episodes lasting 1–3 months 
(to 49%), making 1–3 months the most common duration since 2011–12 (Table S6.58). 
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Information and education only 
Episodes for someone else’s drug use with a main treatment type of information and 
education only were more likely to be provided to female clients (58%) (Table S6.64).  
These episodes tended to be provided to younger clients. More than two-fifths (42%) were 
for clients in the 10–19 (26%) or 20–29 (16%) age groups (Figure 6.6). Female clients were 
more likely to be in the youngest and the oldest age groups compared to males who were 
more likely to be of middle age: 29% of episodes provided to females were for clients aged 
10–19, compared with 21% of episodes for male clients, while 57% of episodes were for males 
aged 20–49 compared with 48% for females. (Table S6.62). Over the 5 years from 2008–09, the 
proportion of episodes for clients aged 10–19 increased from 14% to 26%, while the 
proportion for those aged 50–59 decreased from 26% to 14% (Figure 6.6). 
 
Source: Table S6.63. 
Figure 6.6: Closed episodes provided for someone else’s drug use with a main treatment type of 
information and education only, by age group, 2008–09 to 2012–13 
Similar to those provided for the client's own drug use and as expected for this type of 
treatment, most (77%) of the episodes provided for someone else’s drug use where 
information and education was the main treatment type lasted 1 day, while a further 13% 
lasted 1–3 months (Table S6.65). Over the 5 years from 2008–09, the proportion of episodes 
lasting 1 day increased (from 51% to 77%, peaking at 85% in 2010–11) while the opposite is 
true for episodes lasting 2–29 days (declining from 28% to 8%) (Table S6.66). 
  
2008–09 2009–10 2010–11 2011–12 2012–13
0
10
20
30
40
10–19 20–29 30–39 40–49 50–59 60 and over
Per cent
Age group (years)
  Alcohol and other drug treatment services in Australia 2012–13 75 
6.3 Referral source 
Half (50%) of episodes provided to clients for someone else’s drug use had a referral source 
of self or family, while 1 in 7 (14%) were referred by a health service (Figure 6.7). While self 
or family has remained the most common source of referral in the 5 years from 2008–09, the 
proportion of closed episodes in which self or family was the referral source has declined 
(from 60% to 50%) (Figure 6.7). Over the same period, the proportion of health service 
referrals also declined (from 23% to 14%), while there has been an increase in the referral 
source of ‘other’ (from 13% to 25%) (Figure 6.7).  
 
Note: ‘Other’ includes persons referred under a legislative act (other than the Drug Diversion Act), or persons referred to treatment through 
community services, government departments, remand or prison, education (through teachers and schools), and the Australian Community 
Service Organisation/Community Offenders Advice and Treatment Service. 
Source: Table S6.17. 
Figure 6.7: Closed episodes provided for someone else’s drug use, by referral source, 2008–09 to 
2012–13  
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6.4 Length of treatment episodes 
Four-fifths (81%) of episodes provided to clients for someone else’s drug use ended within 
3 months—almost one-third (32%) lasted 1–3 months (Figure 6.8).  
As for treatment provided to clients for their own use, episodes with a main treatment type 
of information and education only or assessment only were most likely to end within 1 day. 
Episodes with counselling and support and case management had similar duration patterns, 
most commonly lasting 1–3 months (36% and 49% of episodes, respectively) (Figure 6.8).  
 
Source: Table S6.18. 
Figure 6.8: Closed episodes provided for someone else’s drug use, by main treatment type and 
duration, 2012–13  
Nationally, the median duration of closed episodes for someone else’s drug use was 4.4 
weeks (31 days) (Table S6.20). This is strongly influenced by counselling which is the main 
treatment type for 68% of episodes. Over the 5 years from 2008–09, the median duration of 
closed episodes decreased from 36 days with a high of 42 days in 2011–12.  
The median duration for episodes with a main treatment type of support and case 
management only or other increased (from 22 to 36 days and 47 to 75 days, respectively) 
(Figure 6.9). There has been no change to the median duration for episodes with the 
remaining main treatment types over the same period. 
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Source: Table S6.21. 
Figure 6.9: Closed episodes provided for someone else’s drug use, by main treatment type and 
median duration, 2008–09 to 2012–13  
6.5 Reason for cessation 
In 2012–13, three-quarters (75%) of completions recorded an expected cessation. Unexpected 
cessations accounted for 1 in 9 (11%) completions and ‘changes to treatment’ (3%) (Table 6.1). 
Over the 5 years from 2008–09, there was an increase in the proportion of episodes with 
expected cessations for clients receiving treatment for someone else’s drug use (from 69% to 
75%), while the opposite is true for episodes with unexpected cessations (decreasing from 
17% to 11%) (Table S2.16). 
Table 6.1: Reason for cessation grouped by indicative outcome type, 2012–13 
Reason for cessation % 
Expected cessation 74.9 
Unexpected cessation 11.0 
Administrative cessation 3.1 
Other 10.9 
Total 100.0 
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7 State and territory comparisons 
Alcohol and other drug treatment can vary by state and territory for a range of reasons, 
including differences in the client profile, such as demographics and drug use patterns, and 
in service delivery, such as treatment priorities, policy and legislation. This chapter 
highlights similarities and differences in alcohol and other drug treatment between state and 
territory jurisdictions. It also focuses on episodes rather than clients. Information on 
individual states and territories is available in Appendix D (online). 
Demographic characteristics 
Among the states and territories, the proportion of episodes provided to males ranged from 
63% in Western Australia, Tasmania and the Australian Capital Territory to 71% in South 
Australia (Table S2.3). The proportion of episodes provided to Indigenous clients varied 
greatly across the states and territories, ranging from 7% in Victoria to 62% in the Northern 
Territory (Table S2.5). Most episodes were provided to clients aged 20–39, as is the case 
nationally. The proportion of episodes provided to clients aged 20–29 ranged from 25% in 
New South Wales and the Australian Capital Territory to 30% in Queensland, while the 
proportion provided to clients aged 30–39 ranged from 25% in Queensland and the Northern 
Territory to 30% in New South Wales (Table S2.8).  
Principal drug of concern 
Alcohol was the most common principal drug of concern in all states and territories, ranging 
from 37% of episodes in Queensland to 60% in the Northern Territory (Figure 7.1). The 
Northern Territory was half as much again above the national average (41%) for episodes 
where alcohol was the principal drug of concern (Table S5.1).  
After alcohol, cannabis was the next most common principal drug in all states and territories 
except South Australia, where amphetamines were more common and the Northern 
Territory where volatile solvents were more common. In Queensland, the proportion of 
episodes with cannabis as the principal drug of concern was well above the national average 
(34% compared with 24% nationally), while the opposite was true for the Northern Territory 
(11%). The Australian Capital Territory reported a lower proportion of episodes where 
cannabis was the principal drug of concern and the proportion of episodes where heroin was 
the principal drug was double the national average (16% compared with 8% nationally) 
(Table S5.1).  
Amphetamines were the third most common principal drug of concern nationally, 
accounting for 1 in 7 (14%) episodes. However, in South Australia, the proportion of 
episodes with amphetamines as the principal drug was substantially higher than the national 
average, accounting for almost 1 in 4 (24%) episodes (Table S5.1).  
Nationally, both volatile solvents and morphine account for only 1% each of total episodes 
when they are the principal drug of concern. The Northern Territory was substantially above 
the national average for volatile solvent treatment, with 14% of closed episodes having 
volatile solvents as the principal drug of concern. The proportion of episodes where 
morphine was the principal drug of concern was substantially higher than the national 
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average in both Tasmania and the Northern Territory (5% and 4% of episodes, respectively) 
(Table S5.1). 
 
Source: Table S5.1.  
Figure 7.1: Closed episodes provided for own drug use, by selected principal drugs of concern, 
states and territories, 2012–13 
Main treatment type 
Counselling was the most common main treatment type in 5 out of 8 states and territories in 
2012–13, comprising between 33% and 61% of closed episodes in those states (Table S6.2). 
Assessment only was the most common main treatment type in South Australia and the 
Northern Territory (43% and 44% respectively), while in the Australian Capital Territory, 
information and education only was the most common (22%). The profile of main treatment 
types varied greatly between states and territories. Withdrawal management, for example, 
was the main treatment type in 1% of closed episodes in Tasmania, but comprised 21% in 
Victoria. Similar fluctuations occurred for most main treatment types. 
Referral source 
Except for South Australia, self or family was the most common referral source in all states 
and territories, spanning 34% in Queensland to 56% in the Australian Capital Territory 
(Figure 7.2). Referral from a health service was also common (24% nationally), and this was 
the most common referral source in South Australia (28%). Referrals from police or court 
diversion programs accounted for 17% of episodes (these programs divert people with minor 
drug offences from the criminal justice system). Among the states and territories, this ranged 
from 9% in the Australian Capital Territory to 30% in Queensland. Referrals from the 
corrections system were lowest in Western Australia (3%) and highest in the Northern 
Territory (14%). 
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Note: ‘Other’ includes persons referred under a legislative act (other than the Drug Diversion Act), or persons referred to treatment through 
community services, government departments, remand or prison, education (through teachers and schools), and the Australian Community 
Service Organisation/Community Offenders Advice and Treatment Service. 
Source: Table S2.14. 
Figure 7.2: Closed episodes to all clients, by referral source, states and territories, 2012–13  
Length of treatment episodes 
Among the states and territories, the proportion of closed episodes that ended within 
1 month ranged from 31% in Tasmania to 71% in South Australia (Table S2.19). 
Nationally, the median duration of episodes closed in 2012–13 was about 3 weeks (22 days) 
(Figure 7.3). Among the states and territories, the median duration ranged from just under 
1 week (6 days) in Queensland and South Australia to more than 2 months (63 days) in 
Tasmania.  
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Source: Table S2.21.  
Figure 7.3: Closed episodes by median duration, states and territories, 2012–13  
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8 Other data sources 
8.1 Hospitals 
Information on hospitalisations is available from the National Hospital Morbidity Database 
(NHMD). This database includes almost all public hospitals that provided data for the 
NHMD in 2012–13. The exception was a mothercraft hospital in the Australian Capital 
Territory. The great majority of private hospitals also provided data, the exceptions being the 
private free-standing day hospital facilities in the Australian Capital Territory, the single 
private free-standing day hospital in the Northern Territory and a private free-standing day 
hospital in Victoria. 
A hospital separation refers to a completed episode of admitted hospital care ending with 
discharge, death, transfer or a portion of a hospital stay beginning or ending in a change to 
another type of care (for example, from acute care to rehabilitation). The hospital separations 
data do not include episodes of non-admitted patient care provided in outpatient clinics or 
emergency departments. 
Drug-related separations refer to hospital care with selected diagnoses of substance-use 
disorder or harm (accidental, intended or self-inflicted) due to selected substances (see 
Appendix B for details). Hospital separations where the diagnosis of drug-related harm or 
disorder is additional to the principal diagnosis such as problems related to certain chronic 
conditions caused by the use of drugs like tobacco and alcohol have been excluded. Hospital 
separations for drug-related injuries and drug-related allergic responses have also been 
excluded.  
Drugs described in this section include legal, accessible drugs such as alcohol and tobacco, 
drugs that are available by prescription or over the counter, such as analgesics and 
antidepressants, and drugs that are generally not obtained through legal means, such as 
heroin and ecstasy. Therefore, a proportion of the separations reported here may result from 
harm arising from the therapeutic use of drugs, and the inclusion of therapeutic use in these 
data may mean the burden on the hospital system appears larger than expected. 
About 113,000 hospital separations with a drug-related principal diagnosis were reported in 
2012–13 (Table 8.1), which represents 1% of all hospital separations, a similar proportion to 
previous years.  
In 2012–13, sedatives and hypnotics continued to account for the highest proportion of 
hospital separations with a drug-related principal diagnosis (64% of all such separations), 
with alcohol making up 88% of separations for sedatives and hypnotics. On its own, alcohol 
accounted for 56% of all drug-related hospital separations (Table 6.1). Of all separations with 
a drug-related principal diagnosis, 13% were for analgesics, with opioids (heroin, opium, 
morphine and methadone) accounting for half of this group (7% of all drug-related 
separations). Stimulants and hallucinogens, including cannabis and cocaine, accounted for 
11% of all separations where the principal diagnosis was drug-related. 
Separations can be either same-day (where the patient is admitted and separated on the same 
day) or overnight (where the patient is admitted to hospital and separates on a different 
date). In 2012–13, overnight separations continued to be more common for drug-related 
treatment than same-day separations, accounting for 60% of all drug-related separations.  
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Table 8.1: Hospital separations by drug-related principal diagnosis and duration, 2012–13 
 Same-day separations  Overnight separations  Total separations 
Drug-related principal diagnosis Number %  Number %   Number % 
Analgesics 
Opioids (includes heroin, opium and 
methadone) 
2,599 5.8  4,992 7.3  7,591 6.7 
Non-opioid analgesics (includes 
paracetamol) 
1,915 4.3  5,610 8.2  7,525 6.7 
Total analgesics 4,514 10.0  10,602 15.6  15,116 13.4 
Sedatives and hypnotics 
Alcohol 29,105 64.8  34,206 50.2  63,311 56.0 
Other sedatives and hypnotics 2,801 6.2  6,160 9.0  8,961 7.9 
Total sedatives and hypnotics 31,906 71.0  40,366 59.3  72,272 63.9 
Stimulants and hallucinogens 
Cannabinoids (includes cannabis) 1,227 2.7  3,181 4.7  4,408 3.9 
Hallucinogens (includes LSD and ecstasy) 100 0.2  115 0.2  215 0.2 
Cocaine 261 0.6  183 0.3  444 0.4 
Tobacco and nicotine 19 —  41 0.1  60 0.1 
Other stimulants (includes 
amphetamines, volatile solvents) 
2,249 5.0  4,616 6.8  6,865 6.1 
Total stimulants and hallucinogens 3,856 8.6  8,136 11.9  11,992 10.6 
Antidepressants and antipsychotics 1,993 4.4  5,931 8.7  7,924 7.0 
Volatile solvents 374 0.8  431 0.6  805 0.7 
Other and unspecified drugs of concern  
Multiple drug use 2,247 5.0  2,354 3.5  4,601 4.1 
Unspecified drug use and other drugs not 
elsewhere classified 
49 0.1  250 0.4  299 0.3 
Total other drugs of concern  2,296 5.1  2,604 3.9  4,900 4.4 
Fetal and perinatal related conditions 0 . .  27 —  27 — 
Total 44,939 100.0  68,097 100.0  113,036 100.0 
Note: Separations with a care type of ‘Newborn’ (without qualified days), and records for ‘Hospital boarders’ and ‘Posthumous organ procurement’ 
have been excluded. 
Source: AIHW analysis of the National Hospital Morbidity Database 2012–13. 
The total number of drug-related hospital separations has increased from 80,913 in 2003–04 
to 113,036 in 2012–13 (Table 8.2). At the same time, total hospital separations have increased, 
with drug-related hospital separations consistently making up about 1% of all hospital 
separations across this period. 
Alcohol has consistently been the drug-related principal diagnosis with the highest number 
of hospital separations from 2003–04 to 2012–13, with the number of separations increasing 
from 40,774 to 63,311 in that time.  
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Table 8.2: Hospital separations by drug-related principal diagnosis, 2003–04 to 2012–13 
Drug of concern 2003–04 2004–05 2005–06 2006–07 2007–08 2008–09 2009–10 2010–11 2011–12 2012–13 
Analgesics 
Opioids 6,058 5,849 5,595 6,618 6,992 7,168 7,515 7,517 7,677 7,591 
Non-opioid analgesics 6,005 6,525 6,504 5,604 5,679 6,704 6,691 6,557 7,031 7,525 
Sedatives and hypnotics 
Alcohol 40,774 42,976 46,683 52,021 54,923 57,532 61,125 61,467 63,230 63,311 
Other sedatives and hypnotics 9,571 9,702 9,750 10,062 10,424 10,619 10,404 10,089 9,960 8,961 
Stimulants and hallucinogens 
Cannabinoids 2,672 2,881 3,497 3,263 3,047 3,270 3,364 3,745 4,157 4,408 
Hallucinogens 190 416 412 362 449 187 169 151 150 215 
Cocaine 188 305 234 220 234 230 290 179 286 444 
Tobacco and nicotine 49 37 47 59 36 51 50 51 59 60 
Other stimulants 4,550 4,005 4,350 4,621 3,844 3,447 3,182 3,997 5,758 6,865 
Antidepressants and antipsychotics 6,575 6,756 6,615 6,701 6,753 7,661 7,540 7,650 7,907 7,924 
Volatile solvents 925 1,023 872 816 734 825 780 763 842 805 
Other drugs of concern  
Multiple drug use 3,037 2,823 3,078 3,384 3,307 3,039 3,234 4,189 4,384 4,601 
Unspecified drug use and other drugs of concern 267 228 206 187 167 241 242 290 297 299 
Fetal and perinatal conditions 52 46 45 41 43 50 30 34 25 27 
Total 80,913 83,572 87,888 93,959 96,632 101,024 104,616 106,679 111,763 113,036 
Rate of separation(a) (per 100,000 population) 408 417 433 456 460 470 478 481 496 493 
(a) Crude rate is based on the Australian estimated resident population as at 31 December of the reference year. 
Note: Separations with a care type of ‘Newborn’ (without qualified days), and records for ‘Hospital boarders’ and ‘Posthumous organ procurement’ have been excluded. 
Source: AIHW analysis of the National Hospital Morbidity Database 2012–13. 
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8.2 Online Services Reporting 
The number of treatment episodes reported through the AODTS NMDS for Aboriginal and 
Torres Strait Islander people does not represent all alcohol and other drug treatments 
provided to Indigenous people in Australia. Information on drug services specifically aimed 
at Indigenous Australians (funded by the Australian Government) is included in the Online 
Services Report (OSR) data collection, managed by the AIHW. Key information is provided 
below and additional information on the definitions used in the OSR, including the 
definition of ‘episodes of care’, is in Appendix B. 
Residential treatment and rehabilitation refers to residential programs where clients receive 
formal rehabilitation for substance use. In 2012–13, around 2,600 episodes of care were 
provided to clients in Australian Government–funded Indigenous residential 
treatment/rehabilitation services (Table 8.3). Of these episodes of care, 74% were for male 
clients. It is important to note that these data are not directly comparable with AODTS 
NMDS data, since definitions of treatment episodes differ between the 2 collections. 
In 2012–13, around 24,000 episodes of care were provided to clients accessing Australian 
Government–funded Indigenous sobering-up or residential respite services. Sobering-up 
clients are in residential care overnight and do not receive formal rehabilitation, whereas 
residential respite clients spend 1–7 days in residential care for the purpose of respite and do 
not receive formal rehabilitation. Nearly half (48%) of these episodes were for male clients. 
‘Other care’ refers to a diverse range of non-residential programs, including preventive care, 
after-care, follow-up and mobile assistance/night patrol. In 2012–13, there were 
approximately 278,000 episodes of ‘other care’. The high number of ‘other care’ episodes, 
compared with residential or sobering-up episodes, is due to their short-term nature, with 
some clients receiving multiple episodes of care over the course of the year (see Appendix B). 
Over half (55%) of the episodes of ‘other care’ were for females clients 
There were 5 organisations with a large client base that began reporting in 2012–13 that 
dramatically increased the number of episodes of care, especially for non-residential,  
follow-up and aftercare services. If episodes of care for these services were excluded, the 
total episodes of care would be around 113,300, much closer to the numbers reported in 
previous years (68,000 in 2008–09, 76,000 in 2009–10, 94,000 in 2010–11 and 74,000 in  
2011–12). The increase may also be partly due to improvements in data recording and 
management at health organisations. 
Table 8.3: Estimated number of episodes of care provided by Australian Government-funded 
Indigenous substance use–specific services, by sex and treatment type, 2012–13 
(a) Sex was reported as ‘unknown’ in 95 episodes of care and these have been excluded for analysis purposes. 
Source: Aboriginal and Torres Strait Islander health services report 2011–12 (AIHW 2014a) 
 Male  Female  Total 
Treatment type Number %  Number %  Number % 
Residential treatment/rehabilitation 1,952 73.9  642 24.3  48 100.0 
Sobering-up/residential respite 11,580 48.0  9,195 38.1  3,349 100.0 
Other care(a) 113,429 40.8 
 
152,459 54.8 
 
12,279 100.0 
Total 126,961 41.6  162,296 53.2  15,676 100.0 
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8.3 Specialist Homelessness Services 
The Specialist Homelessness Services Collection (SHSC) began on 1 July 2011. The SHSC 
describes all clients who receive services from specialist homelessness agencies and the 
assistance they receive, including clients with an alcohol and other drug issue. 
For this report, a client is identified as having a current alcohol and other drug issue in this 
collection if they provided any of the following information: 
• Their formal referral source to the specialist homelessness agency was a ‘drug and 
alcohol service’. 
• They reported ‘problematic drug or substance use’ or ‘problematic alcohol use’ as a 
reason for seeking assistance. 
• At some stage during their support period, a need was identified, provided or referred 
for ‘drug/alcohol counselling’. 
• They reported they had been in a rehabilitation facility in the last 12 months. 
In addition to supporting clients who are homeless, a key aim of specialist homelessness 
services is to prevent homelessness from occurring among those who find themselves at risk 
of becoming homeless. Services provided by Specialist Homelessness Services (SHS) agencies 
include accommodation and associated support services. For further details regarding the 
scope and coverage of the SHSC, see Appendix B. 
The SHSC includes data on the use of specialist homelessness services by clients with an 
alcohol and other drug issue. This section presents information provided by SHS agencies on 
clients with a current alcohol and other drug issue for 2012–13. 
Drug and alcohol-related support  
There were nearly 194,000 (SHS clients aged 10 years or over reported in 2012–13 
(AIHW 2013b). Of these, 12,964 (7%) were clients with a current alcohol and other drug issue.  
Nationally, there were 1.3 clients per 100,000 population with a current alcohol and other 
drug issue who accessed accommodation services from SHS agencies in 2012–13. Across 
jurisdictions, rates ranged from 3.4 per 100,000 population for the Northern Territory to 0.6 
for Western Australia. 
For other types of support services provided (excluding accommodation services), the 
national rate was 30.9 per 100,000 population for general assistance and support, and 23.0 
per 100,000 for specialised services.  
Specialist Homelessness Services clients  
For clients with a current alcohol and other drug issue, those aged 30–39 had the highest rate 
of SHS agency use (119 per 100,000 population) followed by 40–49 year olds (92) for 2012–13. 
Rates of SHS agency use were higher for males than females (71 and 43 per 100,000 
population, respectively).  
The rate of SHS clients with a current alcohol and other drug issue for Indigenous 
Australians was 11 times that for non-Indigenous Australians (4,599 and 409 per 100,000 
population, respectively).  
There were over 1,500 clients with a current alcohol and other drug issue aged 10–19.  
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A specialist homelessness agency/outreach worker was the most frequently recorded source 
of referral to SHS agencies (12%) for clients with a current alcohol and other drug issue 
during 2012–13. The next most frequently recorded sources were referrals from other 
agencies (government or non-government) (11%) and referrals from drug and alcohol 
services (9%).  
More than half of SHS clients (53%) with a current alcohol and other drug issue reported an 
episode of homelessness in the 12 months before presenting, compared to 28% of those 
clients without a current alcohol and other drug issue (AIHW 2013b). 
Service use 
Main reason for seeking SHS agency assistance  
Around 1 in 7 SHS clients (14%) with an alcohol and other drug issue had time out from 
family/other situation as the main reason for seeking assistance, followed by unemployment 
(13%) and relationship/family breakdown (12%). In terms of alcohol and other drug issues 
being the main presenting reason, only 5% of SHS clients with a current alcohol and other 
drug issue had this reason recorded as their main reason for seeking assistance. 
When all presenting reasons for seeking assistance are considered, unemployment (65%) and 
financial difficulties (52%) are the most frequently reported reasons. 
Services and assistance  
About 111,000 services were provided to SHS clients with a current alcohol and other drug 
issue in 2012–13. Of these, nearly 8 out of 10 (78%) related to general support and assistance, 
such as providing advice and information (support services not related directly to 
housing/accommodation services). Only 2% of services were provided for drug/alcohol 
counselling. 
Length of support provided  
More than two-thirds of clients with a current alcohol and other drug issue received over 
180 days of support (67%) in 2012–13. About 1 in 16 clients received 5 days or less (6%). 
8.4 National Opioid Pharmacotherapy Statistics 
Annual Data 
Although the AODTS NMDS captures some information on pharmacotherapy treatment, 
more comprehensive information on pharmacotherapy treatment provided in relation to 
opioid use is available from the National Opioid Pharmacotherapy Statistics Annual Data 
(NOPSAD) collection.  
Treatment of opioid dependence using pharmacotherapy is administered according to the 
laws of the relevant state or territory, and within a framework that may include not only 
medical treatment but also social and psychological treatment. 
The Australian Government contributes funds for the provision of pharmacotherapy drugs 
via pharmaceutical benefits arrangements. These drugs are prescribed by medical 
professionals and provided to clients through clinics and pharmacies approved by state and 
territory governments. Three pharmacotherapy drugs are currently available for the 
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treatment of opioid dependence in Australia: methadone, buprenorphine and 
buprenorphine-naloxone (naloxone is added to deter injection). 
Clients 
The most recent report on the NOPSAD collection (AIHW 2014c) showed that over 47,000 
people were on a course of pharmacotherapy treatment for their opioid dependence on a 
snapshot day in June 2013. The number of people receiving opioid pharmacotherapy 
treatment almost doubled between 1998 (from around 25,000 people) and 2013, but growth 
in client numbers slowed in recent years (to less than 1% a year from 2010 to 2013). 
Around two-thirds (69%) of clients in 2013 were aged 30–49, and this proportion has been 
fairly consistent since 2006. However, from 2006 to 2013 the proportion of clients aged less 
than 30 more than halved (from 28% to 11%), and the proportion of clients aged 50 and over 
more than doubled (from 8% to 19%). These trends suggest an ageing cohort of people in 
opioid pharmacotherapy treatment.  
Around two-thirds (65%) of clients receiving pharmacotherapy on a snapshot day in June 
2013 were male. This proportion was similar for each of the 3 pharmacotherapy types 
(methadone, buprenorphine and buprenorphine-naloxone) and has remained stable since 
2006. 
About 1 in 10 clients (9%) who received pharmacotherapy identified as Aboriginal or Torres 
Strait Islander. This excludes Victoria and Western Australia which do not report Indigenous 
status). Indigenous people were around 3 times as likely to have received pharmacotherapy 
treatment as the non-Indigenous population. Indigenous clients were more likely to be 
treated with methadone (73%) than non-Indigenous pharmacotherapy clients (66%). 
Clients receive pharmacotherapy treatment for a range of opioid drugs. These include illicit 
opioids (such as heroin) and pharmaceutical opioids, which are obtained illicitly or are 
available by prescription (such as morphine and oxycodone) or over-the-counter (such as 
codeine–paracetamol combinations). At the national level, opioid pharmacotherapy clients 
were about twice as likely to report heroin as an opioid drug of dependence than they were 
for opioid pharmaceuticals; however this varied by jurisdiction. 
Around two-thirds (67%) of clients were treated with methadone in 2013, and the remaining 
one-third (33%) were treated with a form of buprenorphine. Treatment with methadone 
ranged from 31% of clients in the Northern Territory to 79% of clients in the Australian 
Capital Territory. 
Prescribers 
Methadone and buprenorphine are controlled drugs, and health professionals need 
authorisation to prescribe them to clients. Nationally, there were 2,025 authorised prescribers 
of opioid pharmacotherapy drugs in 2013, an increase of 15% from 2012. The majority of 
these prescribers were authorised to prescribe more than 1 type of drug (71%) and worked in 
the private sector (82%). 
Dosing points 
Most clients need to attend a dosing point regularly to take their opioid pharmacotherapy 
drug under supervision. Nationally, there were 2,355 dosing points in Australia in 2013. The 
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majority were located in pharmacies (88%), followed by hospitals, public clinics and 
correctional settings such as prisons. 
8.5 Prisoner health 
Prisoners typically have far greater health needs than the general population, with high 
levels of drug use, mental health disorders, chronic disease, communicable disease and 
disability (AIHW 2013c; Hockings et al. 2002; Indig et al. 2010). State and territory 
governments are responsible for providing health services to prisoners. In most states and 
territories, health departments deliver these services, although in some, these services are 
provided by the department responsible for corrective services or by private organisations 
(AIHW 2013c). The AIHW’s National Prisoner Health Data Collection (NPHDC) contains 
data on prisoner health in Australia. The following information is based on the most recent 
collection, as reported in The health of Australia’s prisoners 2012 (AIHW 2013c). 
Alcohol and other drug use 
Almost 4 in 5 (78%) prison entrants during the survey period were daily smokers 
(AIHW 2013c). This is much higher than the general population aged 18 and over, with less 
than 1 in 8 people age 18 years and over (13%) being daily smokers in 2013 (AIHW 2014b). 
However, prisoners are younger than the average age of the general population, which will 
influence their drug use prevalence. Similar differences apply to weekly or irregular 
smokers, comprising 6% or prison entrants (AIHW 2013c) but only 3% of the general 
population aged 18 and over.  
Nearly half (46%) of prison entrants consumed alcohol in the previous 12 months at levels 
placing them at a high risk of alcohol-related harm, while a further 29% were at a low risk of 
alcohol-related harm (AIHW 2013c). By comparison, among the general population in 2013, 
19% of people aged 18 years and over consumed alcohol at levels placing them at high risk of 
harm across their lifetime, while 61% were at low risk (AIHW 2014b). 
Consuming alcohol at high risk levels was more likely for those in the younger prisoner age 
groups (50% for entrants aged 18–24 compared with 39% for those aged 45 and over), 
although there was little difference in the low risk proportion of prison entrants 
(AIHW 2013c). 
Seven in 10 (70%) prison entrants reported using illicit drugs in the 12 months before their 
imprisonment (AIHW 2013c). This was higher than the general population aged 18 and over, 
with less than 2 in 10 (15%) having used illicit drugs in the previous 12 months 
(AIHW 2014b). In both contexts, however, illicit drug use was less common among those 
aged in their mid-40s and over.  
Cannabis was used by half (50%) of prison entrants in the previous 12 months, and was the 
most commonly used illicit drug. Among the general population aged 14 and over, 1 in 10 
people (10%) reported using cannabis in the previous 12 months in 2013 (AIHW 2014b). Use 
of amphetamines was also common among prison entrants, particularly in the younger age 
groups (39% for 18–24 and 43% for 25–34, compared with 16% for those aged 45 and over).  
A large proportion of prison entrants reported having comorbid mental health and drug 
issues. Of those who had been told they had a mental health disorder, 50% had a high risk of 
alcohol-related harm, 86% were current smokers and 76% had used drugs in the 12 months 
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before their current imprisonment (Figure 6.36). Proportions were similar for those referred 
to mental health services after assessment.  
Health services provided to prisoners 
Of the 9,027 visits to prison clinics during the 2-week data collection period, 5% related to 
alcohol or other drug use (AIHW 2013c). Three-fifths (61%) of these visits resulted in 
treatment being provided and a further two-fifths (42%) resulted in advice and education 
(more than 1 service could be provided). For almost half (46%), only assessment was 
provided.  
During the 1-day data collection period, 5% of prisoners received drugs for opioid 
dependence and 1% received drugs for nicotine dependence (AIHW 2013c). Those in the  
25–34 and 35–44 age groups were most likely to receive drugs for opioid dependence (9% 
and 7%, respectively), while those in the 18–24 age group were most likely to receive drugs 
for nicotine dependence (3%). 
Information on the differences between the data collection periods is available in The health of 
Australia’s prisoners 2012 (AIHW 2013c).  
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Appendix A: Data quality statement for the 
AODTS NMDS 
Summary of key data quality issues  
Data are reported by each state and territory regardless of funding type. Because all services 
are publicly funded, they receive at least some of their funding through a state, territory or 
Australian Government program. The actual funding program cannot be differentiated; 
however services are categorised according to their sector, with government funded and 
operated services reported as public services and those operated by non-government 
organisations reported as private services. 
National data are affected by variations in service structures and collection practices between 
states and territories and care should be taken when making comparisons between them. 
Also, the AODTS NMDS has been implemented in stages, so comparisons across years, 
particularly the earlier years of the collection, need to be made with caution. Data for  
2001–02 and 2002–03 have not been included in the 2012–13 annual report due to these 
comparability issues.  
The AODTS NMDS reports both main and additional treatment types. However, Victoria, 
Western Australia and Tasmania do not differentiate between main and other treatment 
types. Caution should be used in comparing episodes from these states with those of other 
states and territories.  
As a unit of measurement, the ‘closed treatment episode’ used in the AODTS NMDS cannot 
provide information on the number of clients who access publicly funded alcohol and other 
drug treatment, nor can it provide information on the extent of concurrent, sequential or 
recurrent service use. This is because it is possible for a single individual to access more than 
1 service at a time, for different treatments and for different substance-use problems.  
However, in 2012–13, the AODTS NMDS implemented an SLK for the first time. This linkage 
key enables the number of clients receiving treatment to be counted while continuing to 
ensure the privacy of these individuals, in addition to reporting on closed treatment 
episodes. 
With the introduction of the SLK, a number of client-based analyses will be possible 
including: 
• estimating the number and rate of clients receiving treatment and the remoteness and 
socioeconomic distribution of the client in the 2012–13 and 2013–14 annual reports  
• more complex analyses on patterns of drug use and pathways through treatment, as data 
with unique client counts accumulate over time. 
Description 
The AODTS NMDS presents data about alcohol and other drug treatment services, their 
clients, drugs of concern and the types of treatment received. The AODTS NMDS counts 
treatment episodes completed during the collection period, which for this collection was 
1 July 2012 to 30 June 2013. This includes all clients who had completed 1 or more treatment 
episodes at an alcohol and other drug treatment service that was in scope during 1 July 2012 
to 30 June 2013. 
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The AODTS NMDS is a collection of data from publicly funded treatment services in all 
states and territories, including those directly funded by the Australian Government 
Department of Health (DoH). Publicly funded alcohol and other drug treatment agencies 
collect the agreed data items and forward this information to the appropriate health 
authority as arranged. Agencies ensure that the required information is accurately recorded.  
For most states and territories, the data provided for the national collection are a subset of a 
more detailed jurisdictional data set used for planning at that level. 
Institutional environment 
Under a Memorandum of Understanding with the DoH, the AIHW is responsible for the 
management of the AODTS NMDS. The AIHW maintains a coordinating role in the 
collection, including providing secretariat duties to the AODTS NMDS Working Group, 
undertaking data development and highlighting national and jurisdictional implementation 
and collection issues. The AIHW is also the data custodian of the national collection and is 
responsible for collating data from jurisdictions into a national data set and analysing and 
reporting on the data.  
The AIHW is a major national agency set up by the Australian Government under the 
Australian Institute of Health and Welfare Act 1987 to provide reliable, regular and relevant 
information and statistics on Australia’s health and welfare. It is an independent statutory 
authority established in 1987, governed by a management board, and accountable to the 
Australian Parliament through the Health portfolio. 
The AIHW aims to improve the health and wellbeing of Australians through better health 
and welfare information and statistics. It collects and reports information on a wide range of 
topics and issues, from health and welfare expenditure, hospitals, disease and injury and 
mental health to ageing, homelessness, disability and child protection. 
The AIHW also plays a role in developing and maintaining national metadata standards. 
This work contributes to improving the quality and consistency of national health and 
welfare statistics. The AIHW works closely with government and non-government 
organisations to achieve greater adherence to these standards in administrative data 
collections to promote national consistency and comparability of data and reporting. 
One of the main functions of the AIHW is to work with the states and territories to improve 
the quality of administrative data and, where possible, to compile national data sets based on 
data from each jurisdiction, to analyse these data sets and disseminate information and 
statistics. 
The Australian Institute of Health and Welfare Act 1987, in conjunction with compliance with 
the Privacy Act 1988 (Cwlth), ensures that the data collections managed by the AIHW are 
kept securely and under the strictest conditions with respect to privacy and confidentiality. 
For further information see the AIHW website <www.aihw.gov.au>. 
Timeliness 
The state and territory health departments and the Australian Government DoH provide 
data to the AIHW using the AIHW’s online data validation tool (Validata). This tool allows 
data suppliers to upload their data files and have them validated immediately. For the  
2012–13 collection, data were due for submission through the Validata at the end of 
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November 2013 with final approval of all data due at the end of December 2013. The 2012–13 
collection was finalised in mid-February 2014.  
Accessibility 
Publications containing AODTS NMDS data, including the annual Alcohol and other drug 
treatment services in Australia reports, are available on the AIHW website 
<www.aihw.gov.au>. These reports are available for download free of charge. To enhance 
data availability, a series of extensive supplementary tables accompanying the annual report 
is also available online. 
Requests for unpublished data can be made by contacting the AIHW on (02) 6244 1000 or by 
email to info@aihw.gov.au. A cost-recovery charge may apply to requests that require 
substantial resources. Depending on the nature of the request, requests for access to 
unpublished data may require approval from the data custodians or the AIHW Ethics 
Committee. 
Interpretability 
Contextual information on the alcohol and other drug treatment sector is available in the 
annual Alcohol and other drug treatment services in Australia reports. Supporting information 
about the data includes footnotes to tables and figures and details about the data items and 
methods used in reporting, as well as glossary items. 
Metadata for the AODTS NMDS is available from METeOR, the AIHW’s online metadata 
repository. METeOR specifications for the collection can be accessed from 
<http://meteor.aihw.gov.au/content/index.phtml/itemId/466861>. 
Relevance 
The AODTS NMDS contains information on treatment episodes provided by publicly 
funded alcohol and other drug treatment services.  
Data on agencies 
The AODTS NMDS contains information on publicly funded alcohol and other drug 
treatment services. Agencies are excluded from the AODTS NMDS if they: 
• do not receive any public funding 
• provide accommodation as their main function (including half-way houses and 
sobering-up shelters) 
• are located in prisons or detention centres 
• are located in acute care or psychiatric hospitals and only provide treatment to admitted 
patients 
• have the sole function of prescribing or providing dosing for opioid pharmacotherapy 
(these agencies are excluded because of the complexity of this sector). 
Australian Government-funded primary health care services and substance-use services are 
in scope for the AODTS NMDS, but most of these agencies do not contribute to the collection 
as they currently provide data to other collections.  
For each agency in the AODTS NMDS, data are collected on the geographical location of the 
agency. 
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Data on treatment episodes 
The AODTS NMDS contains information on all treatment episodes provided by in-scope 
agencies where the episode was closed in the relevant financial year. A treatment episode is 
considered closed where: 
• The treatment is completed or has ceased. 
• There has been no contact between the client and treatment provider for 3 months. 
• There is a change in the main treatment type, principal drug of concern or delivery 
setting. 
Treatment episodes are excluded from the AODTS NMDS if they: 
• are not closed in the relevant financial year 
• are for clients who are receiving pharmacotherapy and not receiving any other form of 
treatment that falls within the scope of the collection 
• only include activities relating to needle and syringe exchange 
• are for a client aged under 10. 
For each treatment episode in the AODTS NMDS, data are collected on: 
• the client: sex, date of birth, Indigenous status, country of birth, preferred language, 
source of referral and injecting drug status  
• whether the client is receiving treatment for their own drug use or someone else’s drug 
use 
• the drugs of concern (principal drug of concern and up to 5 additional drugs of concern)  
• the method of use for the principal drug of concern 
• types of treatment (main treatment type and up to 4 additional treatment types) 
• the start and end dates of the episode and the reason the episode was closed. 
Data on clients 
The AODTS NMDS does not contain a unique identifier for clients and information about 
clients is collected at the episode level. For the 2012–13 collection, an SLK was introduced to 
enable the number of clients receiving treatment to be counted while continuing to ensure 
the privacy of these individuals receiving treatment. 
The SLK is constructed from information about the client’s date of birth, sex and an 
alphacode based on selected letters of their name.  
Because SLK data are not available for all clients, an imputation strategy has been developed 
to adjust the data to account for this. Further information about the imputation methodology 
applied to these data can be found in Appendix C. 
Accuracy 
Data for the AODTS NMDS are extracted each year from the administrative systems of the 
health departments or are provided by the treatment agencies directly to the health 
departments. These data are then collated by the health departments according to the 
definitions and technical specifications agreed to by the departments and the AIHW. 
Data for the AODTS NMDS are available from 2001–02; however, due to comparability 
issues, only data from 2003–04 onwards are used in this report. 
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Almost all jurisdictions submitted over 90% of in-scope treatment services provided data for 
the AODTS NMDS in 2012–13, except for New South Wales who provided 80% of in-scope 
agencies; the other jurisdictions ranged from 91% in the Australian Capital Territory to 100% 
in Western Australia, the Northern Territory and Tasmania. Each in-scope treatment service 
is required to provide information on each agency related to the service (including delivery 
outlets). However, some services only provide information on the main administrative 
centre. As a result, the number of treatment agencies may be under counted (information on 
the number of agencies for which data are not provided is not available).  
Overall, the coverage of episode data in the AODTS NMDS for 2012–13 is good. For most 
data elements, less than 2% of records have missing data (including not stated or unknown 
responses) while around 6% of records have an unknown Indigenous status. Of the records 
relating to episodes provided to clients receiving treatment for their own drug use, reason 
for cessation is not available for 4%, method of drug use is not available for 6% and injecting 
drug use status is not available for 16%. 
Not all jurisdictions code drug of concern using the full Australian Standard Classification of 
Drugs of Concern 2011 (ABS 2011a) but rather use a short list of drug codes. As a result, some 
specific drugs may be under-reported. For example, oxycodone may be recorded as ‘opioid 
analgesics n.f.d.’ rather than the specific oxycodone code. 
State and territory issues 
New South Wales 
New South Wales Health collects data from all Australian Government/state 
government-funded agencies as part of requirements stipulated in a signed service 
agreement at the commencement or renewal of each funding agreement. Data are provided 
monthly by agencies to their respective Local Health Districts (LHD). There are a number of 
data collection systems in use and development. The New South Wales Minimum Data Set is 
collected by those systems from which the collection of the AODTS NMDS is provided. New 
South Wales is developing a State Baseline Build related to alcohol and other drugs that will 
roll out to New South Wales through the CHIME and Cerner systems over the next few 
years. The majority of NGO data are collected via the Network of Alcohol and other Drug 
Agencies (NADA) online system. NADA is the peak organisation for the non-government 
drug and alcohol sector in New South Wales. 
Victoria 
The Victorian Drug Treatment Service Program provides a range of services to cover the 
needs of clients experiencing substance abuse issues. The Victorian Government purchases 
these drug treatment services from independent agencies (non-government organisations) 
on behalf of the community, and has developed the concept of an ‘episode of care’ as the 
fundamental unit for service funding. An episode of care is a particular course of treatment 
in which the client achieves at least 1 significant treatment goal under the care of an alcohol 
and other drug worker. 
The episode of care is a measure of successful client outcomes. It aims to develop 
performance measurement beyond activities, throughputs and outputs, to measure what the 
client gets out of treatment. Agencies funded to provide drug treatment services in Victoria 
have service provision targets, which are defined in terms of number of episodes of care to 
be provided by service type and by target group (for example, youth or adult). As a 
requirement of their funding agreement with the Victorian Department of Health, agencies 
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are required to submit data quarterly, detailing their provision of drug treatment services 
and achievement of episodes of care. A subset of this data is contributed to the AODTS 
NMDS annually. 
Victorian alcohol and other service providers use either SWITCH, FullADIS or their own 
internal information systems to report quarterly activity. However, since 2007–08, hospital 
and community health centres have used the HealthSMART client management systems to 
report on alcohol and other drug treatment activity. 
Victoria does not differentiate between main and other treatment types. As such, Victoria is 
not directly comparable with other jurisdictions because every treatment type provided is 
reported as a separate episode. Caution should be used in comparing Victorian episodes 
with those of other states and territories. 
Victoria only provides information about non-government agencies that receive public 
funding. 
In Victoria, assessment only episodes include brokerage services wherein clients with drug 
conditions who have received sentences are assessed, a treatment plan developed, and the 
necessary treatment purchased from community-based alcohol and other drug treatment 
agencies. The very nature of these types of episodes results in durations that may exceed 
90 days. Following the implementation of a new operational system for brokerage services, 
from October 2011 brokerage assessments for treatment are closed when the client is referred 
to the nominated agency funded to delivery, rather than at the completion of treatment by 
that agency. This will result in a significant reduction in the duration of these episodes. As 
the actual completion date was not available for episodes from October 2011 onwards, 
episodes for these brokerage assessments were given a nominal completion date that was 
equal to the commencement date as most assessments are completed within 1 day. Actual 
completion dates were reported from 2012–13. 
Queensland 
The Queensland Department of Health collects data from all Queensland Government 
alcohol and other drug treatment service providers and from all Queensland Illicit Drug 
Diversion Initiatives—Police and Court Diversion clients. The Australian Government 
currently collects data from the Australian Government–funded agencies operating in 
Queensland. 
The Queensland Department of Health has a state-wide web-based clinical information 
management system supporting the collection of AODTS NMDS items for all Queensland 
Government alcohol and other drug treatment services.  
Since 2007, the Queensland Department of Health has funded the Queensland Network of 
Alcohol and Drug Agencies Ltd (QNADA) to collate and deliver to the Queensland 
Department of Health aggregated AODTS NMDS data for the AOD non-government sector. 
Care should be taken when interpreting principal drug of concern over time for Queensland, 
as Queensland did not provide data consistent with the AODTS NMDS specifications in 
2001–02. 
Treatment provided to people diverted to services by police and the courts is recorded as 
information and education only. Actual treatment involves a 2-hour treatment session that 
includes extensive alcohol and drug assessment to determine dependence, assessment of 
risk-taking behaviours, provision of advice and information on reducing/ceasing drug use 
and harm minimisation, motivational intervention, provision of resources and referral. 
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Western Australia 
In Western Australia, clients are able to access treatment services from multiple sites within a 
single episode depending on client needs and appointment availability.  
Data are provided by both government and non-government sectors. Non-government 
services are contracted by the Drug and Alcohol Office (DAO) to provide alcohol and drug 
services. They have contractual obligations to incorporate the data elements of the 
AODTS NMDS in their collections. They are also obliged to provide data in a regular and 
timely manner to DAO. These data are collated and checked by DAO before submission to 
the AIHW annually. 
Due to the increase in integrated services that include government and non-government 
service providers, caution should be used in comparing services in Western Australia with 
those in other states and territories and across years. Services in Western Australia are not 
directly comparable with other states, or previous years, because of the growth of integrated 
services that include government and non-government service providers. 
In Western Australia, a reform in the way non-residential treatment services are provided in 
the Perth metropolitan area has resulted in the co-location and integration of some 
government and non-government services. Time series data do not adequately illustrate 
these changes. 
Western Australia reviews the geographical demographics of their clients regularly 
throughout the year and adjusts the locations of their service delivery outlets accordingly to 
meet the demands of the population. Therefore, variation between Remote and Very remote 
locations exists between years. 
Clients are generally able to access the agencies from multiple sites within any 1 episode, 
depending on the client’s need and the availability of appointments within the alcohol and 
other drug treatment service. Examples of where these situations occur are when clients: 
• follow a specific worker from 1 service delivery outlet to another 
• change workers during an episode and the workers are located at different service 
delivery outlets 
• attend 1 service delivery outlet for the initial service contact (commencement of episode) 
due to availability of appointment times and move to a more convenient service delivery 
outlet during the episode 
• move between service delivery outlets to fit service contacts within clients’ other 
personal needs. 
Western Australia does not differentiate between main and other treatment types. Caution 
should be used in comparing Western Australian episodes with those of other states and 
territories. As such, Western Australia is not directly comparable with other jurisdictions 
because every treatment type provided is reported as a separate episode. Note that a small 
number of episodes provided in Western Australia through the Non-Government 
Organisation Treatment Grants Program (NGOTGP) will have additional treatment types.  
South Australia 
Data are provided by government (Drug and Alcohol Services South Australia—DASSA) 
and non-government alcohol and other drug treatment services.  
Non-government alcohol and other drug treatment services in South Australia are subject to 
service agreements with the South Australian Minister for Mental Health and Substance 
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Abuse. As part of these service agreements, non-government organisations are required to 
provide timely client data in accordance with the AODTS NMDS guidelines. Data are 
forwarded to DASSA for collation and checking. DASSA then forwards cleaned data to the 
AIHW annually. DASSA does not collect information directly from those services funded by 
the NGOTGP. These data are provided to DoH via AIHW. 
This year, for the first time, the South Australian Police, Drug Diversion Assessment 
Program data has been included in the collection. This has seen an increase in episodes with 
a referral source of police diversion and a main treatment type of assessment only. 
Tasmania 
Data are provided by both government (Alcohol and Drug Services—ADS) and 
non-government organisations (NGOs). 
NGOs funded by the Tasmanian Government provide AODTS NMDS and key performance 
indicator data under the provisions of a service agreement. AODTS NMDS data are 
submitted to ADS State Office either 6-monthly or yearly. Data quality reports are fed back 
to the NGOs and training/information on data capture practices are provided as required. 
ADS uses the iPM patient administration system as its key business system. This state-wide 
system is in use across the 3 Tasmanian Health Organisations (THOs), which include 
inpatient, residential, outpatient and community service settings. It has been modified to 
capture the AODTS NMDS data items. A range of online self-service reporting is used to 
monitor performance activity and data quality. 
Tasmania’s illicit drug diversion treatment data are managed and extracted from the Drug 
Offence Reporting System (DORS). This system resides with Tasmania Police. A high 
proportion of treatment episodes in Tasmania with the principal drug of cannabis can be 
attributed largely to the inclusion of this data. 
The Tasmania Early Intervention Project (TEIP) commenced in 2011. This project focuses on 
young people and involves a police caution that facilitates a referral for young people to an 
alcohol and other drug treatment service for brief or opportunistic intervention. AODTS 
NMDS data for this program are entered via the iPM patient administration system. 
Training in culturally sensitive practice has been provided for service providers across the 
Tasmanian alcohol and other drug service sector. Despite this, Tasmanian data reporting for 
Indigenous status remains low. 
NGOs funded by the Tasmanian Government provide AODTS NMDS and key performance 
indicator data under the provisions of a service agreement. AODTS NMDS data are 
submitted to Alcohol and Drug Service State Office on either a 6-monthly or yearly basis. 
Data quality reports are fed back to the NGOs and training/information on data capture 
practices are provided as required. 
Australian Capital Territory 
Australian Capital Territory alcohol and other drug treatment service providers supply the 
Health Directorate with their complete data collection for the AODTS NMDS by 31 August 
each financial year, as specified in their Service Funding Agreement. Since 1 July 2007 the 
treatment service providers have been encouraged to use a standardised reporting system 
developed by the Health Directorate to enhance uniformity and reliability of data. 
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Northern Territory 
Alcohol and other drug treatment services in the Northern Territory are provided by 
government and non-government agencies. The bulk of services provided through 
non-government agencies are funded via service-level agreements with the Northern 
Territory Department of Health. All funded agencies are required to provide the AODTS 
NMDS data items to the department on a regular and timely basis as part of a larger data 
collection. Summary statistical reports are sent to all agencies every 6 months detailing client 
activity for the previous 12 months. 
Australian Government Department of Health (DoH) 
DoH funds a number of alcohol and other drug treatment services under the National Illicit 
Drug Strategy Non-Government Organisation Treatment Grants Program (NGOTGP). These 
agencies are required to collect data (according to the AODTS NMDS specifications) to 
facilitate the monitoring of their activities and to provide quantitative information to the 
Australian Government on their activities. Data from these agencies are generally submitted 
to the relevant state/territory health authority, except for a number of agencies in New 
South Wales, Queensland, Western Australia and South Australia, which submit data 
annually to DoH. In 2012–13 for the first time, the data was submitted to DoH via the AIHW. 
In addition to NGOTGP agencies, a small number of agencies funded under the DoH 
Substance Misuse Service Delivery Grants Fund (SMSDGF) reported data to the AIHW. 
Reported numbers for each state and territory in the AODTS NMDS annual report include 
services provided under the National Illicit Drug Strategy NGOTGP and SMSDGF.  
To ensure consistency with previous years’ data, where an organisation’s sub-agencies had 
been given more than 1 establishment identifier, those identifiers were used and so 
sub-agencies were counted as separate agencies. When an organisation’s sub-projects had 
been given 1 establishment identifier, only this establishment identifier was used, and so 
counted as 1 agency. 
Coherence 
The AODTS NMDS was initially developed from 1996–2001 and the first report containing 
data from the data set was published in 2002. The data specifications were significantly 
altered for the 2003–04 collection and data from 2000–01 to 2002–03 are not comparable with 
data from later years. 
In 2011, the Australian Bureau of Statistics (ABS) updated the standard geography used in 
Australia for most data collections from the Australian Standard Geographical Classification 
(ASGC) to the Australian Statistical Geography Standard (ASGS). Also updated at this time 
were remoteness areas based on the 2011 ABS Census of Population and Housing 
(ABS 2011b). The new remoteness areas (RA) will be referred to as RA 2011, and the previous 
remoteness areas as RA 2006.  
Data for previous years reported by remoteness are reported for RA 2006. Data for 2012–13 
are reported for RA 2011. The AIHW considers the change from RA 2006 to RA 2011 to be a 
series break when applied to data supplied for this indicator; therefore remoteness data for 
2011–12 and previous years are not comparable to remoteness data for 2012–13 and 
subsequent years.  
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Appendix B: Information about the data 
and methods 
Age 
Age is calculated as at the start of the episode. 
Alcohol and other drug treatment provided by 
services funded to assist Indigenous Australians 
The number of treatment episodes reported through the AODTS NMDS for Aboriginal and 
Torres Strait Islander people does not represent all alcohol and other drug treatments 
provided to Indigenous people in Australia for 2012–13. Data for the majority of Australian 
Government-funded Aboriginal and Torres Strait Islander substance use–specific services 
are available from the Online Services Report (OSR) data collection (AIHW 2014a). In the 
2012–13 OSR, 63 substance use–specific services provided data.  
This appendix presents a selection of data from the 2012–13 OSR. The OSR and AODTS 
NMDS have different collection purposes, scope and counting rules. For example, the OSR 
collects service-level estimates for client numbers and episodes of care, whereas the AODTS 
NMDS collects unit records for closed treatment episodes. The definitions of ‘closed 
treatment episodes’ (AODTS NMDS) and ‘episodes of care’ (OSR) are not consistent 
(Box B1). 
In 2012–13, 27 out of the 63 Australian Government–funded substance use–specific services 
reporting in the OSR also reported to the AODTS NMDS.  
Box B1: Comparison of treatment episode definitions in the OSR and AODTS 
NMDS  
The OSR definition of ‘episode of care’ starts at admission and ends at discharge (from 
residential treatment/rehabilitation and sobering-up/respite). In the case of ‘other care’, the 
definition of ‘episode of care’ relates more to the number of visits or phone calls undertaken 
with clients. In contrast to the definition of ‘closed treatment episode’ used in the AODTS 
NMDS, the definition used in this collection does not require agencies to begin a new 
‘episode of care’ when the main treatment type (‘treatment type’) or primary drug of 
concern (‘substance/drug’) changes. It is therefore likely that this concept of ‘episode of 
care’ produces smaller estimates of activity than the AODTS NMDS concept of ‘closed 
treatment episode’.  
The OSR collection, managed by the AIHW, records information about clients of any age, 
whereas the AODTS NMDS reports only about clients aged 10 and over. Any comparisons 
drawn between the collections should therefore be made with caution. 
Substance use-specific services 
In 2012–13, an estimated 49,686 people were seen by Australian Government–funded 
Aboriginal and Torres Strait Islander substance use–specific services (Table B1).  
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Table B1: Estimated number of clients seen by Australian Government–funded Aboriginal and 
Torres Strait Islander substance use–specific services, by jurisdiction and Indigenous status,  
2012–13  
Indigenous status NSW Vic/Tas Qld WA SA NT Total 
Indigenous 4,547 2,650 4,791 5,030 3,279 20,501 40,798 
Non-Indigenous 1,446 275 2,542 868 415 2,524 8,070 
Total clients (number) 23 90 141 177 24 363 818 
Total clients (%) 6,016 3,015 7,474 6,075 3,718 23,388 49,686 
Note: The total estimated number of clients refers to individual clients, and does not include clients that attended groups only.  
Source: Aboriginal and Torres Strait Islander health services report 2011–12 (AIHW 2014a) 
Substance-use treatment and assistance 
Aboriginal and Torres Strait Islander primary health–care services provide a variety of 
health care services, including extended care roles (for example, diagnosis and treatment of 
illness and disease, 24-hour emergency care, dental/hearing/optometry services), preventive 
health care (for example, health screening for children and adults), health-related community 
support (for example, school-based activities, transport to medical appointments) and 
support in relation to substance-use issues. 
The number of clients who received alcohol or other drug treatment at Aboriginal and Torres 
Strait Islander primary health–care services is not collected in the OSR. Similarly, the number 
of reported episodes of care that related solely or partially to alcohol or other drug treatment 
is not collected. However, the drug types for which treatment was provided are known. In 
2012–13, all or most services listed issues relating to alcohol (100%), cannabis (97%) and 
tobacco/nicotine (63%) among the top 5 most importance substance-use issues (Table B2). 
Due to changes in the questionnaire, comparisons between 2012–13 and previous reporting 
periods cannot be made.  
Table B2: Five most common substances/drugs for which treatment/assistance provided by 
Australian Government–funded Aboriginal and Torres Strait Islander substance-use specific 
services, 2012–13 
Substance use issue Major cities Inner regional Outer regional Remote Very remote Total 
Alcohol 12 11 13 11 16 63 
Cannabis/marijuana 11 11 13 10 16 61 
Tobacco/nicotine 4 6 10 7 13 40 
Multiple drug use 7 8 9 2 8 34 
Amphetamines 9 6 6 1 5 27 
Total number of services 12 11 13 11 16 63 
Note: Percentage of services that cover substance use issues on an individual client basis. 
Source: Aboriginal and Torres Strait Islander health services report 2012–13 (AIHW 2014a). 
Data quality statements 
Data quality statements for the National Hospital Morbidity Database, Online Services 
Report Data Collection, Specialist Homelessness Services Collection, National Opioid 
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Pharmacotherapy Statistics Annual Data and National Prisoner Health Data Collection are 
available from <www.aihw.gov.au>. 
The data quality statement for the AODTS NMDS is available in Appendix A. 
Duration 
Duration is calculated in whole days. 
Drugs of concern 
The AODTS NMDS contains data on drugs of concern that are coded using the ABS’s 
Australian Standard Classification of Drugs of Concern 2011 (ASCDC) (ABS 2011a). In this 
report, these drugs are grouped (Table B3). 
Table B3: Groupings of drugs of concern 
Group ASCDC codes Category Includes 
Analgesics  1000–1999 Codeine   
  Morphine   
  Buprenorphine   
  Heroin   
  Methadone   
 Other opioids oxycodone, fentanyl, pethidine 
  Other analgesics paracetamol  
Sedatives and 
hypnotics  
2000–2999 Alcohol ethanol, methanol and other alcohols 
  Benzodiazepines clonazepam, diazepam and temazepam 
  Other sedatives and 
hypnotics 
ketamine, nitrous oxide, barbiturates and kava 
Stimulants and 
hallucinogens  
3000–3999 Amphetamines amphetamine, dexamphetamine and methamphetamine  
  Ecstasy (MDMA)   
  Cocaine   
  Nicotine   
  Other stimulants and 
hallucinogens 
volatile nitrates, ephedra alkaloids, phenethylamines, 
tryptamines and caffeine 
Cannabinoids 7000–7199 Cannabis  
Other 4000–6999 
9000–9999 
Other anabolic agents and selected hormones, antidepressants and 
antipsychotics, volatile solvents, diuretics and opioid 
antagonists 
Not stated 0000–0002 Not stated   
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Hospital separations data 
The hospital separation data included in this report was extracted from the AIHW National 
Hospital Morbidity Database using a selection of codes from the International statistical 
classification of diseases and related health problems, 10th revision, Australian modification 8th 
edition (ICD-10-AM) (NCCC 2012) (see Table B4). 
Table B4: Relationship between the drug of concern and the ICD-10-AM codes 
 Drug of concern identified in principal diagnosis ICD-10-AM codes  
Analgesics 
Opioids (includes heroin, opium, morphine and methadone) 
 
F11.0–11.9, T40.0–40.4 
Non-opioid analgesics (includes paracetamol) F55.2, T39.0, T39.1, T39.3, T39.4, T39.8, T39.9,  
Sedatives & hypnotics 
Alcohol (ethanol) 
 
E52, F10.0–10.9, G31.2, I42.6, K29.2, K70.0–70.9, 
K85.2, K86.0, T51.0–51.9, Z71.4 
Other sedatives and hypnotics (includes barbiturates & 
benzodiazepines; excludes ethanol) 
F13.0–13.9, T41.2, T42.3–42.8 
Stimulants and hallucinogens 
 Cannabinoids (includes cannabis) 
 
F12.0–12.9, T40.7 
 Hallucinogens (includes LSD & ecstasy) F16.0–16.9, T40.8, T40.9 
 Cocaine F14.0–14.9, T40.5 
 Tobacco & nicotine F17.0–17.9, T65.2, Z58.7, Z71.6 
Other stimulants (includes amphetamines, pseudoephedrine, 
volatile nitrates and caffeine) 
F15.0–15.9, T40.6, T43.6, T46.0, T46.3 
Antidepressants and antipsychotics 
Antidepressants and antipsychotics 
 
F55.0, T43.0–43.5 
Volatile solvents 
Volatile solvents 
 
F18.0–18.9, T52.0–52.9, T53.0–9, T59.0, T59.8 
Other and unspecified drugs of concern 
Multiple drug use  
 
F19.0–19.9  
Unspecified drug use and other drugs not elsewhere 
classified (includes psychotropic drugs not elsewhere 
classified; diuretics; anabolic and androgenic steroids and 
opiate antagonists) 
F55.1, F55.3–6, F55.8, F55.9, N14.1–3, T38.7,  
T43.8–9, T50.1–3, T50.7, Z71.5 
 
Fetal and perinatal related conditions 
Fetal and perinatal related conditions (includes conditions 
caused by the mother’s alcohol, tobacco or other drug 
addiction) 
 
P04.2–4, Q86.0 
 
Note: Data for 2012–13 were reported to the NHMD using the ICD-10-AM (NCCC 2012). 
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Population rates 
In this publication, crude rates were calculated using the ABS estimated resident population 
(ERP) at the midpoint of the data range, that is, rates for 2012–13 data were calculated using 
the ERP at 31 December 2012. 
Reason for cessation 
The AODTS NMDS contains data on the episode end reason (reason for cessation). In this 
report, these end reasons are grouped (Table B5). Data for the individual end reasons are 
available in the online supplementary tables.  
A different method was used for grouping end reasons in previous reports and therefore 
trend comparisons across reports should be made with caution. It is possible to compare data 
at the individual end reasons using the supplementary tables. 
Table B5: Grouping of cessation reasons by indicative outcome type 
Outcome type Reason for cessation 
Expected cessation Treatment completed 
Ceased to participate at expiation 
Ceased to participate by mutual agreement 
Unexpected cessation Ceased to participate against advice 
Ceased to participate without notice 
Ceased to participate due to non-compliance 
Administrative cessation Change in main treatment type 
Change in delivery setting 
Change in principal drug of concern 
Transferred to another service provider 
Other Drug court or sanctioned by court diversion service 
Imprisoned (other than drug court sanctioned) 
Died 
Other 
Not stated 
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Remoteness 
This report uses the ABS’s Australian Statistical Geography Standard (ASGS) Remoteness 
Structure 2011 (ABS 2011a) to analyse the remoteness of alcohol and other drug treatment 
agencies. This structure allows areas that share common characteristics of remoteness to be 
classified into broad geographic regions of Australia. These areas are: 
• Major cities  
• Inner regional  
• Outer regional  
• Remote  
• Very remote. 
The Remoteness Structure divides each state and territory into several regions on the basis of 
their relative access to services.  
Examples of places that are considered Major cities in the ASGS classification include 
Canberra and Newcastle. Hobart and Bendigo are Inner regional areas and Cairns and 
Darwin are Outer regional areas. Katherine and Mount Isa are Remote areas and Tennant 
Creek and Meekatharra are Very remote. 
For this report, the remoteness of the agency was determined using the Statistical Area 
Level 2 (SA2) of the agency. Some SAs are split between multiple remoteness areas. Where 
this was the case, the data were weighted according to the proportion of the population of 
the SA in each remoteness area.  
The ASGS has replaced the Australian Standard Geographical Classification (ASGC) 2006 
(ABS 2006). Remoteness areas for previous reports were calculated under the ASGC. 
Therefore remoteness data for 2011–12 and previous years are not comparable to remoteness 
data for 2012–13 and subsequent years.  
Service sectors 
From 2008–09, agencies funded by the Australian Government DoH under the NGOTGP 
were classified as ‘non-government’ agencies. Before this, many of these agencies were 
classified as ‘government’ agencies. Trends in service sectors of agencies should be 
interpreted with caution.  
Specialist homelessness services data 
All agencies that receive funding under the National Affordable Housing Agreement 
(NAHA) or the National Partnership Agreement on Homelessness (NPAH) to provide 
specialist homelessness services are in scope for the SHSC in general, but only those that 
received funding for at least 4 months during the 2012–13 financial year are in scope for the 
2012–13 reporting period. Covered agencies are those in-scope agencies for which details 
have been provided to the AIHW by the relevant state/territory department. 
Specialist homelessness agencies provided assistance to an estimated 244,176 clients in 
412,614 support periods in 2012–13 (AIHW 2013b). It should be noted that these figures have 
been adjusted for non-responses. 
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Data collected include basic sociodemographic information and the services needed by, and 
provided to, each client. Information about each client’s situation before and after receiving 
SHS agency services is also collected. 
For further information on the SHS collection, refer to Specialist Homelessness Services 2012–13 
(AIHW 2013b).  
There are a number of considerations related to the 2012–13 SHSC data:  
• Data presented in this report exclude data for clients who were aged less than 10 at the 
beginning of their first support period in 2012–13. 
• Data presented in this section are unweighted, meaning that there has been no 
adjustment for the undercounting of support periods that result from non-response. The 
data, therefore, are not comparable with other data published from the SHS Collection.  
• Only those agencies that received NAHA or NPAH funding for at least 4 months during 
the 2012–13 financial year are in scope for the 2012‒13 reporting period. Covered 
agencies are those in-scope agencies for which details have been provided to the AIHW 
by the relevant state/territory department. 
• Of all agencies that were in scope of the collection for at least 1 month during 2012‒13, 
90% submitted information for all 12 collection months, and 95% submitted data for at 
least 1 month. 
• The rate of invalid/’don’t know’/missing responses was high for a number of 2012‒13 
SHSC data items. 
• Matching of data from individual clients who presented at different agencies and/or at 
different times requires a valid SLK; with 94% of support periods having a valid SLK in 
2012‒13. 
Trends 
Trend data may differ from data published in previous versions of Alcohol and other drug 
treatment services in Australia, due to data revisions. 
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Appendix C: Imputation methodology for 
AODTS clients 
Attributing number of clients to set of missing SLK records 
The AODTS NMDS collects information at the service record level. Service records are 
associated with individual clients by way of an SLK. There are a number of records that have 
missing or invalid SLK data which cannot be attributed to a client. This leads to an 
underreporting of the total number of clients using the services as some (but not all) of the 
records will belong to clients who are not observed via a valid SLK.  
This document describes a potential method of using the available data to, after making a 
number of assumptions about the behaviour of the whole population, impute the total 
number of clients. 
Imputation groups 
Imputation groups are formed to improve the performance of the imputation. The service 
records will be grouped according to properties that are thought to influence the behaviour 
of clients and the quality of SLK data, and then the imputation will be performed at this 
imputation group level. 
Possible properties to group by include such things as location, provider size (measured by 
number of service records) and service type. The data are also grouped according to any 
sub-populations that are going to be reported upon, for example jurisdiction. 
The final imputation groups will be formed by balancing the often-competing priorities of 
having homogenous groups and the need to have groups of sufficient size to ensure that the 
imputation is robust. 
Assumptions and approximations 
Assumption 1: randomness and independence 
This imputation method assumes that which service provider a client attends for each 
incidence of service is random and independent of any other incidents of service the client 
may have. It is further assumed that the validity or otherwise of the SLK recorded on each 
service record is random and independent of both the client and the service provider with 
which the record is associated.  
Assumption 2: distribution of the number of service records per client 
This method also assumes that the distribution of the number of records per client for all 
clients is similar to that observed using the sub-set of records with valid SLKs. 
Approximation 1: no client has more than 10 service records 
This imputation method uses the approximation that no client has more than 10 service 
records.  
In order to implement this approximation, any clients observed to have more than 10 service 
records will be treated as if they have only 10 and the proportion of clients with 10 service 
records will be calculated accordingly. 
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Notation 
We start by defining the notation used in this document. 
𝑁𝑡:  the (unknown) total number of clients 
𝑁𝑡
′:  the imputed total number of clients 
𝑁𝑆𝐿𝐾1:  the number of clients observed using the records with a valid SLK 
𝑃𝑆𝐿𝐾1:  the proportion of clients with at least 1 service record with a valid SLK 
𝑃𝑁𝑖:  the (unknown) proportion of clients with 𝑖 service records 
𝑃𝑁𝑖
′ :  the imputed proportion of clients with 𝑖 service records 
𝑃𝑁𝑖,𝑆𝐿𝐾1: the proportion of clients with 𝑖 service records as observed using records with 
valid SLKs 
𝑛𝑡:  the total number of service records 
𝑛𝑡|𝑁𝑡,𝑃𝑁𝑖: the number of service records given the total number of clients and the 
proportions of clients with 𝑖 service records, 𝑖 = 1,2,… ,10. 
𝑛𝑆𝐿𝐾1:  the number of service records with a valid SLK 
𝑛𝑆𝐿𝐾0:  the number of service records with an invalid SLK 
𝑝𝑆𝐿𝐾0:  the proportion of service records with an invalid SLK 
Methodology 
Given Assumption 1 and Approximation 1, the proportion of clients who have at least 1 
service record with a valid SLK is 
𝑃𝑆𝐿𝐾1 =�𝑃𝑁𝑖�1− 𝑝𝑆𝐿𝐾0𝑖 �10
𝑖=1
. 
Now 
𝑁𝑆𝐿𝐾1 = 𝑃𝑆𝐿𝐾1 × 𝑁𝑡 
so it follows that the total number of clients is  
𝑁𝑡 = 𝑁𝑆𝐿𝐾1𝑃𝑆𝐿𝐾1 . 
To resolve this equation for 𝑁𝑡 we require the values of the 𝑃𝑁𝑖. These are unknown given 
that we are unable to observe the whole population due to the records with invalid SLK 
values. This method imputes the unknown 𝑃𝑁𝑖 using numerical methods and then uses these 
values to impute 𝑁𝑡.  
The process starts with the distribution of number of records per client that has been 
observed using the records with valid SLKs �𝑃𝑁𝑖,𝑆𝐿𝐾1�. These values are then adjusted so that 
the following conditions are met. 
Constraint 1  
The sum of the imputed proportions is equal to 1. That is 
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�𝑃𝑁𝑖
′
10
𝑖=1
= 1 
Constraint 2 
The imputed proportion of clients with 1 service record is less than or equal to the 
observed equivalent proportion among clients with records with valid SLKs. That is 
𝑃𝑁1
′ ≤ 𝑃𝑁1,𝑆𝐿𝐾1 
This constraint is used because some of the clients observed to have only 1 record will, 
in fact, have additional records with invalid SLKs. It is unlikely that the true 
proportion of clients with 1 service record is higher than that observed using records 
with valid SLKs. 
Constraint 3 
The total number of service records that the imputed total number of clients and the 
imputed distribution of records per client imply is equal to the observed number of 
service records. That is 
𝑛𝑡|𝑁𝑡′,𝑃𝑁𝑖′ = 𝑁𝑡�(𝑖 × 𝑃𝑁𝑖′ )10
𝑖=1
= 𝑛𝑡 
This constraint is used to ensure that the imputed values are consistent with the 
observed number of records. 
Penalty function 
Under Assumption 2 we want to limit how much the imputed proportions differ from 
the proportions observed via the records with valid SLK data. To achieve this we use a 
penalty function that increases as the distance between the imputed and observed 
proportions increases. This function is defined to be 
𝑓�𝑃𝑁1,𝑆𝐿𝐾1,𝑃𝑁2,𝑆𝐿𝐾1, … ,𝑃𝑁10,𝑆𝐿𝐾1,𝑃𝑁1′ ,𝑃𝑁2′ , … ,𝑃𝑁10′ � =��𝑃𝑁𝑖′ − 𝑃𝑁𝑖,𝑆𝐿𝐾1�2𝑃𝑁𝑖,𝑆𝐿𝐾110𝑖=1  
Using numerical methods the 𝑃𝑁1′ ,𝑃𝑁2′ , … ,𝑃𝑁10′  are chosen such that the penalty function is 
minimised, subject to the 3 constraints. 
The final step is to use the imputed proportions to calculate the imputed total number of 
clients: 
𝑁𝑡
′ = 𝑁𝑆𝐿𝐾1
∑ 𝑃𝑁𝑖
′ �1− 𝑝𝑆𝐿𝐾0𝑖 �10𝑖=1  
The resulting number is then rounded to the nearest integer. 
Discussion 
This imputation technique uses available information to impute the total number of clients. 
The methodology takes into account the proportion of records with invalid SLK data and the 
distribution of the number of service records per client as observed via the records with valid 
SLK data.  
It is apparent that the assumptions made do not hold for every client or service record. It is 
reasonable to expect that a client’s attendance at a service provider will be affected by 
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location and any prior contact they had with a provider. It should also be noted that some 
service providers failed to collect SLK for any service record during the reference period. 
Despite the known cases where Assumption 1 does not hold, it is reasonable to hope that, 
across the population as a whole, the assumption is a reasonable representation of the 
populations of clients and service records. 
It is believed that the impact of Approximation 1 will be small because, given Assumption 1, 
the chance that a client with more than 10 service records is not observed via a record with a 
valid SLK is extremely small. The chance diminishes as the proportion of records with an 
invalid SLK decreases and across jurisdictions the highest proportion observed is about 0.3. 
It should also be noted that the largest proportion of clients with 10 or more service records 
observed in the data at the jurisdiction level was only 0.007. 
One known factor of particular interest to some jurisdictions that was not taken into account 
was the fact that a number of agencies failed to collect valid SLK data for any service records. 
The way to adjust the imputation to make allowance for this would be to alter the value of 
the proportion of service records with an invalid SLK that is used in the calculations. This 
alteration would add complexity to the imputation and require a number of additional 
assumptions about the behaviour of clients. Whether this complexity would improve the 
performance of the imputation relies on just how sound those assumptions are. Given that in 
some cases there is little data to guide the assumptions there is a fair chance that the 
performance of the imputation would be degraded and so this approach is not 
recommended. 
There are many different penalty functions that could be used in this imputation. The 
function used was chosen because, compared to the other penalty functions investigated, it 
produced imputed proportions that were generally as close or closer to the observed 
proportions. It also most consistently resulted in a distribution that was similar in shape to 
the observed distribution of the number of records per client. 
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Table C1: Comparison of population characteristics for valid SLK episodes and all episodes, by states and territories, 2012–13  
  NSW Vic Qld WA SA Tas ACT NT 
  Valid % Total % Valid % Total % Valid % Total % Valid % Total % Valid % Total % Valid % Total % Valid % Total % Valid % Total % 
Client type 
                Own drug use 98.1 96.8 94.6 94.3 97.2 96.1 94.5 94.1 99.4 99.4 91.3 91.1 98.8 98.7 92.2 91.9 
Other's drug use 1.9 3.2 5.4 5.7 2.8 3.9 5.5 5.9 0.6 0.6 8.7 8.9 1.2 1.3 7.8 8.1 
Sex 
                Male 66.2 67.3 65.7 65.6 68.8 69.4 63.8 63.4 71.0 70.5 63.5 63.3 63.4 63.2 71.0 70.5
Female 33.8 32.6 34.1 34.3 31.2 30.6 36.2 36.6 29.0 29.4 36.5 36.7 36.6 36.8 29.0 29.5 
Not stated 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 
Indigenous status 
               Indigenous 11.6 13.1 6.9 6.9 18.6 17.6 22.2 21.6 14.8 14.9 7.5 7.5 10.2 10.3 61.2 61.9
Non-Indigenous 86.4 84.4 86.7 86.7 75.1 76.8 77.8 78.2 58.7 59.0 82.7 82.6 82.9 82.2 37.8 36.8 
Not stated 2.0 2.5 6.4 6.4 6.3 5.6 0.0 0.2 26.5 26.1 9.8 9.8 6.9 7.4 0.9 1.4 
Age group (years) 
               10–19 6.5 7.8 13.2 13.2 13.2 15.8 17.5 17.4 10.8 10.6 14.1 14.2 16.7 16.7 21.3 21.0
20–29 24.5 25.2 28.4 28.3 29.2 30.2 27.6 27.3 23.7 23.7 27.4 27.4 25.6 25.5 27.4 27.3 
30–39 29.6 30.0 27.0 27.0 26.8 25.3 28.3 28.4 28.8 28.9 26.9 26.8 27.7 27.6 25.3 25.1 
40–49 23.9 22.9 19.5 19.4 18.7 17.5 16.9 17.0 23.1 23.1 18.3 18.2 18.5 18.5 18.1 18.3 
50–59 11.5 10.6 8.4 8.4 8.5 7.8 7.1 7.3 9.5 9.6 9.5 9.5 9.1 9.2 6.3 6.1 
60 and over 3.9 3.5 3.4 3.5 3.5 3.1 2.5 2.6 4.1 4.1 3.8 3.8 2.3 2.3 1.7 1.9 
Unknown 0.0 0.0 0.0 0.2 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.2 
Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
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Glossary 
additional drugs: clients receiving treatment for their own drug use nominate a principal 
drug of concern that has led them to seek treatment and additional drugs of concern, of 
which up to 5 are recorded in the AODTS NMDS. Clients receiving treatment for someone 
else’s drug use do not nominate drugs of concern. 
additional treatment type: clients receive 1 main treatment type in each episode and 
additional treatment types as appropriate, of which up to 4 are recorded in the AODTS 
NMDS.  
administrative cessation: includes episodes that ended due to a change in main treatment 
type, delivery setting or principal drug of concern, or where the client was transferred to 
another service provider (see Appendix A for more information on reason for cessation). 
alcohol: a central nervous system depressant made from fermented starches. Alcohol inhibits 
brain functions, dampens the motor and sensory centres and makes judgment, coordination 
and balance more difficult (NDARC 2010). 
amphetamines: stimulants that include methamphetamine, also known as 
methylamphetamine. Amphetamines speed up the messages going between the brain and 
the body. Common names are speed, fast, up, uppers, louee, goey and whiz. Crystal 
methamphetamine is also known as ice, shabu, crystal meth, base, whiz, goey or glass. 
Australian Standard Geographical Classification (ASGC): was used from 1984 to 2011 by 
the Australian Bureau of Statistics for the collection and dissemination of geographically 
classified statistics. The ASGC provided a common framework of statistical geography 
which enabled the production of statistics that were comparable and could be spatially 
integrated. 
Australian Statistical Geography Standard (ASGS): is the Australian Bureau of Statistics' 
new geographical framework effective from July 2011. The ASGS replaces the Australian 
Standard Geographical Classification (ASGC). 
Benzodiazepines: also known as 'minor tranquillisers', are most commonly prescribed by 
doctors to relieve stress and anxiety and to help people sleep. Common names include 
Benzos, tranx, sleepers, downers, pills, serras (Serepax®), moggies (Mogadon®), normies 
(Normison®). 
closed episode: a period of contact between a client and a treatment provider or team of 
providers. An episode is closed when treatment is completed, there has been no further 
contact between the client and the treatment provider for 3 months or treatment is ceased 
(see reason for cessation). 
cocaine: belongs to a group of drugs known as stimulants. Cocaine is extracted from leaves 
of the coca bush (Erythroxylum coca). Some of the common names for cocaine include C, coke, 
nose candy, snow, white lady, toot, Charlie, blow, white dust and stardust. 
expected cessation: includes episodes where the treatment was completed, or where the 
client ceased to participate at expiation or by mutual agreement (see Appendix A for more 
information on reason for cessation). 
ecstasy: the popular street name for a range of drugs containing the substance 
3, 4-methylenedioxymethamphetamine (MDMA)—a stimulant with hallucinogenic 
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properties. Common names for ecstasy include Adam, Eve, MDMA, X, E, the X, XTC, the 
love drug. 
heroin: one of a group of drugs known as opioids, which are strong pain killers with 
addictive properties. Heroin and other opioids are classified as depressant drugs. It is also 
known as smack, skag , dope, H, junk, hammer, slow, gear, harry, big harry, horse, black tar, 
China white, Chinese H, white dynamite, dragon, elephant, boy, home-bake or poison. 
illicit drug use: the use of legal drugs in a legal manner, and includes tobacco smoking and 
alcohol consumption (MCDS 2011). 
licit drug use: includes: 
• the use of illegal drugs—a drug that is prohibited from manufacture, sale or possession 
in Australia, for example, cannabis, cocaine, heroin and ecstasy 
• misuse, non-medical or extra-medical use of pharmaceuticals—drugs that are available 
from a pharmacy, over-the-counter or by prescription, which may be subject to misuse, 
for example opioid-based pain relief medications, opioid substitution therapies, 
benzodiazepines, over-the-counter codeine, and steroids 
• use of other psychoactive substances—legal or illegal, potentially used in a harmful way, 
for example, kava, or inhalants such as petrol, paint or glue (but not including tobacco or 
alcohol) (MCDS 2011). 
main treatment type: the principal activity that is determined at assessment by the treatment 
provider to treat the client’s alcohol or other drug problem for the principal drug of concern. 
median: the midpoint of a list of observations ranked from the smallest to the largest. 
nicotine: the stimulant drug in tobacco. It is highly addictive. 
principal drug of concern: the main substance that the client stated led them to seek 
treatment from an alcohol and drug treatment agency. 
reason for cessation: the reason for the client ceasing to receive a treatment episode from an 
alcohol and other drug treatment service; these are: 
• ceased to participate against advice: where the service provider is aware of the client’s 
intention to stop participating in treatment, and the client ceases despite advice from 
staff that such action is against the client’s best interest 
• ceased to participate at expiation: where the client has fulfilled their obligation to satisfy 
expiation requirements (for example, participation in a treatment program to avoid 
having a criminal conviction being recorded against them) as part of a police or court 
diversion scheme and chooses not to continue with further treatment 
• ceased to participate by mutual agreement: where the client ceases participation by 
mutual agreement with the service provider, even though the treatment plan has not 
been completed. This may include situations where the client has moved out of the area. 
• ceased to participate involuntarily: where the service provider stops the treatment due 
to non-compliance with the rules or conditions of the program 
• ceased to participate without notice 
• change in the delivery setting 
• change in the principal drug of concern 
• change in the main treatment type 
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• death 
• drug court or sanctioned by court diversion service: where the client is returned to 
court or jail due to non-compliance with the program 
• imprisoned (other than sanctioned by a drug court or diversion service) 
• treatment completed: where the treatment was completed as planned 
• transferred to another service provider: this includes situations where the service 
provider is no longer the most appropriate and the client is transferred or referred to 
another service. For example, transfers could occur for clients between non-residential 
and residential services or between residential services and a hospital. Excludes 
situations where the original treatment was completed before the client transferred to a 
different provider for other treatment. 
referral source: the source from which the client was transferred or referred to the alcohol 
and other drug treatment service. 
standard drink: contains 10 grams of alcohol (equivalent to 12.5 millilitres of alcohol). Also 
referred to as a full serve. 
treatment type: the type of activity that is used to treat the client’s alcohol or other drug 
problem; these are: 
• assessment only: where only assessment is provided to the client. Note that service 
providers would normally include an assessment component in all treatment types. 
• counselling: is the most common treatment for problematic alcohol and/or other drug 
use and can include cognitive behaviour therapy, brief intervention, relapse intervention 
and motivational interviewing  (ADCA 2013) 
• information and education only 
• pharmacotherapy, where the client receives another type of treatment in the same 
treatment episode: includes drugs such as naltrexone, buprenorphine and methadone 
used as maintenance therapies or relapse prevention for people who are addicted to 
certain types of opioids. Where a pharmacotherapy is used for withdrawal, it is included 
in the ‘withdrawal’ category. Due to the complexity of the pharmacotherapy sector, this 
report provides only limited information on agencies whose sole function is to provide 
pharmacotherapy. 
• rehabilitation: focuses on supporting clients in stopping their drug use and helping to 
prevent psychological, legal, financial, social and physical consequences of problematic 
drug use. Rehabilitation can be delivered in a number of ways including residential 
treatment services, therapeutic communities and community-based rehabilitation 
services (AIHW 2011).  
• support and case management only: support includes activities such as helping a client 
who occasionally calls an agency worker for emotional support. Case management is 
usually more structured than ‘support’. It can assume a more holistic approach, taking 
into account all client needs including general welfare needs, and it includes assessment, 
planning, linking, monitoring and advocacy (Vanderplaschen et al. 2007). 
• withdrawal management (detoxification): includes medicated and non-medicated 
treatment to assist in managing, reducing or stopping the use of a drug of concern. 
tobacco: see nicotine. 
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treatment episode: The period of contact between a client and a treatment provider or a 
team of providers. Each treatment episode has 1 principal drug of concern and 1 main 
treatment type. If the principal drug or main treatment changes, then a new episode is 
recorded. 
unexpected cessation: includes episodes where the client ceased to participate against 
advice, without notice or due to non-compliance (see Appendix A for more information on 
reason for cessation). 
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over 700 agencies provided over 160,000 treatment 
episodes for alcohol and other drug issues to an 
estimated 108,000 clients in australia in 2012–13. most 
episodes were for clients receiving treatment for their 
own drug use, and these clients tended to be male and 
in their 20s and 30s. alcohol was the most common 
principal drug of concern, accounting for almost half of 
these closed episodes, and counselling was the most 
common type of treatment.
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